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Abstract
Beta-particle dosimetry in radiation synovectomy, which is a radiation therapy to
treat rheumatoid arthritis, was evaluated using Monte Carlo radiation transport sim-
ulation in a mathematical model of the treated joint and using experiments in joint
phantoms and the knees of cadavers. Radiachromic film dosimeters and reactor-
produced radionuclides were used in the experiments. Results of the dosimetry eval-
uation are presented as absorbed dose factors (cGy-cm2 /MBq-s) at depth in bone,
articular cartilage, the fluid-filled joint capsule, and synovium, and can be used to ex-
trapolate beta dose distributions in treated joints. Next, use of the 1°B(n,a) nuclear
reaction as a probe to examine the pathology of rheumatoid arthritis was developed.
The approach is to use the nuclear reaction to determine whether killing the surface
layer of synovial lining cells alone is sufficient to arrest the progression of RA in the
joint, or whether killing the entire synovium is required. While the question was
not answered here, preliminary studies of 10B uptake in excised samples of human
rheumatoid synovium were completed. Prompt gamma neutron activation analysis
was used to demonstrate and quantify the temporal distribution of boron particulate
and boric acid uptake in the samples; substantial uptake was seen to occur within
the first hour of incubation. Neutron-induced alpha-track autoradiography was used
to in an attempt examine the spatial distribution. Although the autoradiography
experiments did not reveal the desired spatial distribution, other information was
obtained.
Thesis Supervisor: Jacquelyn C. Yanch
Title: Associate Professor
Thesis Reader: Sonya Shortkroff
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Chapter 1
Introduction
The aims of this thesis are: to evaluate beta-particle dosimetry in radiation synovec-
tomy, which is a radiation therapy to treat rheumatoid arthritis, using Monte Carlo
radiation transport simulation, experiments in joint phantoms, and experiments in the
knees of cadavers; to provide a rationale for the use of the l°B(n,a) nuclear reaction
to examine the pathology of rheumatoid arthritis; and to determine the temporal and
spatial distribution of 10B uptake in excised samples of live, human rheumatoid syn-
ovium. Presentation of the thesis is organized as follows. In this chapter, background
information regarding motivation for the work is provided, and theoretical and ex-
perimental techniques used to complete it are introduced. In Chapter 2, rheumatoid
arthritis and radiation synovectomy are reviewed. Rheumatoid arthritis is a painful
degenerative disease affecting the synovial joints. Treatments for the disease, includ-
ing radiation synovectomy, are described, as are the synovial joints and the effects of
rheumatoid arthritis on those joints.
Evaluating beta-particle dosimetry in radiation synovectomy is a difficult problem
for a variety of reasons (see below). The approach taken in this thesis was to evaluate
the dosimetry in 3 different ways: through Monte Carlo simulation of radiation trans-
port in a mathematical model of the rheumatoid joint, through experiments in joint
phantoms using radiachromic film dosimeters and reactor-produced radionuclides,
and through experiments in the knees of fresh, human cadavers using radiachromic
film dosimeters and reactor-produced 165 Dy.
In Chapter 3, the Monte Carlo computer code used to simulate radiation transport
in a mathematical joint model is introduced. EGS4 is the code which was used, and
a complete description of the code's approach to electron transport simulation is
presented. In Chapter 4, use of EGS4 as a tool to evaluate the dosimetry of 8 beta-
emitting radionuclides of interest in radiation synovectomy is described. The results
of the computer simulations can be used to estimate absorbed dose distributions in
treated joints.
M
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In Chapter 5, experiments aimed at verifying the accuracy of the Monte Carlo
predictions of beta-particle dosimetry in radiation synovectomy are presented. As
mentioned above, experiments were conducted in both joint phantoms and the knees
of cadavers using radiachromic film dosimeters and reactor-produced radionuclides.
Comparisons of the experimental results with the EGS4 results are made.
In the remainder of the thesis, the focus is shifted from beta-particle dosimetry in
radiation synovectomy to use of the 0°B(n,a) nuclear reaction to examine the pathol-
ogy of rheumatoid arthritis. Chapter 6 is devoted to presenting data which support
the hypothesis that killing the surface layer of synovial lining cells in rheumatoid
joints is sufficient to temporarily arrest the progression of rheumatoid arthritis in the
joint and provide patients with symptomatic relief of the disease. Use of the l°B(n,a)
nuclear reaction as a probe to test the hypothesis is developed. The 10B(n,a) nuclear
reaction was chosen specifically because the range of the emitted particles is short,
on the order of 10 /Sm. The reaction thus can be used to selectively damage and
kill only boronated cells and their nearest neighbors. While the hypothesis itself is
not tested in this thesis, preliminary studies of 10B uptake in excised samples of live,
human rheumatoid synovium are presented in Chapter 7. Prompt gamma neutron
activation analysis is used to quantify the temporal distribution of 10B uptake in the
samples, while neutron-induced alpha-track autoradiography is used in an attempt to
determine the spatial distribution.
Finally, in Chapter 8 important conclusions drawn from the work of this thesis are
reviewed and recommendations for future research are made. The recommendations
include descriptions of in vitro and in vivo experiments aimed at determining the
thickness of synovium which must be killed to arrest the progression of rheumatoid
arthritis and provide patients with symptomatic relief of the disease, i.e., is it sufficient
to kill only the lining cells or must the entire synovium be killed. The possible
development of neutron capture therapy as novel treatment for the disease also is
presented.
1.1 Beta-particle Dosimetry in Radiation Synovec-
tomy
Radiation synovectomy is a radiation therapy to treat rheumatoid arthritis, a painful,
degenerative disease affecting the synovial joints. The procedure consists of the in-
jection of a short-lived, low-energy beta-emitting radionuclide into the joint capsule
where it comes into direct contact with the diseased tissue (rheumatoid synovium) [1].
Phagocytic cells along the tissue surface quickly absorb radioactive particulate from
the joint capsule [2, 3, 4]. Then as the radionuclide decays, radiation absorbed dose is
imparted to the rheumatoid synovium. Provided the amount of radioactivity injected
LS Johnson|MIT Nuclear Engineering Dept.
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is sufficiently large to deliver a therapeutic dose to the tissue, it will be killed. Tissue
which regenerates over time is expected to be free of disease for 2 to 5 years, and the
progression of rheumatoid arthritis in the joint is thereby temporarily arrested [1].
It is important to realize from the start that there is no cure for rheumatoid
arthritis and that the radiation therapy-like other treatments-is aimed instead at
slowing the progression of the disease and relieving its signs and symptoms. Up to
100% of patients treated with radiation synovectomy are reported to experience relief
of pain, reduced joint swelling, and increased joint mobility at 6 months, 1 year, and
2 years after injection [5]. Improvement however is dependent on a variety of factors,
including the condition of the joint before treatment and whether or not a therapeutic
radiation dose is delivered to all the rheumatoid joint tissue. At the same time, one
wants to ensure that other, healthy, joint components located nearby (e.g., bone and
articular cartilage) are not subjected to an unnecessary radiation hazard. It is for
these reasons that beta-particle dosimetry in radiation synovectomy is of interest.
Before discussing approaches to beta-particle dosimetry however, it is instructive to
review the concept of absorbed dose and the role of dosimetry in radiation therapy.
Concept of absorbed dose
The ultimate radiobiological effects of beta-emitting radionuclides injected into rheuma-
toid joints are initiated by processes in which atoms and molecules of the joints' tis-
sues are ionized or excited. Some of the ionization events result in the production of
chemically active species, i.e., free radicals, in regions near the paths traversed by the
emitted particles. Free radical production is the direct result of energy deposition in
the tissues and their presence is recognized as playing a central role in the generation
of a wide variety of biological damage, and other changes, from which subsequent ra-
diobiological effects evolve. In general, as the number of ionization events increases,
so does the production of free radicals, and therefore the production of biological
damage.
Over a wide range of conditions, it is considered an excellent approximation to as-
sume that the average number of ionizations and excitations in the volume of interest
is proportional to the amount of energy deposited in the volume [6]. The absorbed
dose, i.e., the average amount of energy imparted per unit mass, therefore is of cen-
tral importance for the production and evaluation of the radiobiological effects of
radiation synovectomy.
Role of dosimetry in radiation therapy
The role of dosimetry in radiation therapy is to provide quantitative information
regarding absorbed dose distributions in patients. In particular, it is of interest to
know accurately the absorbed dose imparted to target tissues and whether or not
LS Johnson[I MT Nuclear Engineering Dept.
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the incidental irradiation of other, "non-target," tissues subjects the patient to an
unnecessary or undesirable radiation hazard. In beta-particle dosimetry in radiation
synovectomy, the target tissue is rheumatoid synovium, and the other, non-target,
tissues to be considered include bone and articular cartilage.
In general, there are 3 methods for estimating absorbed dose distributions in
radiation synovectomy or any other radiation therapy. These include: (1) direct
measurement in humans, (2) extrapolation from measured data in animals, phantoms,
and cadavers, and (3) calculations based on mathematical models. Estimates of
absorbed dose distributions also can be extrapolated from clinical results, but this
"empirical" method lacks scientific rigor and is not considered here.
1.1.1 Calculations based on mathematical models
Typically in radiation dosimetry, the ranges of beta particles emitted from internally
distributed radionuclides are small compared to the size of the tissues or organs
containing the radioactivity. When this is the case, it has been considered permissible
to assume that the entire kinetic energy of the emitted particles is deposited in the
source [6]. This clearly is not a reasonable assumption in radiation synovectomy,
however, since the ranges of the emitted beta particles (up to 10 mm depending on
the radionuclide [1, 7, 8]) is large compared to the size of the source (less than 1 mm
[9, 10, 11]). In addition, the radiation absorbed dose to other, "non-source," regions
of the joint (e.g., synovium at depth, bone, and articular cartilage) also are of interest
in radiation synovectomy. Alternative approaches therefore must be used.
For beta-particle sources located at or near target tissues, beta dose point kernels
have been developed to represent the distribution of absorbed dose in a tissue medium
as a function of distance from a point-isotropic beta-emitting source. By suitable
integration over the point kernels, dose distributions can be readily determined for a
wide variety of source-to-target configurations.
The approach is best illustrated with the aid of an example. In 1973, Husak et
al. [9] used the beta dose point kernel method to calculate beta-particle dosimetry
in radiation synovectomy. Their approach was to assume that radionuclides injected
into the rheumatoid joint are absorbed by the synovial surface and are uniformly
distributed over it so that they form a thin plane source of activity.
The absorbed dose rate R (rad/s) at a distance s from a thin plane source of finite
thickness d then is calculated as:
1 f +d
R(s) = d. PR(z) dz, (1.1)
where R4(z) is the absorbed dose rate at distance z from an infinitely thin plane
LS JohnsonlI IT Nuclear Engineering Dept.
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source of uniformly distributed beta-particles and is given by:
Rp(z) = 2rnkE,],g , zx(x) dx, (1.2)
where a is the number of disintegrations per cm2 per second, n is the number of beta-
particles emitted per disintegration, k is 1.6x10-8 g-rad/MeV, Ea,g is the average
energy of the emitted beta-particles (MeV), and R,=. is the penetration range in
tissue of the most energetic beta-particle emitted (cm). The symbol ,(x) represents
the point isotropic specific absorbed fraction, i.e., the fraction of the energy emitted
from a point isotropic source that is absorbed at distance z per unit mass of tissue.
The specific absorbed fraction can be calculated using tabulated values of the
dimensionless scaled absorbed dose distribution function F(~) [12]. The function
F,(~) and the specific absorbed fraction are related as follows:
F(~) = 47rpX2 z9 oO(z), (1.3)
where x = z/x 9o, 90o is the distance from the point isotropic source at which 90% of
the emitted energy is absorbed (cm), and p is the density of the medium (g/cm3 ).
Now, if the expression 2xzx(x) in Eqn. 1.2 is replaced with Fp()/2pxx 9o, the re-
sulting expression is as follows:
~Rp(z) = nkE.fg Ff)dz. (1.4)
This equation can be solved by numerical integration using tabulated values of the
function Fp(~) [12].
Husak et al. have solved the equation. Their results present the dependence
of absorbed dose in tissue on distance (up to 0.6 mm) from thin plane sources of
s98Au and 90 Y, two radionuclides which have been used extensively in clinical trials
in radiation synovectomy (see Chapter 2).
But the point kernel method has been developed for homogeneous media only. As
a consequence, the approach taken by Husak et al. was to approximate the joint as
a homogeneous soft tissue volume and to neglect the incidental irradiation of other
joint components, such as bone and articular cartilage. Doses to these other, "non-
target," joint components were not calculated. As mentioned above however, one of
the roles of dosimetry in radiation therapy is to provide the quantitative information
necessary for radiotherapists to ensure that non-target tissues are not subjected to
an unnecessary or undesirable radiation hazard. Doses to bone and articular carti-
lage in radiation synovectomy therefore must be considered. Absorbed dose to the
bone surface (10 pm) is particularly of interest since the International Commission
on Radiation Protection (Vienna, Austria) has identified this tissue region as one
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of two principal radiosensitive targets to be protected in procedures involving bone
irradiation [13].
In addition, the tabulated beta dose point kernels referenced above and used by
Husak et al. to calculate beta dosimetry in radiation synovectomy are based on a
model which neglects the production and transport of secondary electrons and the
fluctuation of energy loss with distance [14, 15]. Prestwich et al. have reported
Monte Carlo calculations of beta dose point kernels that do include the transport of
secondary electrons and the effects of energy fluctuations [14]. Their approach shows
a dose distribution for 90 Y in water that is 7% lower at the origin than that predicted
by the above methods and significantly higher at distances greater than 5 mm from
the source. While these results have shown improved agreement with experiment,
a systematic error in the energy-loss straggling algorithm has been revealed [15],
indicating yet another limitation of the accuracy of the point kernel method.
1.1.2 Other methods
As mentioned above, other methods for estimating absorbed dose distributions in
radiation therapy are available. These include direct measurements in humans, which
often can be difficult to obtain (see Chapter 5), and extrapolation from measured data
in animals, phantoms, and cadavers. Other mathematical methods, e.g., the Monte
Carlo method, also can be used. The approach taken in this thesis was to evaluate
beta-particle dosimetry in radiation synovectomy 3 different ways.
First, Monte Carlo simulations of radiation transport in a mathematical model
of the rheumatoid joint were completed for 8 radionuclides of interest in radiation
synovectomy. Each of these radionuclides either has been used in clinical trials or is
of interest due to its favorable half-life, emission energies, and radiochemistry. Sim-
ulation begins by choosing a starting position, direction, and energy for the emission
of a single beta-particle from within the radiation source region. The emitted particle
is transported through the mathematical joint model by the Monte Carlo computer
code. At each point in the particle's "life" where a choice of interaction type, scatter-
ing direction, distance to the next interaction, etc. has to be made, a random number
is generated by the code and used to determine the event's outcome from known prob-
ability distributions which describe the likelihood of occurrence of each of the possible
outcomes. Simulated interactions include all the major events, such as the produc-
tion of secondary "knock-on" electrons and bremsstrahlung photons. "Continuous"
energy loss and multiple scattering through minor interactions with atomic electrons
also are accounted for. Simulation ends when the emitted beta-particle and all its
secondaries no longer have enough energy to excite the absorbing media. At this
point, a new beta-particle is "emitted" from within the radiation source region, and
the process is repeated. The simulations are described in detail in Chapter 4.
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Second, experiments were conducted in joint phantoms using radiachromic film
dosimeters and reactor-produced radionuclides. The joint phantoms were built using
aluminum as a substitute for bone and solid water (a specially formulated, commer-
cially available plastic) as a substitute for soft tissue and articular cartilage. Both
soft tissue and articular cartilage are composed primarily of water and their radiation
absorption and scattering characteristics are well simulated with water substitutes.
Planar radioactive sources of uniform activity (similar to those assumed by Husak et
al. to exist in joints treated with radiation synovectomy) were made by soaking filter
papers in liquid solutions of Dy2 03 (stable, natural Dy) and Ho203 (stable, natu-
ral Ho) dissolved in nitric acid. The wet filter papers then were dried, stacked and
stitched together, and irradiated at the MIT Nuclear Reactor Laboratory, yielding
thin plane sources of 165Dy and 166Ho which were inserted into the joint phantoms and
allowed time to decay. Radiachromic film dosimeters were used to measure depth-
dose data in the phantom. The experiments, dosimeters, and results are explained in
detail in Chapter 5.
Third, experiments were conducted in the knees of fresh, human cadavers using
radiachromic film dosimeters and reactor-produced 165Dy. The knees were surgically
opened and several dosimeters were stitched into strategic locations throughout the
joints. The knees then were sewn tight and injected with a therapeutic dose of ra-
dioactivity. After allowing time for decay, the knees were reopened and the dosimeters
were removed for analysis. These experiments also are explained in detail in Chapter
5.
1.2 Use of the 10B(n,a) Nuclear Reaction to Ex-
amine the Pathology of Rheumatoid Arthri-
tis
In Chapter 6, the focus of the thesis is shifted from beta-particle dosimetry in radia-
tion synovectomy to the use of the '°B(n,a) nuclear reaction to examine the pathology
of rheumatoid arthritis. For the most part, radiation synovectomy can be described
as attempting to kill the entire synovial membrane. Existing data suggest, however,
that removal of only the surface layer of lining cells may be sufficient to arrest the pro-
gression of rheumatoid arthritis and provide patients with temporary, symptomatic
relief of the disease. These data are presented in Chapter 6, along with a series of
experiments aimed at testing the above hypothesis.
The proposed approach is to selectively irradiate and kill either the lining cells
alone or the entire synovium using the 'OB(n,a) nuclear reaction. This reaction was
chosen specifically because the range of the high-LET particles emitted is very short,
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on the order of 10 /im. As a consequence, the resulting radiation damage is very
cell-specific, restricted only to boronated cells and their nearest neighbors. While
these experiments have not been attempted in this thesis, preliminary studies of 10B
uptake in excised samples of live, human rheumatoid synovium were completed.
Samples of rheumatoid synovium obtained from the operating room were incu-
bated with either boron particulate or boric acid for varying periods of time. The
boron particulate is hypothesized to be absorbed by the surface layer of lining cells
only. These lining cells are phagocytic and have been shown to actively absorb a
wide variety of particulate matter injected into synovial joints [2, 3, 4]. The boric
acid, on the other hand, is a water soluble compound; and like other water soluble
compounds, it is expected to diffuse freely and rapidly throughout the entire synovial
membrane. Prompt gamma neutron activation analysis was used to quantify the tem-
poral distribution of bulk 10B uptake by human rheumatoid synovium, for both boron
preparations. Neutron-induced alpha-track autoradiography was used to determine
the spatial distribution. The experiments and results are presented in Chapter 7.
Finally, in Chapter 8 important conclusions drawn from the thesis are reviewed
and recommendations for future work are made. In particular, in vitro and in vivo
experiments aimed at determining the thickness of rheumatoid synovium which must
be removed for successful therapy are presented. The possible development of neutron
capture therapy as a novel treatment for rheumatoid arthritis also is described.
1.3 Conclusion
The aims of this thesis are: to evaluate beta-particle dosimetry in radiation synovec-
tomy using Monte Carlo radiation transport simulation, experiments in joint phan-
toms, and experiments in the knees of cadavers; to provide a rationale for the use
of the '°B(n,a) nuclear reaction as a probe to examine the pathology of rheumatoid
arthritis; and to determine the temporal and spatial distribution of 10B uptake in
excised samples of human rheumatoid synovium.
In this chapter, the framework of the thesis was outlined, and the theoretical and
experimental techniques used to complete it were introduced. In the next chapter,
rheumatoid arthritis and radiation synovectomy are reviewed.
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Chapter 2
Rheumatoid Arthritis and
Radiation Synovectomy
2.1 Introduction
One of the oldest diseases known to affect humans, rheumatoid arthritis is a chronic,
autoimmune disease characterized by recurrent swollen, inflamed, and painful joints.
Although rheumatoid arthritis has many clinical manifestations, its distinguishing
characteristic is a persistent inflammation of the tissue (synovium) which lines the
joint. Treatment is generally aimed at relieving the inflammation. In some patients,
however, the inflammation may prove unresponsive to the conventional modes of
treatment; and the synovium instead may be removed, or killed. Radiation syn-
ovectomy has been developed as an effective, quick, and low-cost means of killing
rheumatoid synovium.
In this chapter the effects of rheumatoid arthritis on synovial joints are described.
Conventional treatments for the disease are reviewed, and radiation synovectomy
is introduced. Discussions of the importance of understanding beta dosimetry in
radiation synovectomy and determining the thickness of tissue which must be removed
for successful treatment also are included.
2.2 Synovial Joints
The joints of the human body often are classified into two main functional groups:
synovial and non-synovial. The synovial joints comprise the majority of the body's
articulations and are characterized by the extensive, almost frictionless movement of
bones upon one another. Examples of synovial joints include the knee, shoulder, and
hip. The non-synovial joints, e.g., the suture joints of the skull, provide only limited
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movement, if any.
2.2.1 Anatomy
In the synovial joint, the ends of the two articulating bones are ensheathed by a strong
fibrocollagenous capsule and are separated from each other by a capillary thin layer of
a highly viscous fluid, the synovial fluid. As shown in Fig. 2-1, the fluid is contained
within a capsule that is defined by a specialized secretory epithelium, the synovium.
Synovium lines the capsule everywhere except over the ends of the articulating bony
surfaces [16].
The ends of the two bones are covered with a thin layer (0.5 to 3 mm depending
on the size of the joint [17, 18]) of smooth, spongy articular cartilage. The articular
cartilages are the actual load bearing surfaces of the joint and thus are designed to
resist the repetitive rubbing and considerable deformation to which they are subjected
over the years. Synovial fluid serves as a lubricant for the cartilages.
Structures around the joint, which provide strength, support, and stability, include
collagenous ligaments and tendinous muscle attachments. In some complex joints
(e.g., the knee) there are also internal ligaments to prevent overstretching or twisting
and fibrocartilaginous menisci to stabilize and guide gliding movements.
2.2.2 Synovium
Principal among structures found in synovial joints, the synovium performs at least
three main functions. It provides an unobtrusive, low-friction lining for the joint. It is
responsible for secreting and maintaining the lubricating synovial fluid. And it plays
an important role in maintaining joint stability.
Synovium is composed of collagen fibers, elastic fibers, and synovial lining cells
[19]. The collagen and elastic fibers form a wide-meshed network along the synovial
surface and continue into the interior of the membrane where they are connected to
underlying, loose connective tissues. Cauliflower-like protrusions of synovial lining
cells near the surface emerge from beneath the superficial fibers.
Synovial lining cells often are divided into two major cell types, the macrophage-
like type-A cells and the fibroblast-like type-B cells [19]. Type-A cells are phagocytic,
i.e., they have the ability to engulf and destroy particulate matter, as shown in
Figure 2-2. These cells have elongated bodies and send processes mostly toward the
joint capsule where they emerge and are available to remove waste from the synovial
fluid. Type-B cells are secretory. They also send processes toward the joint capsule,
and evidence has shown that these cells secrete proteoglycans and hyaluronic acid
which play important roles in the metabolism of synovium and in the formation of
synovial fluid. In some areas, both type-A and type-B lining cells may be absent.
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Figure 2-1: Diagram of a simple synovial joint showing the ends of the two articulating
bones separated from each other by synovial fluid which is contained within the joint
capsule.
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large particle
· expulsion
Figure 2-2: Phagocytosis refers to the process in which a cell's plasma membrane
infolds around a large particle and forms a vesicle which then moves into the cell.
The ingested particles typically are digested and expelled.
At these points, the underlying, loose connective tissue is exposed directly to the
synovial fluid.
Other cells found in the synovium include mast cells, a variable number of fat cells,
and fibroblasts, which are cells capable of generating collagen fibers. In addition, an
abundant supply of capillaries and nerve fibers runs through the mesh of collagen and
elastic fibers and underlying connective tissue [19].
2.3 Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, autoimmune disease affecting the synovial joints.
While its precise etiology remains a mystery, rheumatoid arthritis is known to begin
as a persistent inflammation of the synovium [20, 21]. If left untreated, the inflam-
mation eventually leads to significant pain, deformation, and disability. Despite its
destructive potential, the course of rheumatoid arthritis can be quite variable. Some
patients may experience only mild symptoms with minimal joint damage, while oth-
ers may suffer relentless, progressive rheumatoid arthritis with marked deformity in
several joints. Most patients will experience an intermediate course [20, 21].
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2.3.1 Epidemiology
Approximately 1% of the adult population is affected by rheumatoid arthritis [21].
Women are affected approximately three times more often than men. The prevalence
increases with age, and differences between the sexes diminish in the older age groups.
Rheumatoid arthritis is seen throughout the world and affects all races. Onset of
the disease typically is during the fourth or fifth decade of life, with 80% of all
patients developing rheumatoid arthritis between the ages of 35 and 50 [21]. A small
proportion eventually become severely disabled.
The first criteria for the classification of the disease were published in 1958. These
criteria were used heavily for 30 years and then revised in 1988 [22]. Designed pri-
marily for epidemiologic purposes and not for the diagnosis of individual cases, the
criteria are intended to be useful guidelines for identifying the disease. They include:
morning stiffness in and around joints lasting at least one hour before maximal im-
provement; swelling of the tissue around three or more joints; swelling of the proxi-
mal interphalangeal (finger), metacarpophalangeal (hand), or wrist joints; symmetric
joint swelling; subcutaneous nodules; a positive test for rheumatoid factor; and ra-
diographic evidence of bone erosions. To make a diagnosis of rheumatoid arthritis,
at least the first four symptoms must have been present for six or more weeks [22].
2.3.2 Pathology
The precise cause of rheumatoid arthritis is unknown. Indeed, it is probable that
many different stimuli can activate the inflammatory response, and more is known
about the genetic susceptibility of individuals to the disease than about causitive
agents. In any event, rheumatoid arthritis is known to begin as an inflammation
of the synovium. Inflammation is a defense mechanism which aims to protect the
host tissue from foreign invaders. Synovial inflammation which is allowed to persist
over time, however, leads to a number of destructive structural changes in the joint.
Development of the disease can be summarized as follows.
Onset
The first cells to be involved in the immune response are antigen-presenting cells, e.g.,
macrophages or dendritic cells in the synovium. The antigen-presenting cells ingest,
process, and present foreign protein antigens to the circulating T-lymphocytes of the
immune system. The T-lymphocytes, in turn, initiate a cellular immune response and
stimulate the differentiation of B-lymphocytes into antibody-secreting plasma cells.
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Progression
As the immune response becomes organized, the increase in the number of T-cells,
B-cells, and secreted antibodies evolves within an expanding scaffold of new blood
vessels and an intensely active layer of highly proliferative synovial lining cells. The
development of new blood vessels in the synovium is essential to the progression
of rheumatoid arthritis, since they facilitate the delivery of nutrients to the rapidly
increasing number of lining cells.
Each of the steps in the above progression is mediated by the presence of cytokines,
which are small proteins secreted by the lining cells, immunocytes, and macrophages.
While cytokines are known to have the ability to affect gene expression in cells, their
activities are complex and poorly understood [21]. For example, one cytokine may
stimulate the proliferation of cells under some conditions but inhibit its growth under
others. Cells identified as targets of one cytokine also may be the cells responsible for
secreting other cytokines. Different cytokines may serve similar functions, and their
interactions may be synergistic, additive, or inhibitory. In spite of this complexity,
there is little argument that cytokines play a central role in the amplification and
perpetuation of chronic synovial inflammation and, as a consequence, in the eventual
destruction of bone and articular cartilage [23].
Destruction
The precise mechanism by which bone and articular cartilage destruction occurs has
yet to be completely resolved. Although the synovial fluid contains a number of
enzymes potentially able to destroy bone and articular cartilage, the majority of
the destruction typically occurs when the proliferating synovium becomes sufficiently
organized to invade the affected joint. The organization is characterized by what
often is referred to as an extravagant growth of synovial lining cells. The result is the
development of an offensive front of tissue, which grows to form slender finger-like
projections, or "pannus." Behaving much like a localized neoplasm, the developing
pannus eventually grows to protrude into the joint capsule where it spreads to cover
the articular cartilages [21].
Activated by the presence of various cytokines, the large number of synovial lining
cells in the invading pannus begin to secrete high concentrations of enzymes capable of
destroying articular cartilage and bone. It is important to realize that very little gross
destruction of articular cartilage is necessary before its normal function is weakened to
the point that progressive, irreversible disintegration follows in response to the normal
movements of weight-bearing joints. Over time the disintegration can lead to the
complete loss of articular cartilage in some areas, leaving the underlying subchondral
bone exposed and vulnerable to erosion.
Once destruction of the articular cartilages is well underway, attempts to protect
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Table 2.1: The histopathologic stages of rheumatoid arthritis. Adopted from Harris.
age Pathology
1 Presentation of antigen to T cells
2 T cell, B cell, and vascular proliferation
3 Synovial proliferation without pannus,
4 Formation of pannus,
degradation of cartilage by enzymes
5 Erosion of bone,
invasion of cartilage by pannus
Symptoms
None
Malaise,
mild stiffness and swelling
Joint pain and swelling,
morning stiffness,
malaise and weakness
Same as stage 3
Same as stage 3,
loss of function and early deformity
affected joint from progressive, irreversible degradation generally are considered to
be futile [23]. Treatments thus are aimed at delaying the onset of articular cartilage
destruction, primarily through the relief of synovial inflammation. The above stages
of rheumatoid arthritis are reviewed in Table 2.1 [21].
2.3.3 Treatment
The goals of treatment of rheumatoid arthritis are: (1) relief of pain, (2) reduction
of inflammation, (3) preservation of joint function, (4) inhibition of the pathologic
process, and (5) facilitation of healing [23]. There is a wide variety of medications
available which are capable of providing pain relief and some reduction in inflamma-
tion in most patients. None of the medications are curative, and therefore all must be
viewed as palliative, i.e., aimed at relieving the signs and symptoms of the disease.
Medical management of rheumatoid arthritis involves 3 general approaches. The
first is the use of aspirin and other nonsteroidal antiinflammatory drugs (e.g., ibupro-
fen, fenoprofen, naproxen, and sulindac) to control the local inflammatory process.
While these drugs are rapidly effective at alleviating the signs and symptoms of
rheumatoid arthritis, they appear to have little effect on the progression of the dis-
ease. They also are associated with a wide spectrum of toxic side effects. Elderly
patients are particularly at risk for certain toxic effects. None of these drugs has been
shown to be more effective than aspirin in the treatment of rheumatoid arthritis [23].
The second approach is the use of disease-modifying drugs which appear to have
the capacity to decrease elevated levels of certain reactants in treated patients and
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thus are thought to modify the destructive capacity of the disease. This group in-
cludes gold compounds, D-penicillamine, antimalarials, and sulfasalazine. Unfortu-
nately, each of these drugs is associated with considerable toxicity and, as a result,
require careful patient monitoring. In addition, these drugs appear to have mini-
mal antiinflammatory effects and therefore must be used in combination with the
first group of drugs. It has been reported that as many as two-thirds of patients
develop some clinical improvement after therapy with disease-modifying drugs [23].
Despite this result, there is minimal evidence that they actually delay the long-term
development of bone erosions and the eventual loss of joint structure and function
[23].
The third approach is the use of immunosuppressive and cytotoxic drugs. These
have been shown to be effective in some patients, yet no more so than the disease-
modifying drugs. They also appear to predispose some patients to the development
of malignant tumors [23], and as a consequence, these drugs have been reserved for
patients who have clearly failed to respond to other forms of treatment.
At the onset of disease, it is difficult to predict the natural course an individual
patient's illness will take. The usual approach thus is to attempt to relieve the
patient's symptoms and synovial inflammation with nonsteroidal antiinflammatory
drugs. Some patients may have mild rheumatoid arthritis that requires no additional
treatment. Other patients however may have symptoms that cannot be controlled
adequately with this group of drugs.
At some point in most patients' course of illness, the use of nonsteroidal antiin-
flammatory drugs proves to be insufficient, and the use of disease-modifying drugs is
entertained. It must be kept in mind however that all disease-modifying drugs es-
sentially provide what can be described as an immuno-suppressive effect and require
prolonged administration. Even with a successful response to the use of disease-
modifying drugs, occasional synovial inflammation may persist in a limited number
of joints in some patients; and problems associated with progressive loss of articular
cartilage, bone erosions, or deformity may require additional treatment. As men-
tioned above, use of the third group of drugs generally is reserved only for the most
severe cases, in which the possible delay of complete joint destruction is believed to
outweigh the risk of inducing cancer.
In patients whose joints already have been severely damaged by progressive rheuma-
toid arthritis, drug treatments alone may prove insufficient. For relief of pain or
modest functional improvement, some patients elect to have joint surgery. Total joint
replacements, for instance, can be done on a number of joints, with the most successful
procedures primarily carried out on hips and knees.
In addition, surgical synovectomy has proven to be useful in some patients with
persistent rheumatoid arthritis in a single joint, especially the knee [24]. The proce-
dure entails opening the joint to surgically remove the inflamed synovium and thereby
MIT Nuclear Engineering Dept. 
LS Johnson
I IT Nuclear Engineering Dept. LS Johnsoni
Chapter 2. Rheumatoid Arthritis and Radiation Synovectomy 28|
provide the patient with symptomatic relief of rheumatoid arthritis for 2 to 5 years
[25]. Surgical synovectomy is however unavoidably associated with a variety of risks
and disadvantages: from infection, hemorrhage, and anesthesia to the high cost of
hospitalization and painful rehabilitation. In addition, it is technically difficult, if
not impossible, to remove all the inflamed synovium lining the joint. It is for these
reasons that alternative methods of treatment are desirable.
2.4 Radiation Synovectomy
Radiation synovectomy has been developed as an effective, low-cost alternative to
surgery for patients who have proven unresponsive to the traditional modes of treat-
ment [7, 8]. The procedure consists of the injection of a short-lived, low-energy
beta-emitting radionuclide directly into the joint capsule where it is free to mix with
the synovial fluid and migrate throughout the joint, as shown in Fig. 2-3. Phagocytic
lining cells along the synovial surface quickly absorb some of the radioactive partic-
ulate from the capsule. Then as the radionuclide decays, kinetic energy is deposited
in the rheumatoid synovium. Provided the amount of activity injected is sufficient to
deliver a therapeutic dose to the tissue, it will be killed. Resulting histologic changes
include regression of destructive pannus, reduced production of destructive enzymes
and proinflammatory cytokines, and eventually sclerosis of the synovium [1]. The
expectation is that the treated joint will be free of disease, at least temporarily, and
the pain and symptoms of rheumatoid arthritis thereby temporarily alleviated.
Advantages over surgery include an increased likelihood of removing all the in-
flamed synovium, a reduced potential for the formation of blood clots and infection,
a requirement for local anesthesia only, and the fact that the radiation treatment is
much less costly and time consuming (see Table 2.2). Results of clinical trials, in
general, are equally as appealing, with improvement having been reported in up to
100% of treated joints [5]. As with surgery however, the treatment is not curative
and is aimed instead at relieving the pain and symptoms of rheumatoid arthritis.
Since the inflamed synovium itself is removed, rather than the offending agent, the
symptoms of the disease typically are expected to return, often within 2 to 5 years
[26]. At which time, patients can be reinjected [27].
Radiation synovectomy is regularly practiced in Australia and Canada, and ad-
ditionally used in a few European centers. On a global basis, it is not extensively
performed. And in the US, the technique is virtually nonexistent. Resistance gener-
ally is held to be due primarily to concerns about excessive extraarticular irradiation
due to leakage of radioactivity from the joint [7].
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joint
radionuclide
injection needle
not to scale
Figure 2-3: In radiation synovectomy, a beta-emitting radionuclide is
into the joint capsule in order to kill rheumatoid synovium.
Radiation synovectomy versus surgery. Adopted from
Radiation synovectomy
$2000-5000
Weeks to rehabilitate
2-5 y symptomatic relief
Extraarticular irradiation,
radiation damage
in healthy joint components
injected directly
Harling et al.
Surgery
$20,000-30,000
Months with some hospitalization
Same
Infection,
hemorrhage,
anesthesia
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Table 2.2:
Item
Cost
Time
Relief
Dangers
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-
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Table 2.3: Radionuclides of interest in radiation synovectomy
Radionuclide Max Energy Half-life
32p 1.71 MeV 346 h
90Y 2.25 64.2
153Sm 0.80 46.8
165 Dy 1.28 2.3
1 66Ho 1.85 27
186Re 1.07 90
8ss Re 2.12 16.8
198Au 0.96 64.8
2.4.1 Radionuclides of interest
Radionuclides of interest in radiation synovectomy are listed in Table 2.3. These 8
beta-emitters either have been used in clinical trials or are of interest due to their
favorable half-lives, emission energies, and radiochemistry.
In the past, the "ideal" radionuclide for the treatment has been considered to be a
short-lived low-energy beta-emitter with little or no coincident gamma-ray emission.
Low-energy beta particles have been desirable because they typically deposit all of
their kinetic energy within a few mm of tissue or less, a thickness which is on the order
of the thickness of rheumatoid synovium. Short physical half-lives have been desirable
since leakage of radioactivity from the joint requires time, and atoms which decay
before leaking do not subject the patient to unnecessary extraarticular irradiation.
Before injection, these radionuclides usually are attached to larger molecules or
particles to limit leakage of activity from the joint. The larger molecules or particles
must be small enough to be phagocytized, but not so small as to allow rapid biological
removal from the joint. The most appropriate size range is generally considered to be
2 to 5 psm [28]. In addition, the particles should be biodegradable and easily removed
from the joint after radioactive decay.
In the past, the radiopharmaceuticals most commonly injected have been inorganic
colloids. Unfortunately, leakage of these colloids from the joint has sometimes led to
significant radiation doses to the liver, spleen, and draining inguinal lymph nodes
[29]. Recent advances in radiopharmaceutical design and synthesis, however, could
eventually lead to the generation of a new class of radiation synovectomy agents
which will exhibit minimal leakage of activity from the treated joint [30, 31]. In
the remainder of this section, previous clinical trials in radiation synovectomy using
1 9 8Au, 90 y, 3 2p, and le6 Dy are discussed.
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198Au
The first radionuclide to be injected into rheumatoid joints was 98Au (in Vienna,
Austria in 1952) [32]. The decay of '19Au results in the emission of a beta-particle
(maximum energy 0.96 MeV) 98.6% of the time. Emission of the particle is always
followed by a 411.7 keV gamma-ray.
In a later study (in London, England in 1963), Ansell et al. demonstrated im-
provement in 23 of 30 patients who had been injected with 185 to 370 MBq (5 to
10 mCi) 19 8Au [33]. The patients were evaluated 12 months after injection, and im-
provement was loosely defined as an increase in joint movement or a reduction in
pain or swelling. Similar results were reported by Topp et al. (in Toronto, Canada
in 1970) [3] with 12 of 18 patients showing complete disappearance of effusion (i.e.,
joint swelling due to an increased synovial fluid volume) at the end of one year and
also by Virkkunen et al. [34] with 67 of 85 patients improving.
Although these and other studies [32, 33, 3, 34, 35] indicated that radiation syn-
ovectomy with 9 8Au showed promise in the management of rheumatoid arthritis,
they also noted leakage of 198Au from the joint varying from 0-60% of the injected
activity. In a patient group that otherwise could be regarded as healthy, the result-
ing extraarticular irradiation was considered to be unacceptable, and methods were
sought to reduce the leakage.
90y
Throughout the 1970s, 90 Y gradually replaced 198Au as the radionuclide of choice in
radiation synovectomy. It is a pure beta-emitter (maximum energy 2.3 MeV) with a
64 h half-life. Because 90 Y does not emit a coincident gamma-ray, it generally was held
to be safer for the patient. In addition, the greater penetration of its beta particles
was believed to increase the likelihood of removing the entire volume of rheumatoid
synovium [36, 37]. And the injected sY radiocolloids (prepared as citrates, hyroxides,
silicates, and resins) were found to be somewhat less likely to leak from treated joints
[8].
Oka and Hypen (in Finland in 1974) [38] reported 60% improvement in 48 knees
at one year after injection with 220 MBq (6 mCi) 90Y resin colloid. Improvement
again was loosely defined as an increase in joint movement or a reduction in pain or
effusion.
A larger study, by Menkes et al. [39], included 1240 patients treated in a variety
of synovial joints. They demonstrated a result similar to that of Oka and Hypen,
with 50 to 60% of their patients showing improvement. In addition, Menkes et al.
reported observing the best results in the knee.
Leakage of radioactivity from the joint remained a problem however. Although
the overall leakage rates had been reduced, radiation doses to the draining lymph
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nodes still were estimated to be often in excess of 100 Gy [40]. It was presumed
that this excessive leakage was due primarily to the escape of very small particles, or
"fines," from the treated joint [28].
32p
3 2 p chromic phosphate in colloidal suspension also has been used in clinical trials.
It, too, is a pure beta emitter (maximum energy 1.71 MeV) but has a much longer
half-life of 14.3 d. Such a long half-life would seem to preclude the use of 3 2 p in radi-
ation synovectomy, since it would appear to provide ample opportunity for injected
radioactivity to leak from the joint before decay. In practice however research has
indicated that the colloid tends to remain in the joint and is preferentially absorbed
by the synovial lining cells. Because of the longer half-life, the amount of injected
activity also is reduced, generally down to 37 to 110 MBq (1 to 6 mCi) 32 p.
In a study of 112 knees of patients at varying stages of rheumatoid arthritis,
Onetti et al. [41] reported a good result in 73% of their patients treated at the early
stages and in 31% of those treated at the advanced stages. Biopsies collected from
8 patients revealed decreases in the number of lining cells and lymphocytes in the
synovium after treatment.
16s5Dy
Finally, use of '65Dy currently is in clinical trials under the direction of Sledge at
Brigham and Women's Hospital (Boston, MA). 165Dy has a 2.3 h half-life and de-
cays by beta-particle emission (maximum energy 1.3 MeV) with a coincident 95 keV
gamma-ray emitted in 3.6% of the decays.
In a study of 138 knees evaluated at 12 months after injection of 11 GBq (300
mCi) 16sDy, Sledge et al. reported a good result in 63% of the patients, a fair result
in 24%, and a poor result in 13% [7]. Patients with a good result were reported to
have complete, or almost complete, relief of pain in the treated joints; little or no
effusion; and an improved or maintained range of motion. Patients with a fair result
were reported to have partial relief of pain; a diminished, or small, effusion; and to
have maintained their pretreatment range of motion. Patients with a poor result were
reported to have derived no benefit from the treatment, as evidenced by continued
pain, effusion, and a limited range of motion. A second injection was given to the
13% of the patients who did not demonstrate improvement after the first injection. Of
those who returned for follow-up, 54% demonstrated improvement after the second
injection [27].
The radiopharmaceutical used in clinical trials by Sledge et al. is 165Dy ferric
hydroxide macroaggregate. The 165 Dy is produced at the MIT Nuclear Reactor Lab-
oratory (Cambridge, MA) by thermal neutron activation of natural dysprosium ni-
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trate dissolved in 3% nitric acid. The irradiations are performed with a thermal
neutron flux of t 8 x 1012 n/cm2 -s and require 6 h to complete. Roughly 37,000 MBq
(1000 mCi) 165Dy is produced. The radionuclide then is mixed with 1 mg ferrous
sulfate in 0.5 ml 0.1 N hydrochloric acid. One ml 0.2 N sodium hydroxide is added
to precipitate the 165Dy ferric hydroxide macroaggregate which is washed twice with
polyvinylpyrrolidone to remove any small particles, or fines. The average size of the
resulting particles is 3 to 10 am [42].
In combination with the short half-life, the fairly large 165Dy ferric hydroxide
macroaggregate resulted in a significantly reduced radiation hazard for the injected
patients [8]. By scanning for the 95 keV gamma-ray, Sledge et al. demonstrated that
the mean uptake of radioactivity in the liver was less than 1% of the injected dose.
The resulting absorbed dose to the liver was estimated to be 3.2 cGy [43]; similar
studies conducted using 98Au or 90Y colloids typically have reported liver doses of
5.4 to 40 cGy [44]. Uptake of radioactivity in the inguinal lymph nodes also was
evaluated by Sledge et al. They estimated that leakage of 165Dy ferric hydroxide
macroaggregate from injected joints results in an absorbed dose to the lymph nodes
of roughly 17 cGy [43]. As a comparison, lymph node doses due to the leakage of
198 Au or 90Y colloids typically are estimated to be between 270 and 6300 cGy [45].
2.4.2 Beta-particle dosimetry in radiation synovectomy
Empirical dosimetry
Previous attempts to evaluate beta-particle dosimetry in radiation synovectomy are
limited, both in number and completeness. Most often, the approach has been em-
pirical. In numerous clinical trials conducted over the past 40 years, several patients
have been injected with a given dose of one particular radionuclide. Then at regular
time intervals after injection, follow-up reports on reductions in pain and swelling or
increases in joint movement are evaluated to determine whether or not the selected
radionuclide and the amount of injected activity were appropriate.
Definite data on the absorbed dose required for successful treatment have not been
established [8]. Difficult to determine, the absorbed dose depends not only on the
radionuclide (its half-life and the energy spectrum of the emitted particles) and the
amount of injected radioactivity, but also on the spatial and temporal distribution
of the radionuclide in the joint. The distribution of activity varies from patient to
patient and from joint to joint, however, as does the volume of tissue irradiated which
is influenced by the thickness of pannus and the way the synovium is thrown into folds
[1]. It is because of these difficulties that previous approaches to the dosimetry in
radiation synovectomy typically have been empirical.
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Analytical dosimetry
Nonetheless, analytical calculations of synovial dose have been reported [9, 3, 46]. As
described in Chapter 1, analytical approaches to beta dosimetry often involve the use
of tabulated values of beta-dose point kernels [47, 48]. The beta dose point kernels
have been developed to represent the distribution of absorbed dose in tissue as a
function of distance from a point-isotropic beta-emitting or monoenergetic electron
source. By suitable spatial integration of the kernels, absorbed dose distributions can
be calculated for a variety of source-to-target configurations [47, 48]. Tables published
by Cross et al. [47] or Berger [48] provide beta dose point kernels for a number of
electron sources in several media, and these data have been used extensively in beta
dosimetry.
The most detailed of the analytical calculations of beta dosimetry in radiation
synovectomy, by Husak et al., applied the beta dose point kernel method to determine
the dependence of absorbed dose in tissue on distance (up to 0.6 mm) from thin
plane sources of ' 98Au and 90 Y [9]. The point kernel method, however, is based on
a model which neglects the production and transport of secondary electrons and the
fluctuation of energy loss with distance [14, 15].
Prestwich et al. have reported Monte Carlo calculations of beta dose point ker-
nels that do include the transport of secondary electrons and the effects of energy
fluctuations [14]. Their approach shows a dose distribution for 90Y in water that is
7% lower at the origin than predicted by the above methods and significantly higher
at distances greater than 5 mm from the source. While these results have shown
improved agreement with experiment, a systematic error in the energy-loss straggling
algorithm has been revealed [15].
More important than this inaccuracy is the fact that the point kernel method
is applicable only to homogeneous media, i.e., homogeneous with respect to both
elemental composition and density. For beta-particle dosimetry in heterogeneous
media (e.g., synovial joints), other approaches must be used, especially if doses to
other, "non-target," tissues are of interest. In radiation synovectomy, absorbed doses
to bone and articular cartilage are particularly of interest.
Other approaches
Other methods for evaluating beta dose distributions in radiation synovectomy are
available. These include direct measurements in humans, which often can be difficult
to obtain (see Chapter 5), and extrapolation from measured data in animals, phan-
toms, and cadavers. Other mathematical methods, e.g., the Monte Carlo method,
also can be used. The approach taken in this thesis was to evaluate beta-particle
dosimetry in radiation synovectomy 3 different ways.
In Chapter 4, Monte Carlo estimates of beta-particle dosimetry in radiation syn-
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ovectomy are presented. And in Chapter 5, experiments aimed at measuring absorbed
dose distributions in joint phantoms and the knees of fresh, human cadavers are de-
scribed.
2.4.3 What thickness of synovium should be removed?
An unanswered question in radiation synovectomy is what thickness of synovium
should be removed in order to arrest progression of rheumatoid arthritis and provide
patients with symptomatic relief of the disease. For the most part, current treatments
using low-energy beta-emitters or surgery can be described as attempting to remove
the entire synovial membrane. Existing data suggest however, that removal of only
the surface layer of lining cells may be sufficient (see Chapter 6). Because it is the
lining cells which are responsible for secreting high concentrations of proinflammatory
cytokines thought to play a central role in progressive bone and articular cartilage
degradation, it is hypothesized that removing the lining cells alone would eliminate
the source of the cytokines, slow the progressive destruction of bone and cartilage,
and thereby provide patients with symptomatic relief of rheumatoid arthritis for 2 to
5 years. In Chapter 6, the rationale for a series of experiments aimed at testing this
hypothesis in vitro and in vivo is presented.
The proposed approach is to selectively irradiate and kill either the lining cells
alone or the entire synovium using the °'B(n,a) nuclear reaction. This reaction has
been chosen specifically because the range of the high-LET particles emitted is very
short, on the order of 10 pm. As a consequence, the resulting radiation damage is
very cell-specific, restricted only to boronated cells and their nearest neighbors. While
these experiments have not been attempted in this thesis, preliminary studies of 10B
uptake in excised samples of live, human rheumatoid synovium were completed and
are described in Chapter 7.
2.5 Conclusion
Rheumatoid arthritis is a progressive, autoimmune disease characterized by recurrent
swollen, inflamed, and painful joints [23]. While the precise cause of rheumatoid
arthritis remains uncertain, it is known to begin as a persistent inflammation of
the synovium. If left untreated, the inflammation eventually leads to deformation,
disability, and complete loss of joint structure and function.
Traditional treatments for rheumatoid arthritis generally are aimed at relieving
the inflammation, both to slow progression of the disease and to provide patients
with relief of pain, swelling, and stiffness [21]. Most patients respond to the conven-
tional forms of treatment. For those who prove unresponsive, however, alternatives
are needed. Radiation synovectomy has been developed as a quick, effective, low-cost
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means of treating these patients. The procedure consists of the injection of a short-
lived, low-energy beta-emitting radionuclide into the affected joint where it makes
direct contact with the rheumatoid synovium. Provided the amount of radioactivity
injected is sufficient to deliver a therapeutic radiation dose to the tissue, it will be
killed. At the same time, one wants to ensure that other, healthy, joint components lo-
cated nearby (e.g., bone and articular cartilage) are not subjected to an unacceptable
radiation hazard. It is for these, and other, reasons that the dosimetry in radiation
synovectomy is of interest.
In Chapter 4, theoretical estimates of the dosimetry obtained using Monte Carlo
radiation transport simulation in a mathematical model of the synovial joint are
presented. And in Chapter 5, these Monte Carlo estimates are compared with experi-
mental data measured in joint phantoms and the knees of cadavers using radiachromic
film dosimeters and reactor-produced radionuclides. Before the dosimetry in radia-
tion synovectomy is addressed, however, the thesis continues with a discussion of
the approach used to generate the theoretical estimates, namely, the Monte Carlo
simulation of electron transport in absorbing media.
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Chapter 3
EGS4 Monte Carlo Transport of
Electrons
3.1 Introduction
In this chapter, the EGS4 Monte Carlo transport of electrons is described. EGS4 is the
Monte Carlo computer code used in this thesis to evaluate beta dose distributions
in a mathematical model of the treated joint. A complete description of the code's
approach to electron transport simulation is presented. Particular emphasis is given
to the code's approach to low-energy electron transport simulation (kinetic energy
below 2 MeV) since it is the dosimetry of low-energy beta-emitting radionuclides
that is of interest in radiation synovectomy (see Section 2.4.1).
The chapter begins with general discussions of the Monte Carlo method itself and
the mathematical tool used in all Monte Carlo calculations to solve a wide variety
of problems, namely the sampling of random variables. Then the condensed history
method of electron transport is reviewed. Condensed history transport has been
developed to avoid direct simulation of the exceedingly large number of interactions
that electrons undergo while slowing down in an absorbing medium. To reduce the
number of computations required, the cumulative effects that multiple interactions
have on electrons are simulated instead. The approaches used in EGS4 to estimate
the cumulative effects that multiple scattering and continuous energy loss have on
transported electrons are described. Finally, the chapter concludes with discussions
of the code's approaches to the production of secondary particles, the handling of
boundaries, and the scoring of deposited energy.
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3.2 Monte Carlo method
The Monte Carlo method is a powerful and versatile tool useful for solving problems
that are difficult or impossible to adequately solve using other mathematical tech-
niques [49, 50, 51]. While the method now is used in a wide variety of applications, it
originally was developed to solve neutron and photon radiation transport problems,
and it is fair to say that it is in the field of radiation transport simulation that the
method has made it greatest impact [51]. For the purposes of presenting an intro-
duction to the method, the approach taken here thus is to restrict treatment of the
method to its application in radiation transport simulation.
The basic form of the Monte Carlo method is as follows: using a computer, one
conducts a radiation transport "experiment" by simulating the actual physical pro-
cesses that govern the real particle's behavior [51]. The approach is to create a series
of life histories of the source particles by using random sampling techniques to sam-
ple the probability laws that describe the real particle's behavior. Step by step, each
particle is tracked through the simulation geometry until it can no longer contribute
useful information to the problem at hand. Then, tracking of the current particle is
terminated, and a "new" particle is generated from within the radiation source.
For example, suppose it is of interest to predict the probability that a photon
emitted from a given radiation source region is absorbed in a particular target volume.
In this instance, the principal aim of following the life histories is to count, or score,
the number of photons that terminate in the specified volume. Then after all the
photons have been processed, the score is divided by the total number of source
particles initiated, yielding an estimate of the probability in question based on the
average behavior of the transported photons. These two concepts are key features
of the method: (1) determining each transported photon's contribution to the score,
and (2) analyzing the accumulated data to obtain a description of the average particle
behavior in the system of interest.
Since the Monte Carlo method is based on statistical concepts, the answers it
provides are not unique. Rather, they are statistical in nature and subject to the laws
of chance. This aspect of Monte Carlo is a drawback, but not a fatal one since one
can determine how precise the answer is, and obtain more precise answers, if desired,
by conducting more experiments. The degree of precision is inversely proportional to
the square of the total number of experiments, or life histories.
3.2.1 Sampling random variables
As described above, the life history of a particle is constructed from a knowledge
of its path through the system of interest. The particle originates from some point
within the source with a known direction and energy. Then it has a free flight until
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it collides with an atom of the absorbing medium. The collision could result in the
absorption of the particle and the immediate termination of its history. Or it could
result in a scattering interaction, in which case transport of the particle continues
with a new direction and a change of energy. The change of direction and energy is
a statistical process, i.e., there is not a unique direction and energy that results after
scattering. Rather, there is a distribution of probable outcomes for each of these two
variables. To choose an outcome during simulation, the Monte Carlo method relies
on the sampling of known probability density functions that describe the likelihood of
occurrence of each of the possible outcomes.
The sampling of a probability density function can be described as picking a
sequence of values (i.e., "random variables") which, when taken together, obey the
given function. As is shown below, the problem of sampling at random from an
arbitrary probability density function can be conveniently reduced to the problem of
choosing numbers at random from the rectangular distribution, i.e., numbers which
are uniformly distributed on the interval (0,1). Numbers chosen from the rectangular
distribution are called random numbers ~. Two procedures for using random numbers
to sample random variables is described next.
Probability density functions
Consider an arbitrary probability density function f(z) defined such that the proba-
bility that x takes a value between xl and x2 is given by:
21 <X <2=1 f(x)dx. (3.1)
As shown in Figure 3-1, it is assumed that z may take any value between the limits
a and b, either of which may be minus or plus infinity, respectively. Corresponding
to f (x), there is a cumulative probability distribution F(x) defined by:
F() j f(')dx'. (3.2)
The probability that the randomly selected value of z is less than xl, P{x < zl}, is
thus given by F(xl). The function F(x) can be said to be monotonically increasing
with x if f(z) is a properly normalized probability density function between a and b,
with F(a) = 0 and F(b) = 1.
Sampling methods
Direct sampling method. A number of computer algorithms are available for
generating a large number of random numbers ~ uniformly distributed between 0 and
N
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Figure 3-1: Graph of a probability density function, above, and its corresponding
cumulative density function, below.
LS Johnson|IMIT Nuclear Engineering Dept.
f(x)
F(x)
dx
0 b
x
Chapter 3. EGS4 Monte Carlo Transport of Electrons 41
1 [52, 53, 50]. The procedure to use these random numbers to directly sample
random values of the variable x then is accomplished by the following algorithm:
1. select a random number f between 0 and 1
2. set F(x) = , and calculate x = F-'(~).
As an example, consider a photon moving away from a given interaction point
in a certain direction through a medium of constant interaction properties (i.e., con-
stant i) [50]. The physical law governing the distance to the next interaction is the
exponential probability law. That is, the probability that no interaction occurs for a
photon travelling a distance x is e- , where p is the total linear attenuation coeffi-
cient, and jte-ddzx is the probability that an interaction occurs in the distance x to
x + dz. The cumulative probability distribution is:
F(x) = j ie-''dzx' 1 - e'd. (3.3)
A random sample zi is obtained by generating a random number (i, (0 < (i < 1),
and solving the equation (i = 1 - e- ' for xi:
i= - n( ). (3.4)
Rejection sampling technique. The direct method presents difficulties if the
probability density function f(z) cannot be integrated to obtain F(x) or if F-'(f)
is difficult to obtain analytically. Alternate sampling methods then are needed. One
widely-used alternate method is the rejection sampling technique.
Consider two probability density functions f(z) and g(z), where f(z) is assumed
to be difficult to work with and g(x) is assumed to be similar but simpler, as shown
in Figure 3-2. The latter function is taken to have an easily obtainable cumulative
distribution function G(z), which can be inverted to yield G-l'(). Note that:
F() = j h(x')g(x')dz', (3.5)
where the ratio h(x) is defined by:
h(x) f( ) (3.6)
Now, if g(x) represents a close approximation to f(x), h(x) remains close to unity.
Regardless, it can be required that g(x) be chosen so that h(x) does not exceed some
maximum bounding value h,,m in the interval a to b.
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Figure 3-2: Graphs of a difficult probability density function f(z) and an easier prob-
ability density function g(z) which approximates f(z). The ratio h(x) = g(x)/f(z)
is plotted in the lower figure. Here h,a is any finite upper bound for h(x).
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The rejection technique then proceeds as follows:
1. select a random number (i between 0 and 1
2. calculate a tentative value of x from xi = G-l(fi)
3. select another random number fi+l between 0 and 1
4. if 4i+1 > h(zi)/hma,,, then reject the value of xi and return to step 1, else accept
;i.
It is through the use of these and other sampling methods that Monte Carlo can
be used to deduce the average behavior of all the particles in a particular system by
sampling at random the behavior of some.
3.3 EGS4 code
Developed in 1978 at the Stanford Linear Accelerator Center (Stanford, CA), EGS4
(Electron-Gamma Shower, Version 4) is one of a few widely-used Monte Carlo codes
capable of simulating electron and photon transport through materials [54]. It orig-
inally was written to study high-energy electromagnetic cascade showers, such as
those generated at accelerator facilities, but in recent years has undergone a number
of revisions to extend its useful range to include lower energies[54].
Other Monte Carlo electron transport codes also are available in the public do-
main. These include the ETRAN (Electron TRANsport) [55] and ITS (Integrated Tiger
Series) codes [56]. Important differences between EGS4 and these two codes include
their approaches to the simulation of multiple scattering (see Section 3.4.3), the cre-
ation of secondary particles (see Section 3.5), and the handling of boundaries (see Sec-
tion 3.6) [57]. For example, the ETRAN and ITS codes use the Goudsmit-Saunderson
theory of multiple scattering [58] in their approaches to electron transport simula-
tion, whereas the multiple scattering theory of Moliere [59, 60] is used in EGS4. The
Moliere theory has been derived using a small angle approximation (see Section 3.4.3);
the Goudsmit-Saunderson theory has not. While it is generally held that, as a con-
sequence, the Goudsmit-Saunderson theory is more accurate, Bethe has shown that
with some modification of the Moliere formalism, results of the two theories are nearly
equivalent [61].
Compared to the other codes, EGS4 has the advantage of having a high degree
of flexibility in its operation. To run the code, users must write their own coding
of the simulation geometry and algorithms responsible for scoring any quantities of
interest, e.g., the number of photons which terminate in a particular target volume.
The EGS4 code package itself is equipped to simulate only the physics of electron and
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photon transport through materials, i.e., it does not set up the simulation geometry
or tabulate a standard collection of output. As a consequence, the code can be
customized for use in a wide variety of applications. The ETRAN code, on the other
hand, while easier to use, has been described as being virtually impossible to adapt
[57].
Installed and operational in the Whitaker College Biomedical Imaging and Com-
putation Laboratory at MIT (Cambridge, MA), EGS4 is the code used here to com-
plete Monte Carlo simulations of radiation transport in a mathematical model of the
rheumatoid joint (see Chapter 4). Beta-particles (electrons) "emitted" from within
the model's radiation source region were transported through the model by the code,
and deposited energy was scored. In the remainder of this chapter, the code's ap-
proach to electron transport simulation is presented.
3.4 Condensed History Electron Transport
In Monte Carlo radiation transport simulation, particle tracks are generated by sim-
ulating the random nature of individual particle interactions with the medium. To
carry out the simulation, all one needs are complete mathematical descriptions of the
probability relationships which govern: the distance from one interaction point to the
next; the choice of an interaction type at each interaction point; if the interaction is
of a scattering type, the choice of a new energy and a new direction; and the possible
production of additional particles. With this information, the entire life history of
a particles, from the time it leaves its source to the time it is absorbed or passes
out of the system, can be simulated directly. And in the Monte Carlo simulation of
neutron and photon transport, where the total number of interactions each particle
experiences is relatively small, this is an accurate description of what occurs. For
example, not more than 30 Compton scatterings are likely to occur in the reduction
of a photon's energy from 5 MeV to 50 keV [50].
In the case of electron transport, the situation is more complicated. Since electrons
can suffer thousands of collisions and lose only a fraction of their incident energy, di-
rect simulation of every interaction event would be extremely time-consuming. When
electrons are scattered through gold, for instance, a typical electron can be expected
to experience more than 100,000 collisions in slowing down from 50 to 20 keV [62]! For
this reason, direct simulation of every interaction is not considered a viable method
in the majority of electron transport problems. The condensed history method was
developed as an alternative.
Described by Berger in his classic review of Monte Carlo charged particle transport
[62], the approach is to simulate the cumulative effects that multiple interactions have
on a transported electron's energy, location, and direction. The electron's walk is
idealized as a zig-zag path, consisting of free flights interrupted by sudden collisions
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in which its energy and direction are changed. Since each free flight, or step, in a
condensed history random walk can represent hundreds of individual interactions,
the method is hundreds of times faster than direct simulation. Energy and direction
probability density functions for multiscattered electrons are used to determine the
electron's state at the end of each step.
According to Berger the condensed history method can be classified in two pro-
cedures:
Class I. The simpler of the two, it relies entirely on the grouping of all interactions.
Class II. In a more realistic approach, this procedure relies only on the grouping
of minorinteractions, i.e., those in which energy losses or deflections are small. Occa-
sional major events, or 'catastrophic' collisions, in which energy losses or deflections
are very large, are treated separately by conventional random sampling according to
the single-scattering cross sections. EGS4 uses the Class II approach in an electron
transport logic which is summarized in Section 3.4.2.
3.4.1 Transport step sizes
Transport step size can be defined as the distance travelled, or energy lost, between
two points of catastrophic interaction (see below). In a condensed history random
walk, transport step sizes are chosen according to conflicting requirements. On one
hand, the steps should be long enough so that: (1) the number of collisions per step is
sufficiently large to justify the use of probability density functions for multiscattered
electrons (see Section 3.4.3) and (2) the number of steps per electron is sufficiently
small that a large number of walks can be simulated in a reasonable period of time.
On the other hand, the steps should be short enough so that: (1) for the most part, the
electron transport takes place as if in an infinite medium and (2) the average energy
loss and angular deflection per step are kept small. When these last two conditions
are not satisfied, the assumptions used to derive energy and direction probability
density functions for multiscattered electrons become invalid.
In EGS4, the process of transport step size selection begins with the electron's total
(angle integrated) cross section Ut which is dependent on both the electron's kinetic
energy and the medium in which it is travelling. The cross section at represents
the sum of the individual contributions due to elastic Coulomb scattering off the
nucleus, inelastic scattering off atomic electrons, and bremsstrahlung production.
Threshold energies are used to distinguish major, or catastrophic, interactions from
those which are to be grouped together as minor interactions and treated as part of a
continuous energy loss process. The approach is to divide the electron's history into a
series of sections, or steps, within which no catastrophic collisions occur and in which
continuous slowing down (see Section 3.4.4) is assumed. Each step is terminated by
a catastrophic interaction.
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The threshold energies used in EGS4 are given by the variables AE, for electrons,
and AP, for photons. An interaction, for instance, which produces a knock-on electron
having a total energy greater than or equal to AE is considered to be a major event and
is directly included in the simulation. Interactions resulting in a transfer of energy
below the threshold, on the other hand, are considered to be minor and grouped
together as part of the 'continuous' process. Minor interactions primarily include weak
interactions with atomic electrons (excitations and ionizations), multiple Coulomb
scattering off nuclei, and the production of soft bremsstrahlung, i.e., bremsstrahlung
photons with energy less than AP.
The above considerations complicate electron transport in several ways. The
introduction of continuous energy loss, for instance, causes the simulated electron's
total cross section ot to vary along its path, as it loses energy. In addition, the
path of the simulated electron undergoing continuous energy loss between points of
catastrophic interaction is assumed to remain straight, whereas it is not straight in
reality.
To account for a change in cross section along the electron's path, the following
trick is used in EGS4. An additional, fictitious interaction is introduced which results
in straight-ahead scattering, i.e., no interaction at all. It is assumed that the magni-
tude of the cross section for this fictitious interaction ofice is such that the total cross
section t,,,al remains constant along the path, that is:
0t,,eal(ZO) = at,,.al(X) + rfict(X) = Ot,fict(z), (3.7)
where z0 and 2 are the electron's initial and final positions, respectively.
The transport step size, i.e., the distance to the next catastrophic interaction,
is then selected by sampling an equation similar to Eqn. 3.4, where A, the photon
attenuation coefficient, has been replaced by l/Afia, where Afia is the electron's
fictitious mean free path, given by the relation:
M
= NApOt,ict' (3.8)
where M is the molecular weight of the medium, p is its density, NA is Avogadro's
number, and t,fiet is the electron's total, fictitious cross section.
After the electron is transported to the point of interaction, a random number is
generated and compared to the ratio Gat,real(z)/rt,,eal(Zo). If the random number is
larger than the ratio, then the interaction is considered to be fictitious, and trans-
port continues from that point without interaction. Otherwise, the interaction is
considered to be real and handled as described later.
This trick can be shown to work correctly as long as the total cross section de-
creases with decreasing energy. For very low values of AE however, e.g., AE < 580 keV
I
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electron
major event
resulting in
knock-on electron
which is tracked
separately
Figure 3-3: Typical electron track as simulated by EGS4. The electron's path is
broken into a number of small multiple scattering substeps. Along each substep, the
electron is assumed to travel in a straight line. At each substep's end, changes in
the electron's energy and direction due to sub-threshold interactions are determined
using probability density functions for multiscattered electrons. When a point of
catastrophic interaction is reached, it is treated separately by conventional random
sampling according to the single-scattering cross sections.
total energy (70 keV kinetic energy) in low-Z materials, this is not the case. As a
consequence, a systematic error is introduced in low-energy, low-Z problems because
the number of catastrophic interactions is underestimated [63]. The effect is usually
small however, leading to, at most, a 4% error in an electron's total energy loss for a
typical worst case situation [63].
To account for the fact that the simulated electron's straight-line path between
catastrophic interactions does not reflect that of reality, multiple scattering theory is
used to divide the path from one interaction to the next into a number of smaller
multiple scattering "substeps," as shown in Figure 3-3. Along each substep, the
electron is assumed to travel in a straight line. At each substep's end, change in
the electron's direction due to sub-threshold interaction events is determined using
the multiple scattering theory of Moliere [59, 60] (see Section 3.4.3); energy loss is
determined using the continuous slowing down approximation (see Section 3.4.4).
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3.4.2 Electron transport logic
Figure 3-4 is a schematic flow chart showing the essential features of the electron
transport logic used in EGS4. To begin, imagine that an electron has been "emitted"
at some point within the source region of a given radiation transport problem, and
its initial parameters (i.e., energy, position, direction, etc.) are available at the top of
the EGS4 particle parameter stack. The electron transport routine ELECTR reads these
parameters and uses them to determine whether or not the electron's total energy is
large enough to authorize transport. If the electron's energy is greater than the user
determined transport cutoff energy ECUT, then ELECTR initiates transport. On the
other hand, if it is not, then the electron is immediately discarded, meaning that the
EGS4 scoring routines are informed that the current particle is being removed from the
transport stack (see Section 3.6), and another electron is "generated" for simulation.
Assuming that the original electron's energy is large enough to initiate transport,
ELECTR determines: (1) the distance to the next point of major, or catastrophic,
interaction as described in Section 3.4.1, (2) the maximum multiple scattering step
size as described in Section 3.4.3, and (3) the straight-line distance in the current
direction to the nearest boundary. The electron is then transported the shorter of
the three distances. At the end of the step, the net angular deflection and energy
loss resulting from subthreshold interaction events are sampled using the multiple
scattering theory of Moliere (see Section 3.4.3) and calculated stopping power data
(see Section 3.4.4), and the electron's direction and energy are adjusted accordingly.
Lost energy is deposited in the current region. The term region is used to describe
any of the various scoring volumes which define a simulation geometry.
If, as a result of this transport step, the electron has reached the nearest boundary,
then it is handled as described in Section 3.6. On the other hand, if the electron
has not reached a boundary, its energy (now reduced due to continuous energy loss
occurring along the step) is tested once again by ELECTR to determine whether or not
it has fallen below the cutoff. If the energy has fallen below the cutoff, the electron
is discarded and its energy is deposited in the current region. If not, the simulation
continues and ELECTR must determine whether or not a point of major interaction
has been reached. If a point of major interaction has not been reached, then a new
multiple scattering step is simulated. In most electron-transport simulations, this
innermost loop undergoes the heaviest use since many multiple scattering steps often
occur between points of catastrophic interaction. On the other hand, if a point of
major interaction has been reached, then the type of interaction is chosen and the
relevant physical processes are simulated. Parameters for secondary particles (i.e.,
knock-on electrons or bremsstrahlung photons) which result are stored on the particle
stack for subsequent transport simulation. Once transport of the primary particle is
complete, transport of any secondaries is initiated, one particle at a time. A typical
electron track as simulated by EGS4 is shown in Figure 3-3.
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Yes
Is stack empty?
A
T iNo tIs energy > cutoff and
Terminate transport < is electron in geometry?
A
Yes
Determine distance to next major interaction, d
Determine straight-ahead distance to nearest boundary, b,
and select multiple scattering substep size, t
Transport distance L where L = min (d,b,t)
Determine deflection angle and change direction
Yes
(
Has electron left geometry
or is energy < cutoff?
No
Has a point of discrete
interaction been reached?
)
No
K'~
Yes
d=d- t
Figure 3-4: Flow chart describing the electron-transport logic used in EGS4.
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3.4.3 Multiple scattering
In reality, a single multiple scattering substep is characterized by the length t of
curved path an electron takes in moving from its starting point a to an end point
b, as shown in Figure 3-5. Associated with the substep are the projected distance
s of deflection in the original direction and the projected distance p of deflection in
the lateral direction. In EGS4 the lateral deflection occurring along the course of the
substep is ignored, and the multiply-scattered electron is transported a distance 
in the original direction only. At the end of the substep, the angular deflection 0
from the original direction is sampled using the Moliere theory of multiple scattering
[59, 60], and the electron's direction is adjusted accordingly. The scattering angle 6
is dependent on the transport material, the length of curved path t, and the electron
energy E.
It is important to note that, while ignoring the lateral deflection may introduce
problems for electrons allowed by some codes to take large transport steps, in EGS4 this
problem is avoided by breaking the transport history into a number of small multiple
scattering substeps and deflecting the electron at the end of each substep. As a result,
lateral transport of the electron is effectively accomplished [54, 64]. Most electron
transport codes incorporate this approach of using small step sizes to overcome the
lack of direct lateral transport simulation [64].
The Moliere theory of multiple scattering can be described beginning with the
following parameters:
lo = bt/,3 2, (3.9)
X% = xcctlE2I 4 , (3.10)
where bc and Xcc are constants that depend only on the material in which the transport
takes place, 8, is the ratio of the electron's speed to the speed of light, E is the
electron's total energy, and t is the total curved pathlength of the electron substep.
The parameter fl can be interpreted as the number of atoms that participate in
the multiple scattering. Moliere considered his theory valid for o > 20 atomic
interactions [59, 60].
The Moliere multiple scattering angle distribution is given by the following:
f(O)Od = f,(O)Odq, (3.11)
where 6 is the scattering angle and 4 is the reduced angle. They are related by:
4 = I/x.B 1 /2, (3.12)
where B - In B = b = In l 0 . From this definition of B and b, one sees that there is a
lower limit, Oo = 2.718 atomic interactions, below which Moliere's formalism breaks
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" e
final
direction
initial direction
Figure 3-5: A single multiple scattering substep of a real electron. In EGS4 only the
straight-ahead portion of the substep is simulated; the lateral deflection is ignored.
It is important to note, however, that by breaking the transport history into small
multiple scattering substeps and deflecting the electron at the end of each substep,
lateral transport of the electron is effectively accomplished.
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down mathematically. It is interesting to note that the theory often is used in EGS4
below this limit and still produces reliable answers [54, 64].
The angular distribution can be expanded in a power series in 1/B:
ft( 0 f) ()f(2+(0 ++ B B (3.13)
where
f(o)(0) = 2e- 2 (3.14)
and f() and f( 2) are given by Bethe [61]. The expansion is strictly valid only for
B > 1 (o > 2.718 atomic interactions). This restriction essentially imposes an
absolute lower limit on the substep size. Using the criterion fo = 2.718, one sees
from Eqn. 3.9 that the minimum substep size is given by:
tmin = e 2/b 0. (3.15)
For water, ti,, is approximately 4 x 10- 4 cm over a wide range of energies. For
other materials, the relative dependence is approximately governed by a p/,l 2Z,,
factor, where p is the density and Zag is the average atomic number of the transport
material. This is an exceedingly small distance for many practical purposes.
In EGS4, the default value for t,i, is chosen using fo = 1 atomic interaction,
not 2.718 as assumed by Bethe. Below f = 2.718 an extrapolation is performed to
relate B and since the theory is mathematically valid only above Q = 2.718. It
is important to note that at these small substep sizes EGS4 turns off the simulation
of multiple scattering, and elastic scattering of electrons off nuclei is ignored (see
Section 3.4.5 for more on this problem).
An upper limit on the electron substep size has been derived by Bethe [61], who
has shown that Moliere's theory (initially derived as a small angle theory) and the
theory of Goudsmit and Saunderson [58] (which does not rely on a small angle ap-
proximation) are nearly equivalent as long as the following condition is satisfied:
X(t)B(t) < 1. (3.16)
The quantity X22B can be interpreted as the mean-square scattering angle. After some
manipulation, the maximum substep size can be written as follows:
E2 4
tma = 2 (3.17)
The upper limit tma, varies in the same fashion as tin, for different materials, roughly
by a relative p/f 2Zwg factor.
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The limitations of Moliere's theory, therefore, include the following:
1. It is a multiple-scattering theory and thus many atomic collisions are assumed
to contribute to the electron's angular deflection. This assumption effectively
places a lower limit on the substep size.
2. It is based on a small-angle approximation (sin 0 0) and thus angular deflec-
tions are assumed to be small. This approximation effectively places an upper
limit on the substep size.
3. It has been derived only for infinite or semi-infinite homogeneous media. Elec-
tron transport in the vicinity of material interfaces must therefore be treated
very carefully (see Section 3.6).
4. It is only an angular deflection theory. Continuous energy loss due to multiple
scattering is not included.
The principal advantage of Moliere's theory is that the multiple scattering distri-
bution is expressed as a function of the deflection angle. As a result, the distribution
is easily sampled to select multiple scattering deflections for randomly sampled path-
lengths.
3.4.4 Continuous energy loss
In EGS4 energy loss due to multiple scattering is determined using the continuous
slowing down approximation, i.e., it is assumed to equal the distance traveled t times
the stopping power S which expresses the mean energy lost by an electron per unit
length in the transport material. In other words, the statistical fluctuations of energy
losses in successive interactions are disregarded, and electrons are assumed to lose
energy along their tracks in a deterministic, continuous manner, at a rate given by
the stopping power. The losses are due primarily to weak interactions with atomic
electrons and the production of soft bremsstrahlung, i.e., bremsstrahlung photons
with energy less than AP.
The stopping power S for continuous energy loss can be separated into two com-
ponents:
S dE dE dE
S -d- = - du L cao - I oft brem, (3.18)
where dE is the mean energy lost per unit length dz.
Weak collisions. The weak collision component includes all energy losses associ-
ated with the excitation and ionization of atoms or molecules. It can be rewritten as
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the product of the amount of energy transferred in a single collision T and the differ-
ential cross section for transferring that amount of energy to an atomic electron d,
integrated over the range of energy transfers which result in sub-threshold secondary
electrons, that is:
dE dl]
-d 1 ca = TddT. (3.19)dx dT
For energy transfers on the order of atomic excitation energies, integration of the
expression is quite complicated. However when the energy transfer is large compared
to the binding energy of the target electron, it is a good approximation to treat the
collision as obeying the Moller cross section [65], which has been derived using the
assumption that the target electron is free and initially at rest.
If Ted is defined as a value of T sufficiently above the atomic excitation level but
still small compared to AE, then Eqn. 3.19 can be rewritten as:
dE cak = TdTdT + T dT. (3.20)dx Jo dT ed dT
In the first interval, binding of the atomic electrons must be taken into account,
and the M0ller cross section cannot be used. Instead, the integral can be evaluated
using the Bethe-Bloch theory of charged particle interactions [66, 67]. In the second
interval, integration over the Mzller cross section can be completed. When the two
results are combined, the resulting expression for the weak collision component of the
stopping power is as follows:
dx 2NZ lm2(+2))F(,A)
where,
_2 2 2T  +1 [ A] (3.22)F(T, ) =-l± ( AA]+ + In[( )] + - 3
and where e is the charge of an electron, m is the mass of the transported electron
and v is its velocity, N is the number of target atoms per cm3 , Z is the atomic number
of the transport material, T is kinetic energy of the transported electron in units of
rest mass, I is the mean ionization potential, A is the maximum energy transfer, and
6 is a correction factor to account for the density effect, i.e., reduction of the mean
energy loss caused by polarization of the medium. In the default version of EGS4, the
Sternheimer [68, 69] treatment of the density effect is used, but this treatment can
be overridden by interested users.
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Soft bremsstrahlung. The soft bremsstrahlung component of the stopping power,
i.e., the second term on the right-hand side of Eqn. 3.18, takes into account energy
losses due to the emission of bremsstrahlung photons with energy below the produc-
tion threshold AP. It can be rewritten as the product of the bremsstrahlung photon
energy k and the differential cross section for creating a photon of that energy d,.
integrated over the range of energies resulting in the production of sub-threshold
bremsstrahlung photons, that is:
E- I 7 soft brem ~k "= k dk. (3.23)
The bremsstrahlung cross section, differential in emitted photon energy, dEb. is
given in Section 3.5.1. Assumptions and approximations used to derive the cross
section are described there.
It is worth noting that users have the option to modify the above calculation and
normalize the bremsstrahlung cross sections used in the code so that the calculated
soft bremsstrahlung stopping power data are identical to the radiative stopping power
data for electrons given in ICR U-37 [70, 71]. The stopping powers tabulated in ICR U-
37 generally are considered to be the most accurate radiative stopping power data
available [72].
3.4.5 Subtep size restrictions
The procedure for sampling substep sizes is subject to several restrictions as described
in Section 3.4. In particular, the Moliere theory of multiple scattering places a num-
ber of limitations on the size of each substep (see Section 3.4.3). These include the
fact that its size must not exceed the maximum limit t,,,, otherwise the small an-
gle approximation used in the derivation of Moliere's theory becomes invalid [61].
Other restrictions independent of multiple scattering theory include the facts that
the substep size must not exceed the range of the electron or the distance to the next
catastrophic interaction or boundary.
Substep size restrictions have been incorporated in EGS4 to account for these
limitations. In particular, the subroutine FIXTMX has been introduced to limit the
amount of energy an electron may lose along each step or substep to a fixed fraction,
ESTEPE, of the electron's total energy. This technique is similar to the step size
algorithms used in other electron transport codes, such as ETRAN [73]. One must
ensure, however, that the physical quantity of interest is not significantly influenced
by the choice of ESTEPE. To avoid this step size dependence, users are advised to
continually decrease the size of ESTEPE until the quantity of interest is no longer
significantly affected by the changes. In EGS4 the total pathlength t per multiple
scattering substep is deduced from the straight-line pathlength a using a multiple
MIT Nuclear Engineering Dept. LS Johnson~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~I MIT Nuclear Engineering Dept. LS Johnson I
Chapter 3. EGS4 Monte Carlo Transport of Electrons 56
scattering approximation to account for curvature in the path. As smaller and smaller
substep sizes are used, the difference between t and s decreases and the accuracy of
the procedure increases. In many cases, it is this change in t as a function of s which
can lead to an ESTEPE dependence in calculated results [63].
Users also are cautioned against choosing too small a value for ESTEPE, otherwise
multiple scattering may not be simulated. This turning off of multiple scattering
can lead to remarkable artefacts in calculated results since the elastic scattering of
electrons off nuclei is ignored. Users are therefore advised to monitor the number
of times multiple scattering is not simulated. The EGS4 variable NOSCAT has been
included for this purpose. Each time multiple scattering is turned off, the variable
is incremented by 1. It is worth noting that this turning off of multiple scattering
typically is done first for the lowest energy electrons. As a result, the fraction of
NOSCAT substeps can be relatively large (on the order of 1%) before the calculated
results are affected [63].
3.5 Major Interactions
When a point of major, or catastrophic, interaction is reached, EGS4 must choose
which one of the competing processes is to occur. The probability that a given
process occurs is proportional to its cross section. For instance, suppose that at a
point of major interaction, there are j possible types of interaction numbered from 1
to n, such that the total interaction cross section ot is given by:
n
at = aj, (3.24)
j=1
where aj is the cross section for the jth type of interaction.
The number i of the chosen process can be said to be a random variable having
the cumulative distribution function:
F(i) = aj (3.25)
at 
The interaction number i is then determined by choosing a random number , ( <
f < 1), and finding the i which satisfies the relation:
F(i - 1) < < F(i). (3.26)
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3.5.1 Bremsstrahlung production
In EGS4 bremsstrahlung production refers to the creation of secondary photons with
energy above the user-supplied threshold AP by electrons undergoing acceleration in
the electric field of an atom. Two types of interaction are actually possible. The
predominant mode of interaction is a two-body process in which the electron is accel-
erated in the electric field of a nucleus. The second interaction is a three-body process
in which the electron is accelerated in the field of an atomic electron, setting three bod-
ies in motion: the initial electron, a recoiling atomic electron, and the bremsstrahlung
photon. In EGS4 the three-body process is not included directly in the simulation.
Rather, it is included indirectly as a correction factor to the bremsstrahlung cross
section for the two-body process.
The theory used in EGS4 for bremsstrahlung production in the electric field of a
nucleus was initially developed by Bethe and Heitler [74]. Derived for the screened
nucleus using the first Born approximation, the cross section, differential in emitted
photon energy, is written as follows:
dob,,,,(Z, Eo, k) A'(Z, Eo)roaZ{Z + f(Z)}
dk k
x { (1 + (E/Eo)2) [,(k6)- In Z - (4fc(Z) if E > 50 MeV)] (3.27)
E [ 42(6)- In Z - (4fc(Z) if Eo > 50 MeV)j ,
where k is the emitted photon energy, Z is the atomic number of the transport
material, Eo is the electron energy before interaction, E is the electron energy after
interaction, A'(Z, Eo) is an empirical correction factor described below, r is the
classical electron radius (2.82x10 -' 3 cm), a is the fine-structure constant (1/137),
(Z) is a correction factor to account for the three-body process, f"(Z) is a theoretical
Coulomb correction valid only at high energies (>50 MeV) [75], and +1(6) and 02(6)
are screening functions. Using the Thomas-Fermi form factors, 1(6) and k2(6) have
been evaluated by Butcher and Messel [76] and are given by:
+1(6) = (20.867 - 3.2426 + 0.62562 if 6 < 1, otherwise 21.12 - 4.1841n(6 + 0.952))
(3.28)
and
02(6) = (20.029 - 19306 - 0.08662 if < 1, otherwise 21.12 - 4.1841n(6 + 0.952)),
(3.29)
where
kmoc2
6 = 136Z- 1/3 EoE (3.30)
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Bethe obtained the bremsstrahlung cross section in Eqn. 3.27 using a high-energy
approximation, i.e., assuming that the energy of the transported electron both before
and after the bremsstrahlung event is large compared to moc2. At lower energies,
i.e., for Eo < 50 MeV, an empirical correction factor A'(Z, Eo) has been added to the
high-energy cross section to get improved agreement with experiment. In the default
version of EGS4, the correction factor is crudely evaluated using very sketchy data
from curves found in Koch and Motz [77]. However, users now have the option [71]
of replacing these old A'(Z, Eo) values by a more extensive set that is based on data
presented in ICRU-37 [70]. At Eo > 50 MeV, A'(Z, Eo) = 1.
It should be noted that only the energy distribution of newly created bremsstrahlung
photons is determined using the cross section in Eqn. 3.27. The angular distribution
has been treated separately. In the default version of EGS4, the algorithm currently
employed is to set all newly created photons in motion at a fixed angle with respect to
the transported electron direction. This fixed angle has the form 0 = 1/E 0, where 0
is the scattering angle (radians) and Eo is the total energy of the transported electron
in units of moc2 . The angle represents an estimate of the expected average scattering
angle.
Realizing that the angular sampling may be oversimplified for some applications,
Bielajew et al. have written an improved angular sampling routine [78]. It is based
on the following cross section, differential in photon energy and angle, from Koch and
Motz [77]:
d2br,, 4Z2 ro dk f 16y2E (Eo + E)2
dkdO = 137 k yd (y2 + 1)4 Eo (y2 + 1)2 EO2E2 +E 2 4y2 E
+ + x)=r0 (Y + E) 7 In M(y, (3.31)(y2 + 1)2EO2 (y2 + 1)4Eo] } (3.31)
where k is the energy of the emitted photon, is the angle between the outgoing
photon and the incoming electron directions (radians), Z is the atomic number of the
transport material, ro is the classical electron radius, Eo and E are the initial and
final energies of the transported electron, y = EoO, and
M(y) 2EoE + 111(y + 1) (3.32)
The suitability of Eqn. 3.31 for use over a wide range of energies in high and low
Z materials remains to be proven. Essential approximations used to derive the cross
section include: (1) an approximate screening potential, (2) the Born approximation,
(3) a small angle approximation, and (4) an extreme relativistic assumption. Koch
and Motz present encouraging data that demonstrate agreement between experiment
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and Eqn. 3.31 for 4.5 MeV electrons on Au [77]. Although use of the equation violates
all 4 constraints in the cases they showed, the deviation was at worst 10% (at large
angles) and usually much better [77].
Other important approximations used to model the production of bremsstrahlung
in EGS4 include the following:
1. The electron is not deflected by the bremsstrahlung interaction.
2. Electrons and positrons are treated equally with respect to bremsstrahlung pro-
duction. Actually, at low energies, positron bremsstrahlung is suppressed rela-
tive to electron bremsstrahlung.
3. Electrons are not allowed to convert all their kinetic energy into bremsstrahlung.
3.5.2 Knock-on electron production
The production of knock-on electrons, in EGS4, refers to the creation of secondary
electrons with energy above the user-supplied threshold AE. The knock-on electrons
result from collisions with atomic electrons in which the energy transfer is sufficient to
eject the target electron the atom. If the ejected electron energy is below AE, then it
is not "created," and the collision is treated instead as part of the continuous energy
loss process. However, if the ejected electron energy is above the threshold, then the
secondary particle is created and the energy and direction of the primary electron are
adjusted accordingly. For the primary electron, the final energy Ef is given by:
Ef = Eo- tS - Ek k-on, (3.33)
where E 0 is the initial energy, t is the length of curved path taken by the electron,
S is the energy-averaged stopping power which accounts for energy lost during the
step to sub-threshold events, and Ek,,ock- is the energy transferred to the knock-on
electron.
The knock-on collision is treated as obeying the Moller cross section [65], which
has been derived on the assumption that the target electron is free and initially at
rest. When the energy transfer is large compared to the binding energy of the atomic
electron, this is a good approximation. The differential cross section is given by:
dEnMalc= 2ir 2 NZ [C1 +-1(- -C 2 + -(-_ C2 (3.34)dEknok-on mva(E,it, - mca) 2 6 e' e 
where e is the charge of an electron, m is the mass of the transported electron, v is
its velocity, C1 = [(y - 1)/7]2 and C2 = (27 - 1)/72 with 7 equal to Eo/m, and where
, is the fraction of the primary electron kinetic energy lost to the knock-on electron,
and e' is the fraction of primary electron kinetic energy remaining.
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By convention, the slower of the two electrons after the collision is considered to
be the secondary electron. The minimum and maximum energies it may be created
with are AE and (To/2 + m), respectively. The total discrete Moller cross section is
then obtained as follows:
Moller (To/2+m) d=Eoer dEk-od (3.35)
The scattering angles of both electrons are determined using conservation of energy
and momentum relations.
3.6 Boundary Crossing and Scoring
At this point, it is worth repeating that users of EGS4 are responsible for writing
their own coding of boundary crossing and scoring algorithms. As described in Sec-
tion 3.3, the code itself is equipped to simulate only the physics of electron and photon
transport, i.e., it does not set up the simulation geometry or tabulate a standard col-
lection of output data. The reader therefore is advised that the following discussion
on boundary crossing and scoring is restricted to the L-EGS user code [79] operational
in the Whitaker College Biomedical Imaging and Computation Laboratory at MIT
(Cambridge, MA) and may not apply to other user codes.
With that said, boundaries in EGS4 are used to define the interfaces between
regions composed of different materials and the interfaces between scoring regions,
even if they are made of the same material. As a result, boundaries are encountered
in EGS4 in both homogeneous and heterogeneous media.
As described in Section 3.4.2, a single electron transport step size is chosen as
the minimum of: (1) the distance d to the next catastrophic interaction (randomly
sampled using the total cross section ot), (2) the maximum multiple scattering substep
size (limited by the Moliere theory to be less than tma and possibly by the user to be
less than ESTEPE), and (3) the straight-line distance in the current direction to the
nearest boundary.
Given that the minimum distance is that to the next catastrophic interaction or
that limited by either t,,, or ESTEPE, then the transport is handled as described in
Section 3.4.2. If, instead, the minimum distance is that to the nearest boundary,
then the electron is transported to the boundary and the simulation proceeds as
follows. Energy lost by the electron due to subthreshold interactions occurring along
its step to the boundary is deposited in the current region. In addition, the electron's
direction is adjusted to account for multiple scattering along the step. (It is worth
noting that this adjustment requires a multiple scattering algorithm which can be
applied-during simulation-to sample the angular deflection for any one of a range
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Monte Carlo Estimates of Beta
Dosimetry
4.1 Introduction
In general, Monte Carlo radiation transport codes provide information on particle
"histories," and users of the codes may use this information to produce any of a
wide variety of results. A particle history contains sufficient information to describe
in detail all the changes a particle undergoes while travelling through an absorbing
medium. For example, a history includes information on the energy and direction of
the particle at the end of each step in its "walk" through the simulation geometry,
as described in Chapter 3. A history also includes information on the positions at
which secondary radiations are formed and the changes they undergo while travelling
through the system. In principle, the history information can be used to address a
variety of problems that are of interest in dosimetry.
In this chapter, use of the EGS4 Monte Carlo radiation transport code to evaluate
beta dosimetry in radiation synovectomy is described. The chapter begins with a
presentation of the mathematical joint model used in the simulations and includes
discussions of various simulation parameters and the approach used to convert raw
EGS4 output to data which are of dosimetric interest. Investigations of backscatter
contributions to synovial dose and the effect of disease progression on dosimetry in
radiation synovectomy also are discussed.
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point; energy and direction probability distribution functions for multiply-scattered
electrons; and the possible production of bremsstrahlung photons and knock-on elec-
trons. With this information, the entire experience an electron undergoes from the
time it is created to the time it is absorbed or passes of the system can be simulated.
In the next Chapter, use of Monte Carlo electron transport simulation to estimate the
beta-particle dosimetry of various radionuclides of interest in radiation synovectomy
is described.
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4.2 Materials and Methods
4.2.1 . Mathematical joint model
The mathematical model developed for the Monte Carlo simulations is a planar model
of the rheumatoid joint. It is shown in Figure 4-1 along with an inset which illustrates
the juxtaposition and relative size of synovial joint tissues in the region of interest.
Dimensions in the model (e.g., thickness of articular cartilage, thickness of joint cap-
sule, etc.) were selected to correspond with those typically found in larger joints (e.g.,
the knee, shoulder, or hip) since these are the joints which have been most commonly
treated with radiation synovectomy [8]. Each of the dimensions is described below.
In the model, bone (lined at the surface with 1 mm articular cartilage) is separated
by the joint capsule from soft tissue, which represents synovium. The synovium is
sub-divided into a surface layer of lining cells and underlying sub-synovium. Distances
in the model are defined in relation to the articular cartilage-joint capsule interface.
Prior to administration of radioactivity, rheumatoid joints to be treated with
radiation synovectomy generally are aspirated of all fluid [17]. Radioactivity, held in a
liquid suspension, then is injected into the joint capsule where it makes direct contact
with inflamed synovium [1]. Phagocytic lining cells along the synovial surface quickly
absorb radioactive particulate from the capsule. Autoradiographs of the tissue lining
in knees injected with various radionuclides have shown a reasonably even distribution
of radioactivity in these cells for several days after injection [2, 3, 4]. The ends of
the articulating bony surfaces, capped with articular cartilage, do not absorb the
radioactive particulate however since the cells along these surfaces are not phagocytic
[46].
In the model, the radiation source lies uniformly distributed throughout both the
joint capsule and lining cells regions. The joint capsule was modeled as a 0.44 mm
thick slab of water between the articular cartilage and synovium. The layer of lining
cells along the synovial surface was modeled as a 0.30 mm thick slab of tissue. In
healthy synovial joints, the lining cells generally are arranged at the surface in a
layer 1 to 3 cells thick. In rheumatoid joints, their numbers are greatly increased,
occasionally reaching a thickness of 10 to 20 cells [80]. In the model, a layer 15 cells
thick is assumed. A diameter of 20 pm per cell yields a thickness of lining cells in the
model equal to 0.30 mm.
It is worth noting that, since the range of the emitted beta-particles typically
used in radiation synovectomy is so short (average range in tissue < 5 mm), it is
not necessary to model the three-dimensional structure of the entire synovial joint.
Instead, only the structures located within the range of the emitted particles (e.g.,
the first few mm of bone, the layer of articular cartilage, the joint capsule, and the
first few mm of synovium) need to be modeled. Total tissue volumes are taken into
LS JohnsonIMIT Nuclear Engineering Dept.
I
Chapter 4. Monte Carlo Estimates of Beta Dosimetry 65
al lining cells
apsule
Mathematical
Model
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Table 4.1: Elemental compositions and densities
the joint model. Adopted from ICRU-44.
Element
H
C
N
O
Na
Mg
P
S
Ca
C1
P
Bone
3.4%
15.5
4.2
43.5
0.1
0.2
10.3
0.3
22.5
1.92 g/cm 3
Art cart
9.6
9.9
2.2
74.4
0.5
2.2
0.9
0.3
1.1 g/cm 3
of the four absorbing media used in
Tissue
10.0
14.9
3.5
71.6
Joint fluid
11.1
88.9
1.0 g/cm 3 1.0 g/cm 3
account, however, in extrapolating beta dose distributions in
Monte Carlo results (see Section 4.2.5.
treated joints from the
4.2.2 Tissue cross sections
Because Monte Carlo radiation transport calculations often tend to be very time
consuming, the EGS4 code comes equipped with a preprocessor, PEGS4, which uses
theoretical (and sometimes empirical) formulas to compute numerous physical quanti-
ties, e.g., cross section data and branching ratios for each of the absorbing media [54].
The elemental compositions and densities required by PEGS4 to compute these data
for the model's tissues were adopted from ICRU-44: Tissue substitutes in radiation
dosimetry and measurement [81] and are listed in Table 4.1.
Use of the preprocessor requires the user to input values for various parameters.
All the PEGS4 data described here were prepared with the list of parameter values
shown in Table 4.2. For instance, tissue cross section data for electrons and photons
were prepared over the kinetic energy range 1 keV to 10 MeV. In addition, the flag
IAPRIM was set equal to 1, instructing the preprocessor to normalize the cross sections
for bremsstrahlung production so that the calculated radiative stopping power data
are identical to the data presented in ICRU-37 [70, 71], as described in Section 3.4.4.
The radiative stopping power data tabulated in ICR U-37 generally are considered to
be the most accurate data available [72].
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Figure 4-2: Beta spectrum for 3 2 p. Adopted from Hogan et al.
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Table 4.2: Parameter values used in PEGS4 to compute tissue cross section data.
Parameter Value used
Lower energy for electron data (AE) 1 keV
Lower energy for photon data (AP) 1 keV
Upper energy for electron data (UE) 10 MeV
Upper energy for photon data (UP) 10 MeV
IAPRIM 1
4.2.3 Radionuclide spectra
The radionuclides investigated in this work include all those listed in Table 2.3 as being
radionuclides of interest in radiation synovectomy. As mentioned in Section 2.4.1,
these 8 beta-emitters either have been used in clinical trials or are of interest due to
their favorable half-lives, emission energies, and radiochemistry.
The beta-spectral characteristics of the 8 radionuclides are well documented by
Hogan et al. [82] and are shown in Figures 4-2 through 4-9. During the Monte
Carlo simulations, initial kinetic energies of starting beta-particles (see below) were
determined by randomly sampling the appropriate spectrum. Although some of the
radionuclides decay with accompanying gamma-ray emission, the corresponding pho-
ton dose to the tissues represented in the model was not calculated. For the small
volume under investigation however, the absorbed dose due to the emitted photons
is expected to be very small compared to that due to beta particles.
4.2.4 Computer simulations
Using EGS4 and the mathematical joint model shown in Figure 4-1, beta-particle emis-
sion from within the radiation source region and subsequent transport of the emitted
particles through the joint model was simulated, one radionuclide at a time. Simu-
lation begins by choosing a starting position, direction, and energy for the emission
of a single beta-particle from the decaying radionuclide. The starting position is a
point randomly selected from the 0.74 mm thick radiation source region (0.30 mm
joint capsule region plus 0.44 mm lining cells region). The starting direction is chosen
at random over 4r space. The initial kinetic energy of the emitted beta-particle is
determined by randomly sampling the radionuclide's decay spectrum.
The emitted beta-particle then is transported through the joint model by the EGS4
code, as described in Chapter 3. During the transport simulation, the code keeps track
of the amount of energy deposited by the particle and all its secondaries in each of the
4 absorbing media: bone, articular cartilage, the fluid-filled joint capsule, and tissue
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(synovium). To increase the usefulness of the results, the 4 absorbing media were
sub-divided into 50 smaller bins. Total energy deposited by the transported particles
was tallied separately for each bin (see Section 3.6).
Deposited energy was converted to an absorbed dose factor for each bin according
to the following relation:
Fi i= A TpN' (4.1)
where Fi is the absorbed dose factor for the ith bin (cGy-cm 2/MBq-s), AEi is the
energy deposited in the bin (MeV), K is a unit conversion constant, ATi is the thickness
of the bin (cm), p is the density of the absorbing medium in the bin (g/cm3 ), and
N is the number of nuclear disintegrations, integrated over time (MBq-s). Nuclear
disintegrations which do not result in the emission of a beta-particle were taken into
account.
The outermost bins were each 0.025 cm thick, while the innermost bins generally
were 0.020 cm thick. Two exceptions are the 2 joint capsule bins which each are 0.022
cm thick and the lining cells bin which is 0.030 cm thick.
4.2.5 Dose estimates
Radiation doses throughout treated joints can be estimated as a function of time using
the absorbed dose factors described above. For any location in the joint model and
at any time t after injection, the beta dose from injected radioactivity is calculated as
the product of the cumulated activity A(t) in the source region and the bin's absorbed
dose factor Fi divided by an estimate of the joint's total synovial surface area S,yn
so that:
Di(t) = A(t)Fi (4.2)
Jsn
The cumulated activity after time t is given by:
A(t) = A(1- e-XPt), (43)
where Ao is the activity initially deposited in the source region and Ap is the injected
radionuclide's physical decay constant, given by:
In 2
P = pn 2 (4.4)
where Tp is the physical half-life of the radionuclide.
For a very long time relative to the half-life, Eqn. 4.3 reduces to A(t) = Ao . Ap,
LS JohnsoniI MIT Nuclear Engineering Dept.
I
Chapter 4. Monte Carlo Estimates of Beta Dosimetry 77
and the total radiation dose Di becomes:
AoFiD- A F (4.5)
ApSJyn
A very long time relative to the half-life, for most purposes, can be taken to mean
any time t greater than six half-lives, which for the short-lived emitters commonly
used in radiation synovectomy is on the order of 1 to 20 days.
Although leakage of radioactivity from the joint was not included in the Monte
Carlo simulations directly, accommodations for leakage can be made in the dose
estimates. For instance, to accommodate a reduction in dose due to leakage of activity
from the joint, the physical decay constant in Eqn. 4.3 can be replaced with an
effective decay constant AE given by:
AE = n2 TPTB ] ' (4.6)
where TB is the biological half-life of the radionuclide in the joint. Physically, TB rep-
resents the length of time required for one-half the radioactivity present to be removed
through leakage. The resulting equation for estimating absorbed dose distributions
in treated joints as a function of time then is given by:
D(t) = AoFi (1 - e-xBt). (4.7)
AESJyn
The activity required to deliver a prescribed synovial dose to the ith bin Di(t) (ac-
commodating leakage) can be determined by solving Eqn. 4.7 for Ao.
4.2.6 Dose rate estimates
Dose rates throughout treated joints also can be estimated using the absorbed dose
factors described above. For instance, the initial dose rate Di(0) from injected ra-
dioactivity to any location i in the joint model is calculated as:
Di(0) = AoF, (4.8)
Sasyn
And the dose rate at a later time t is given by:
D(t) = AoFii(t) = (1 - e-xAt), (4.9)
is the effective d ay constant.
where E is the effective decay constant.
I
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4.2.7 Backscatter contributions to absorbed dose
In a related investigation, the joint model was used to evaluate the contribution of
radiation backscatter to total synovial dose. Backscattered dose can be defined as the
absorbed dose deposited in the synovium resulting from radiation that is scattered
back from bone into the synovium.
To calculate the backscattered dose, the simulation was run once as described
above with bone, articular cartilage, joint capsule, and tissue (synovium) in place
and again with the bone and articular cartilage regions replaced by soft tissue, yield-
ing a more homogeneous structure. Doses in bins of the tissue-on-tissue model were
subtracted from those in corresponding bins of the tissue-on-bone model. The result-
ing backscattered dose was divided by the dose from the tissue-on-tissue simulation
to yield a percentage backscatter figure, given by:
B = Dbi - Dh, j 100%, (4.10)
where Bi is the percent increase in dose to synovium in the ith bin due to radiation
backscattered from bone, Db,i is the dose to synovium in the ith bin when the bone
and articular cartilage regions are present, and Dh,i is the dose to synovium in the
it h bin when the bone and articular cartilage have been replaced by tissue, yielding
the more homogeneous structure.
4.2.8 Effect of disease progression on dosimetry
Monte Carlo simulation also was used to evaluate the effect of disease progression on
beta dose distributions in radiation synovectomy. As with other forms of therapy, the
likelihood of clinical success has been shown to decrease as the extent of rheumatoid
arthritis progression in the joint prior to treatment increases [26]. To determine
whether the correlation can be attributed to structural changes in the joint which
result in less effective absorbed dose distributions, additional simulations were run
using models developed to represent rheumatoid joints at varying stages of disease
progression.
In all, three stages of rheumatoid arthritis progression were modeled. They are
distinguished by different volumes of fluid in the joint capsule and different numbers
of lining cells along the synovial surface, as shown in Table 4.3. The increasing joint
fluid volumes result in a thicker and thicker joint capsule, from 0.35 mm in a stage 1
joint, to 0.44 mm at stage 2, to 0.53 mm at stage 3. The increasing numbers of lining
cells result in a thicker and thicker lining cells region. Assuming a cell diameter of
20 pm, corresponding thicknesses of the lining cells regions are 0.20 mm in a stage 1
joint, 0.30 mm at stage 2, and 0.40 mm at stage 3.
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Table 4.3: Characteristics of the three stages of advancing rheumatoid arthritis used
in the computer simulations.
Stage Fluid volume Lining cells
1 4 cm3 10 cells
2 5 15
3 6 20
Table 4.4: Parameter values used in the EGS4 simulations.
Parameter Value used
Maximum energy loss per step (ESTEPE) 0.02 (2%)
Electron cutoff energy (ECUT) 10 keV
Photon cutoff energy (PCUT) 10 keV
Number of histories 100,000
IRAYL 1
4.2.9 Simulation parameters
Use of the EGS4 code requires the user to input values for various parameters. All
simulations described here were run with the list of parameters values shown in Ta-
ble 4.4.
The simulations were performed on SunSparc workstations in the Whitaker Col-
lege Biomedical Imaging and Computation Laboratory at MIT (Cambridge, MA).
For each of the 8 radionuclides investigated, 100,000 starting particles were generated
and followed to completion in the joint model. The maximum energy loss per electron
transport step (ESTEPE) was limited to 2% of the electron's total energy. As recom-
mended in Section 3.4.5, an investigation was conducted to ensure that the amount of
energy deposited in each of the scoring bins was not affected by this choice of ESTEPE.
The transport cutoff energy for both electrons (ECUT) and photons (PCUT) was 10
keV. Although photons emitted by decaying radionuclides (e.g., the 95 keV gamma-
ray emitted in 3.6% of 16 5Dy decays) were not included in the simulations, bremsstrahlung
photons were both produced and transported. The photon transport continued until:
(1) the photons left the simulation geometry, (2) they were absorbed, or (3) their en-
ergy fell below the low-energy cutoff PCUT. In addition, the flag IRAYL was set equal
to 1, instructing the code to include Rayleigh, or coherent, scattering of photons.
Typical estimates of uncertainty in the calculated values of Fi were 1-2% in the
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bins nearest (within 2 mm of) the source region and 5-10% in the bins farther (greater
than 2 mm) from the source region. The uncertainty was estimated by dividing the
total number of source particles into four equal groups. Energy deposition for each
group was scored separately. At the end of simulation, the results were used to
calculate an average absorbed dose factor and associated standard deviation for each
bin.
4.3 Results
Results are presented in Figures 4-10 through 4-17 as absorbed dose factors (cGy-
cm2 /MBq-s) versus depth in bone, articular cartilage, the joint capsule, and syn-
ovium. Analogous to the volumetric "S" factor used in MIRD calculations [83], the
absorbed dose factors also lend themselves to clinical application. For example, con-
sider the injection of 270 MBq (10 mCi) '98Au into the knee, one of the earliest
treatments reported to provide a beneficial effect in clinical trials [33]. If uniform
distribution along 250 cm2 of synovium is assumed [9], one can use Figure 4-17 and
Eqn. 4.8 to calculate that the initial dose rate to the region of lining cells along the
synovial surface is 0.055 cGy/s (200 rad/h); to the bone surface it is 0.003 cGy/s (9
rad/h). Integrating over time, the total dose to the lining cells is 18,000 cGy (from
Eqn. 4.5); to the bone surface it is 1000 cGy.
The calculation assumes that all the 198Au remains in the joint until decay. In
practice, the potential for leakage from the joint via the lymphatic system must always
be considered. Leakage however can be highly variable from joint to joint and from
patient to patient. The calculations presented here therefore should be corrected for
leakage on an individual basis. Continuing the sample calculation, Topp et al. [3]
reported that for 18 knees the extra-articular spread of 98Au at 24 h after injection
varied from as low as 1% of the injected activity to as high as 34%. These data
indicate that the biological half-life for removal of activity from the joint varied from
1700 h down to 40 h. For TB equal to 1700 h, the absorbed dose estimates remain
unchanged. For TB equal to 40 h, on the other hand, the corrected absorbed dose
estimates for the lining cells and bone surface are, respectively, 7000 cGy and 400
cGy, which represent a significant change.
As a second example, consider the injection of 74 MBq (2 mCi) 5 3Sm into a
smaller joint, e.g., the wrist. From Figure 4-12, the absorbed dose factor for the
lining cells region is 0.031 cGy-cm 2 /MBq-s. If uniform distribution along 50 cm2 of
s;ynovial surface is assumed, the initial dose rate to the lining cells is 0.05 cGy/s (170
rad/h), from Eqn. 4.8. Assuming no leakage, the total lining cells dose delivered over
time is 11,000 cGy, from Eqn 4.5. Note that, in this example, the bone surface is
not expected to receive any beta dose, since the low-energy beta-particles emitted
by 153Sm are not sufficiently energetic to penetrate the 1 mm thick layer of articular
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Figure 4-10: Absorbed dose factors versus distance in the joint model for 32 p.
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Figure 4-11: Absorbed dose factors versus distance in the joint model for 90Y.
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Figure 4-12: Absorbed dose factors versus distance in the joint model for ' 53Sm.
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Figure 4-13: Absorbed dose factors versus distance in the joint model for 165Dy.
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Figure 4-14: Absorbed dose factors versus distance in the joint model for 166Ho.
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Figure 4-15: Absorbed dose factors versus distance in the joint model for 186Re.
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Figure 4-16: Absorbed dose factors versus distance in the joint model for 188Re.
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Figure 4-17: Absorbed dose factors versus distance in the joint model for 98Au.
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cartilage.
4.3.1 Absorbed dose factors versus distance
From the results presented in Figures 4-10 through 4-17, one can see that the plots of
absorbed dose factors versus distance in the joint model can be described as having
three distinct regions. One region (0.0 to 0.74 mm) is characterized as having dose
factors which are significantly higher than those in the remaining regions. This is
the radiation source region and, physically, it represents the joint capsule and lining
cells regions found in all synovial joints. Because it is the source region, it can be
expected to receive a beta dose significantly higher than that in other parts of the
joint. Clinically, the high dose imparted to the lining cells may be advantageous, since
it is the lining cells which are responsible for secreting proinflammatory cytokines
and destructive enzymes thought to play a major role in bone and articular cartilage
degradation (see Chapters 2 and 6). Killing the lining cells therefore may slow the
development of bone and articular cartilage destruction, at least temporarily.
The second region in the plots includes, on one side of the source, the dose factors
at distances between -1.0 and 0.0 mm and, on the other side, the factors at distances
between 0.74 and 6.0 mm. Physically, these two areas represent, respectively, the
articular cartilage and sub-synovium components in synovial joints. In both, the
absorbed dose factors are seen to decrease exponentially with distance. The rate of
decrease is influenced by the mean beta energy of each radionuclide.
The third region in the plots includes the dose factors at distances between -6.0
and -1.0 mm; it physically represents bone. As in the regions of articular cartilage
and sub-synovium, the decrease in dose factors with distance in bone is seen to be
exponential and dependent on the radionuclide's mean beta energy. The dose factors
in this region are recognized as being distinct however due to the discontinuity at the
bone-articular cartilage interface (at -1.0 mm). The discontinuity is due to differences
in the stopping powers of the two absorbing media.
4.3.2 Backscatter
The concept of backscatter is useful for illustrating the effect of the presence of bone
on beta dose distributions in radiation synovectomy. It has been defined as radiation
scattered by bone back into the soft tissue from which it originated. For the joint
model used here, it was found that the backscatter contribution to absorbed dose in
nearby synovium is negligible. The 1 mm thick layer of articular cartilage at the bone
surface was seen to absorb all backscattered radiation and, hence, prevent absorbed
dose enhancement in synovium.
For 2 of the 8 radionuclides investigated however, minor absorbed dose enhance-
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Table 4.5: Effect of advancing rheumatoid arthritis on absorbed dose d
radiation synovectomy.
Stage Bone surface dose Synovial dose Synovial dose
at 2 mm at 4 mm
1 17 Gy 6.7 0.47
2 16 6.9 0.51
3 15 7.1 0.55
deposition in
ment was seen in the region of articular cartilage. Since the bone surface is located
1 mm away from the plane source region, backscatter becomes a consideration in
radiation synovectomy only when the mean beta energy of the injected radionuclide
is sufficient to allow a reasonable number of energetic electrons to reach the bone sur-
face. Of the 8 radionuclides investigated, only 32 P and 90 Y decay with beta-particle
emission energies sufficiently high. In both instances the enhancement effect was seen
to be small however, increasing the absorbed dose in the bins of articular cartilage
nearest the bone surface by only 3-4%.
4.3.3 Dosimetry and progression of rheumatoid arthritis
Effects of advancing rheumatoid arthritis on the extent and pattern of absorbed dose
distributions in treated joints were examined by running additional simulations using
models developed to represent rheumatoid joints at varying stages of disease. Results
are presented in Table 4.5 for 37 MBq 90Y uniformly distributed along 250 cm2 syn-
ovium. Absorbed dose to the bone surface, synovium at 2 mm, and synovium at 4
mm are shown at disease stages 1, 2, and 3.
As the volume of joint fluid and the number of lining cells increase with advancing
rheumatoid arthritis, the dosimetry can be said to improve. Progressing from the
stage 1 joint to stages 2 and 3, absorbed dose to the bone surface is seen to decrease
14%, while dose to the synovium at a depth of 2 mm increases 6.0%.
4.4 Discussion
Calculation of beta dosimetry in radiation synovectomy is a difficult problem due
to the complex geometry of synovial joints. Nonetheless several different approaches
have been applied. Husak et al. [9], for instance, applied the beta dose point kernel
method [12] to calculate beta dose distributions for 90 Y and 198Au. Recognizing the
fact that radionuclides injected into the joint are absorbed by the synovial surface,
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their approach was to approximate the treated joint as a thin plane sources of uniform
activity in a homogeneous soft tissue volume (see Section 1.1.1). Results show the
dependence of absorbed dose on distance (up to 0.6 mm) from 90Y and ' 98Au sources
having a thickness of 20, 30, or 40 /im. They found that at distances greater than 0.1
mm, absorbed dose to tissue is independent of the plane source thickness used in the
,calculation.
In the present work, the calculations of beta dose at depth in tissue reported
by Husak et al. were compared with the EGS4 Monte Carlo estimates of beta dose
distributions in synovial joints. For 198Au, for instance, Husak et al. calculated that
37 MBq (1 mCi) uniformly distributed on a synovial surface area of 250 cm2 delivers
an absorbed dose at 0.15 mm of approximately 1800 cGy (1800 rad), integrated over
all time. The corresponding value of absorbed dose estimated using the dose factors
for 198Au shown in Figure 4-17 is 1820 cGy. For 37 MBq (1 mCi) 90Y on a surface area
of 250 cm2 , they reported an absorbed dose to tissue at 0.15 mm of approximately
2500 cGy. Using the dose factors in Figure 4-11, an absorbed dose of 2620 cGy is
determined in the present work. Differences in the estimates of absorbed dose for the
two approaches are 1% for 198Au and 5% for 90Y. Additional comparisons with Husak
et al. of absorbed dose at depth are not made since their curves do not continue
beyond 0.6 mm.
Rekonen et al. [46] used a related analytical approach to calculate the beta-particle
dosimetry of 9Y in radiation synovectomy. The calculations show (1) absorbed dose
for 90Y either: a) absorbed by the synovial surface (plane source) or b) suspended in
the joint capsule (volume source); and (2) variation of absorbed dose with depth in
tissue. In this case, the calculation of absorbed dose at depth is for 220 MBq (6 mCi)
90Y uniformly distributed on an infinitely thin plane having an area of 150 cm2. A
Ihomogeneous soft tissue volume again was assumed. Based on their approach, the
absorbed dose at 1.0 mm from the plane source was calculated to equal approximately
12,000 cGy; at 2.5 mm, approximately 5000 cGy. Using the dose factors in Figure 4-
11, the Monte Carlo approach presented here estimates an absorbed dose of 10,400
cGy in the bin 0.9-1.1 mm from the source, and 3300 cGy in the bin 2.3-2.5 mm from
the source. Differences in the results for the two approaches are 13% (at a depth of
1.0 mm) and 34% (at a depth of 2.5 mm).
A different analytical approach was used by Topp et al. [3]. Their results, gen-
erated using the decay scheme of 198Au, show the dependence of absorbed dose to
synovium on both the amount of activity injected and the volume of fluid in the joint
capsule. For a 25 cm3 fluid volume, 300 MBq (8 mCi) 198Au was reported to deliver
40,000 cGy to the synovial surface and 5720 cGy at a depth of 1 mm. For a 50 cm3
fluid volume, the same administered activity was reported to deliver 20,000 cGy to
the surface and 2860 cGy at 1 mm. When comparing these results to those obtained
using Monte Carlo however, it is unclear as to how injected activity and fluid vol-
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ume are best related to an areal concentration of activity. If it is assumed that the
300 MBq '98 Au is uniformly distributed throughout the joint capsule and lining cells
regions (total thickness of 0.074 cm), then a 25 cm3 fluid volume corresponds to a
synovial surface area of 340 cm2 . The resulting doses estimated using the dose factors
presented here are 10,700 cGy to the synovial surface and 2550 cGy at a depth of 1
mm. Differences in the results for the two approaches, in this case, are 73% (at the
surface) and 55% (at a depth of 1 mm).
It is worth noting that the approach taken by Topp et al. has not accounted for
either: (1) aspiration of joint fluid from the capsule before injection or (2) uptake
of radioactivity by the lining cells after injection. Of the 3 analytical approaches
discussed, that of Husak et al., who have taken both these considerations into account
and used beta dose point kernels to evaluate the dosimetry in radiation synovectomy,
is believed to be the most accurate. However, their approach required approximating
the joint as a homogeneous soft tissue volume. As a result, Husak et al. have not
considered the radiation dose imparted to other, healthy, joint components located
nearby, such as bone. Dose to bone is addressed next.
4.4.1 Backscatter calculations and absorbed dose to bone
A thin layer of articular cartilage completely lines the ends of articulating bony sur-
faces in all synovial joints. Although the thicknesses are not well documented, they
can be expected to vary from 0.5 to 2-3 mm depending on the size of the joint [17, 18].
With the simulations reported here, a layer of articular cartilage only 1 mm thick was
seen to be sufficient to prevent radiation backscattered off bone from reaching syn-
ovium. For 3 2 p and 90Y however, minor absorbed dose enhancement was seen in the
region of articular cartilage. Clinically, the enhancement is small enough that the
potential for radiation damage in articular cartilage is not significantly increased by
backscatter.
It is worth noting that articular cartilage has an elemental composition and density
which closely resembles that of soft tissue and water (see Table 4.1). The presence
of articular cartilage in synovial joints therefore acts to reduce the effects of tissue
inhomogeneities on beta dosimetry in radiation synovectomy. In fact, for the low-
energy beta emitters of interest in radiation synovectomy, the joint model developed
for this work is essentially homogeneous. Agreement with the point kernel based
calculations of absorbed dose at depth in a homogeneous soft tissue volume reported
by Husak et al. substantiates this observation.
However, approximating the joint as a homogeneous soft tissue volume does not
allow one to estimate the absorbed dose imparted to bone during radiation synovec-
tomy. Absorbed dose to the bone surface (10 Jsm) is particularly of interest since the
International Commission on Radiation Protection has identified this tissue region
MI
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Table 4.6: Bone surface (rm) beta dose expressed as a percentage of the beta dose
imparted to the lining cells.
Radionuclide Bone surface dose
32p 16%
90y 25
1 5 3 Sm < 0.01
165Dy 0.7
16 6 Ho 15
186 Re 3.8
188Re 19
198Au 2.5
as one of two principal radiosensitive targets to be protected in procedures involving
bone irradiation [13].
Referring to Figures 4-10 through 4-17, absorbed dose to bone is seen to be largely
dependent on the injected radionuclide's mean beta energy, or penetration ability.
Expressed as a percentage of the beta dose imparted to the lining cells, beta dose
to the bone surface is seen in Table 4.6 to vary from 25% of the lining cells dose for
90Y down to less than 0.01% for '53Sm. The author knows of no previous attempt to
evaluate the absorbed dose to non-target tissues in radiation synovectomy.
4.4.2 Dosimetry and rheumatoid arthritis progression
As with other therapies, clinical success in radiation synovectomy is known to depend
largely on the extent of disease progression in the joint prior to treatment, with
success becoming much less likely in joints with advanced symptoms of rheumatoid
arthritis. Among other things, advanced rheumatoid arthritis is characterized by
increased joint fluid volumes and increased numbers of lining cells. Combined, these
two characteristics have the effect of extending the thickness of the radioactive source
region. To determine whether the extended source could result in reduced likelihood
for success in radiation synovectomy with advancing rheumatoid arthritis, additional
simulations were made using EGS4 and incorporating slight alterations in the joint
model.
Reduced likelihood for success was found to be unrelated to the extended source,
however, since the resulting beta dose distributions actually improved [10]. Dose
to synovium increased with advancing rheumatoid arthritis, while dose to the bone
surface decreased. The improvement is attributed to that fact that increased numbers
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Table 4.7: Therapeutic and maximum ranges of the 8 radionuclides investigated.
Therapeutic Maximum
Radionuclide range range
32p 2.2 mm 7.9
90Y 2.8 10.8
153Sm 0.7 3.1
5165Dy 1.3 5.6
166 Ho 2.1 8.7
1S6Re 1.0 4.5
1 88Re 2.1 10.1
198 Au 0.9 3.9
of lining cells have the effect of absorbing more of the injected activity deeper into
the synovium, and thus away from bone. The reduced likelihood for clinical success
in joints with advanced symptoms of rheumatoid arthritis thus must be due to some
other factor.
4.4.3 Therapeutic range
The dose factors presented here are intended to provide the information necessary
for those interested in radionuclide selection, dose prescription, and resulting beta
dose distributions in radiation synovectomy. Radionuclide selection, for instance, is
based, at least in part, on an evaluation of the absorbed dose penetration of each
of the radionuclides under consideration. In particular, one wants to ensure that
the deepest limit of the target volume lies within a radionuclide's therapeutic range
and that other, healthy, joint components located nearby are not subjected to an
unnecessary radiation hazard. The therapeutic range is defined here as the synovial
depth at which the percentage dose is equal to 10% of the maximum synovial dose,
deposited at the synovial surface. While not a useful value for dosimetry purposes,
the therapeutic range is an important parameter in radiation therapy.
Table 4.7 lists therapeutic and maximum ranges of the 8 radionuclides investi-
gated here. In each case, the therapeutic range is seen to be much shorter than the
corresponding maximum range. In addition, the 8 therapeutic ranges are seen to
demonstrate considerably less variation between radionuclides than the 8 maximum
ranges. Since it is the therapeutic range which determines the thickness of synovium
that can be treated and not the maximum range, treatment volume variations between
radionuclides are not large.
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4.5 Conclusion
Beta-particle dosimetry of various radionuclides used in the treatment of rheumatoid
arthritis was estimated using Monte Carlo radiation transport simulation. Absorbed
dose factors (cGy-cm 2/MBq-s) were determined as a function of distance in a math-
ematical model of the rheumatoid joint, with dimensions in the model selected to
correspond with those typically found in larger synovial joints, e.g., the knee, shoul-
der, or hip. The presence of bone in the model was investigated to determine whether
radiation backscatter enhances absorbed dose to synovium in radiation synovectomy.
It was found that the layer of articular cartilage separating bone from synovium is
sufficiently thick to prevent backscattered radiation from reaching the tissue. For 2 of
the 8 radionuclides investigated however, minor absorbed dose enhancement (3-4%)
was seen in the bins of articular cartilage closest to bone.
The absorbed dose factors presented here are intended to provide guidance for
clinicians concerned with radionuclide selection and the amount of activity to admin-
ister in radiation synovectomy. Definite data on the absorbed dose required at depth
in synovium for successful therapy have not been established. For a given areal con-
centration of injected radioactivity uniformly distributed throughout the joint capsule
and along a surface layer of lining cells, however, absorbed dose to tissue (synovium),
articular cartilage, and bone are easily estimated with the results shown in Figures 4-
10 through 4-17.
The absorbed dose factors also provide information, previously unavailable, re-
garding the potential for radiation damage in other, healthy, parts of the joint, such
as bone. Radiation damage to the bone surface (10 ilm) is particularly of interest
since this tissue volume has been identified as a radiosensitive target to be protected
in procedures involving bone irradiation [13]. For the radionuclides investigated here,
absorbed dose to bone was seen to vary from 25% of the synovial surface (or lining
cells) dose for 90Y down to 5% for 98 Au. Clinicians interested in radiation synovec-
tomy therefore will want to ensure that a therapeutic radiation dose can be delivered
to target synovium without subjecting other joint components to an unacceptable or
unnecessary radiation hazard.
In the next Chapter, experimental beta dosimetry in radiation synovectomy is
presented. In the experiments, reactor-produced radionuclides and radiachromic film
dosimeters were used to measure absorbed dose distributions in both joint phantoms
and the knees of fresh, human cadavers. The results are compared with the Monte
Carlo estimates of beta dose distributions in treated joints discussed here.
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Experimental Beta Dosimetry
5.1 Introduction
In general, there are three methods for estimating absorbed dose distributions in
radiation synovectomy or any other radiation therapy. These include: (1) direct
measurement in humans, (2) extrapolation from measured data in animals, phantoms,
and cadavers, and (3) calculations based on mathematical models.
In humans, the direct measurement of beta dose distributions in radiation syn-
ovectomy is possible but it presents severe difficulties. For instance, many of the
radiation dosimeters commonly used today simply are too large to be inserted into
human joints. And dosimeters which may be small enough for insertion present prob-
lems associated with their implantation, accurate positioning, and retrieval. For the
purposes of dosimetry alone, the resulting inconvenience and discomfort to patients
generally is considered to be excessive.
Since direct; measurements in humans are so difficult to obtain, estimates of beta
dose distributions in radiation synovectomy have come to rely on calculation instead
of measurement. For example, Monte Carlo estimates of beta dosimetry in radia-
tion synovectomy were presented in Chapter 4. The estimates were obtained using
Monte Carlo radiation transport simulation to evaluate the extent and pattern of
absorbed dose deposition in a mathematical model of the treated joint. In all, the
beta dosimetry of 8 radionuclides was presented.
The purpose of this chapter is to present a series of experiments aimed at measur-
ing beta dose distributions in joint phantoms and the knees of fresh, human cadavers.
Radiachromic film dosimeters and 2 reactor-produced radionuclides, 165Dy and 166Ho,
were used in the experiments.
The chapter begins with a discussion of the phantom experiments. Included are
descriptions of the radiation dosimeters used to measure absorbed dose, the tissue
substitutes used to build the phantoms, and the procedures used to prepare the
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radioactive sources. Then the chapter continues with a discussion of the experiments
conducted in the knees of cadavers. Results are presented and discussed for both sets
of experiments.
5.2 Experiments in Phantoms
A phantom can be defined as a volume of tissue substitutes used to reproduce radi-
ation absorption and scattering characteristics in order to measure dosimetric quan-
tities at various locations. Tissue substitutes, in general, are intended to simulate
either the body or a portion of the body with respect to: size, shape, position, mass
density, and radiation interaction probabilities. For a given radiation type and energy,
substitutes should absorb and scatter incident radiation to the same extent, within
acceptable limits, as the irradiated tissues do.
In this section, use of synovial joint phantoms to measure depth-dose data that
can be used to extrapolate predictions of beta dose distributions in radiation syn-
ovectomy is described. Results are compared with the dose estimates generated using
Monte Carlo radiation transport simulation in a mathematical model of the joint (see
Chapter 4).
5.2.1 Materials and methods
Tissue substitutes
When selecting a tissue substitute, ideally, one wants to choose a material which has
radiation absorption and scattering properties which are the same as those of the
relevant tissue. In practice, one tries to get as close to a match as possible.
In beta dosimetry, it is the mass scattering power T/p and the mass stopping
powers for collisions S/p and bremsstrahlung production S,,ad/p which should be
similar over the energy interval of interest. The linear scattering power T of a material
expresses the increase in the mean square angle of scattering for a given pathlength
in the material, whereas the linear stopping power S expresses the energy lost by an
electron in travelling a given pathlength in the material. For energies at which nuclear
interactions can be neglected, the total linear stopping power S can be separated into
two components:
S = So + S,,,. (5.1)
The collision stopping power Sot includes all energy losses in collisions which directly
produce knock-on electrons and atomic excitations. The radiative stopping power
Sad includes all energy losses of the primary electron which lead to the production
of bremsstrahlung photons.
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Table 5.1: Electron mass stopping powers (MeV-m2 /kg) and mass scattering powers
(Radian 2-m 2/kg) for BONE. Adopted from ICRU-44.
Energy (MeV) (S/p)col (S/p),,ad S/ip Tip
0.020 1.14E+00 5.90E-04 1.14E+00 2.68E+02
0.040 6.76E-01 6.09E-04 6.77E-01 8.04E+01
0.060 5.06E-01 6.20E-04 5.06E-01 4.00E+01
0.080 4.16E-01 6.33E-04 4.17E-01 2.45E+01
0.200 2.46E-01 7.26E-04 2.47E-01 5.42E+00
0.400 1.90E-01 9.43E-04 1.91E-01 1.85E+00
0.600 1.73E-01 1.21E-03 1.74E-01 1.00E+00
0.800 1.66E-01 1.52E-03 1.68E-01 6.53E-01
1.000 1.63E-01 1.85E-03 1.65E-01 4.68E-01
2.000 1.62E-01 3.81E-03 1.66E-01 1.62E-01
3.000 1.64E-01 6.07E-03 1.70E-01 8.50E-02
Tissue substitutes selected for use in the joint
solid water (a specially formulated, commercially
phantom included aluminum and
available plastic). The aluminum
served as a substitute for bone, and the solid water served as a substitute for articular
cartilage and soft tissue (synovium). Electron mass scattering and stopping power
data for the three tissues-bone, articular cartilage, and soft tissue-and their two
substitutes-aluminum and solid water-are shown in Tables 5.1 through 5.5 over
the energy interval of interest [81].
Solid water. Solid water is an epoxy resin-based material specially formulated to
have electron and photon absorption and scattering characteristics very close to those
of water. Its material composition, elemental composition, and specific gravity are
listed in Table 5.6 [84].
Use of water substitutes as soft tissue substitutes for the purposes of dosimetry
in radiation therapy is not expected to introduce uncertainties in the absorbed dose
estimates greater than 1%. Using a homogeneous, cubic, solid water phantom (30
cm x 30 cm x 30 cm) and a 60Co source, Constantinou et al. measured depth-dose
data within ±1% of that derived for a standard water phantom [85]. Solid water also
has been shown to be superior to other commonly used water substitutes, e.g., Lucite
and polystyrene [84].
A single sheet of solid water (30 cm x 30 cm x 1 mm) was purchased from
M
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Table 5.2: Electron mass stopping powers (MeV-m2 /kg) and mass scattering powers
(Radian2 -m2 /kg) for ARTICULAR CARTILAGE. Adopted from ICRU-44.
Energy (MeV)
0.020
0.040
0.060
0.080
0.200
0.400
0.600
0.800
1.000
2.000
3.000
(SIp)co
1.29E+00
7.61E-01
5.68E-01
4.66E-01
2.74E-01
2.11E-01
1.92E-01
1.85E-01
1.81E-01
1.79E-01
1.81E-01
(SIP)rad
4.01E-04
4.07E-04
4.12E-04
4.20E-04
4.86E-04
6.42E-04
8.36E-04
1.06E-03
1.30E-03
2.71E-03
4.35E-03
S/p
1.29E+00
7.62E-01
5.68E-01
4.66E-01
2.74E-01
2.11E-01
1.93E-01
1.86E-01
1.82E-01
1.81E-01
1.85E-01
T/p
2.06E+02
6.15E+01
3.05E+01
1.86E+01
4.08E+00
1.38E+00
7.50E-01
4.87E-01
3.49E-01
1.20E-01
6.30E-02
Table 5.3: Electron mass stopping powers (MeV-m2/kg) and mass scattering powers
(Radian2 -m2 /kg) for SOFT TISSUE. Adopted from ICRU-44.
Energy (MeV)
0.020
0.040
0.060
0.080
0.200
0.400
0.600
0.800
1.000
2.000
3.000
(S/P)col
1.32E+00
7.77E-01
5.79E-01
4.76E-01
2.79E-01
2.15E-01
1.96E-01
1.89E-01
1.85E-01
1.82E-01
1.85E-01
(S/P)rad
3.94E-04
3.99E-04
4.04E-04
4.12E-04
4.77E-04
6.31E-04
8.22E-04
1.04E-03
1.28E-03
2.67E-03
4.29E-03
SIP
1.32E+00
7.78E-01
5.80E-01
4.76E-01
2.80E-01
2.15E-01
1.97E-01
1.90E-01
1.86E-01
1.85E-01
1.89E-01
T/p
2.05E+02
6.09E+01
3.02E+01
1.84E+01
4.04E+00
1.37E+00
7.42E-01
4.82E-01
3.45E-01
1.19E-01
6.23E-02
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Table 5.4: Electron mass stopping powers (MeV-m2/kg) and mass scattering powers
(Radian 2-m 2/kg) for ALUMINUM. Adopted from ICRU-44.
Energy (MeV)
0.020
0.040
0.060
0.080
0.200
0.400
0.600
0.800
1.000
2.000
3.000
(S/p)cO.
9.84E-01
5.91E-01
4.44E-01
3.66E-01
2.17E-01
1.68E-01
1.54E-01
1.49E-01
1.47E-01
1.48E-01
1.51E-01
(S/P)rad
6.92E-04
7.08E-04
7.17E-04
7.29E-04
8.32E-04
1.08E-03
1.38E-03
1.73E-03
2.11E-03
4.33E-03
6.89E-03
S/p
9.85E-01
5.92E-01
4.45E-01
3.67E-01
2.18E-01
1.69E-01
1.55E-01
1.50E-01
1.49E-01
1.52E-01
1.58E-01
Tip
3.01E+02
9.06E+01
4.51E+01
2.77E+01
6.12E+00
2.09E+00
1.13E+00
7.39E-01
5.29E-01
1.84E-01
9.63E-02
Table 5.5: Electron mass stopping powers (MeV-m2 /kg) and mass scattering powers
(Radian 2-m2/kg) for SOLID WATER. Adopted from Constantinou et al.
Energy (MeV) S/p T/p
0.01 2.19E+00 6.03E+02
0.10 4.00E-01 1.11E+01
1.00 1.11E-01 3.04E-01
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Table 5.6: Composition of solid water. Adopted from Constantinou et al.
Percentage by weight
Components epoxy CB4 (80.48%), polyethylene (10.00),
calcium carbonate (5.77),
phenolic microspheres (3.75)
Elements H (8.09), C (67.22), N (2.40),
0 (19.84), Ca (2.32), C1 (0.13)
Specific gravity 1.015 ± 0.002
Radiation Research, Inc. for use in the joint phantom. The sheet was cut into 25
smaller slabs (each 6 cm x 6 cm x 1 mm), and these were used in the phantom as
articular cartilage and soft tissue substitutes.
Articular cartilage, it should be noted, is a body tissue similar in composition to
soft tissue, as shown in Table 4.1. It, too, is composed primarily of water (60-80%
H2 0), and as a result its radiation absorption and scattering characteristics are well
simulated with water substitutes such as solid water.
Aluminum. Aluminum is a rigid metallic solid which is easily machined into a
variety of shapes. It is commonly used as a good substitute for bone in experimental
radiation dosimetry [86, 87]. Several slabs of aluminum (each 10 cm x 10 cm x 1
mm) were purchased for use as bone substitutes in the phantom.
Joint phantom
The assembled joint phantom is illustrated in Figure 5-1. On one side of the radioac-
tive source (described below), several 1 mm thick slabs of aluminum were stacked
together and served as a substitute for bone. A single slab of solid water (1 mm
thick) positioned between the aluminum slabs and the radioactive source served as
an articular cartilage substitute, to mimic the thin layer of articular cartilage that
caps the ends of the bones in all synovial joints. On the other side of the radioactive
source, several 1 mm thick solid water slabs were stacked together and served as a
substitute for soft tissue (synovium). In the phantom, distances are defined in relation
to the leftmost solid water-radioactive source interface, as indicated in Figure 5-1.
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solid water slab,
1 mm thick,
substitute for art. cart.
aluminum slabs,
1 mm thick each,
substitute for bone
radioactive filter paper assemi
1.5 mm thick,
planar radiation source region
)ly,
solid water slabs,
1 mm thick each,
substitute for tissue
radiachromic film
dosimeters
Figure 5-1: Phantom used to experimentally measure radiation absorbed dose pene-
tration in synovial joints treated with radiation synovectomy. Distances are defined
in relation to the leftmost solid water-radioactive source interface.
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Radioactive source preparation
The phantom's radioactive source region is intended to mimic that of the treated joint.
As mentioned in Chapters 2 and 4, rheumatoid joints to be treated with radiation
synovectomy generally are aspirated of all fluid [17]. Radioactivity, held in a liquid
suspension, then is injected into the joint capsule where it makes direct contact with
inflamed synovium [1]. Phagocytic lining cells along the synovial surface quickly
absorb radioactive particulate from the capsule. Autoradiographs of the tissue lining
in knees injected with various radionuclides have shown a reasonably even distribution
of radioactivity in these cells for several days after injection [2, 3, 4]. The ends of the
articulating bony surfaces, capped with articular cartilage, do not absorb radioactive
particulate however since the cells along these surfaces are not phagocytic [46]. The
radioactive source region in treated joints thus can be described as including the
fluid-filled joint capsule and the synovial lining cells. In the phantom experiments,
planar radioactive sources of 165Dy and 166Ho were prepared to mimic this region.
165Dy. Two planar sources of 65Dy with initial radioactivity of the order 9000 MBq
were prepared by dipping ten thin squares of cellulose filter paper, each 7.5 mg/cm2
thick and 6 x 6 cm2 in area, once each in a solution containing 1.75 mg Dy20 3 (stable,
natural Dy) dissolved in 5.0 ml nitric acid (3% HNO3). The soaked papers were dried
in air by hanging them vertically but rotating each a few times in the vertical plane
while still wet. The object of the change in the rotational position was to achieve
greater uniformity in the distribution of dysprosium on the papers. Ten filter papers,
each 7.5 mg/cm2 thick, were used so that the density thickness of the phantom's
source would approximates of treated joints. The density of cellulose is 0.5 g/cm3 .
When the papers had dried, they were stacked and stitched together at the four
corners using a needle and thread. The dried filter paper assembly then was irradiated
at the MIT Nuclear Reactor Laboratory (Cambridge, MA) for 54 min at full power
(thermal neutron flux - 7.5 x 1012 neutrons/cm 2-s). Activation of stable 164Dy on
the papers resulted in the production of 8.6 x 103 MBq 6 5Dy. After allowing 80
minutes decay time for radiation protection purposes, the filter paper assembly was
inserted into the joint phantom. At the time of insertion, the activity of 65Dy in the
assembly was roughly equivalent to 5.0 x 103 MBq. This activity was allowed at least
10 half-lives to decay. 16SDy has a 2.3 h half-life.
166Ho. A planar source of 166Ho with initial radioactivity of 250 MBq was prepared
following the procedures described above for 65Dy, with the following exceptions.
One mg Ho20 3 (stable, natural Ho) was dissolved in 5.0 ml nitric acid (3% HNO3),
and the solution was used to soak the filter papers. In addition, the irradiation time
was 6 h, instead of 54 min.
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Activation of stable ' 65Ho on the papers resulted in the production of 250 MBq
166Ho. After allowing 2 h decay time for radiation protection purposes, the 240 MBq
166 Ho remaining on the papers was inserted into the joint phantom. The activity was
allowed at least 10 half-lives to decay. 166Ho has a 27 h half-life.
Dosimeters
Many types of detectors are available for measuring absorbed dose. The detector
response can be any radiation-induced change in its physical, chemical, or biologi-
cal properties, provided that the change can be quantified and is uniquely related
to the radiation dose. Some of the more commonly used detectors include various
gas ionization devices, thermoluminescence dosimeters (TLDs), film emulsions, liquid
scintillators, chemical (Fricke) dosimeters, and solid-state diodes.
When choosing a detector for use in radiation dosimetry, important considerations
to bear in mind include its size and elemental composition. Size is important in that
the detector must be small enough to minimize perturbations in the particle fluence
but large enough to undergo a sufficient number of interactions to yield a signal
that can be read with precision. Elemental composition is important in that the
detector's composition should be as similar as possible to that of the surrounding
materials, again to minimize perturbations in the particle fluence.
The dosimeters used in this work were GafChromic DM1260 radiachromic film
dosimeters purchased from Far West Technology, Inc. (Goleta, CA). The film is
a thin, laminated-plastic material having radiation absorption properties similar to
those of soft tissue. It consists of a very thin ( 7 m) radiachromic sensor coating
(a proprietary substance) on a polyester film base (: 100 am). When exposed to
ultraviolet or ionizing radiation with energy greater than 4 eV, the coating undergoes
a radiation-induced color change by photoionization. The change, from colorless to
deep blue, occurs gradually as a function of absorbed dose.
The photochemical reaction involved is a unimolecular decomposition of any one
of a variety of aminotriphenyl methane dye derivatives. The decomposition is followed
by an intramolecular electron rearrangement to form the stable and deeply colored
corresponding dye [88, 89]. No processing is required to bring about this color change.
Some important dosimetric characteristics of the films include: a linear response
to ionizing radiation over a wide range of doses; dose-rate independence; energy
independence of response down to a few keV; an equivalent response to electrons and
photons; low atomic number composition (primarily H, C, N, 0); and the fact that
the radiation-induced image is quite stable [90].
A major advantage of the radiachromic film dosimetry system is the straightfor-
ward manner in which the radiation response is analyzed. A reader designed specif-
ically for standard radiachromic film dosimetry is a simple photometer, as shown in
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Figure 5-2: Block diagram of a simple radiachromic film dosimeter reader.
Figure 5-2. Light, filtered to the film's peak absorption wavelength, is transmitted
through the dosimeter where it is received by a silicon photodiode and converted into
an electrical signal. The signal is fed into a high input impedence operational ampli-
fier, and the output is displayed on a meter as optical density OD. Optical density
is related to transmission according to the following relation:
OD = log TOT (5.2)
where To is 100% transmission and T is transmission after coloration. A calibration
curve depicting the change in optical density AOD as a function of absorbed dose D
is used to quantify the dose imparted to the dosimeters.
Portions of a 12.7 cm wide roll of GafChromic film were cut into 6 cm x 6 cm
squares for insertion into the joint phantom. The size of the film squares is large
enough so that four 1 cm x 1 cm samples cut from the center are separated from
any edges by at least 1.5 times the range of the most energetic beta-particle emitted,
a distance which is sufficiently large to prevent boundary, or edge, effects in the
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measurements.
The cut film squares were sandwiched between the slabs of aluminum and solid
water, as shown in Figure 5-1. Upon the insertion of a radioactive source, the films
were used to measure the absorbed dose deposited at several depths in the phan-
tom. Depths, or distances, in the phantom were defined in relation to the leftmost
solid water-radioactive source interface, which is intended to represent the articular
cartilage surface abutting the joint capsule.
Calibration. The calibration curve for the GafChromic film used in these experi-
ments is shown in Figure 5-3. The curve was generated by first irradiating samples
of the film with known radiation doses, then measuring the change in OD and plot-
ting the results. The irradiations were conducted under controlled conditions using
gamma radiation from a calibrated 60Co source at the National Institute of Standards
and Technology (Bethesda, MD). Samples of the film were sealed inside polymer-
aluminum laminate packets, held between two 5.0 mm thick blocks of polystyrene,
and exposed to 100, 200, 400, 700, or 1000 Gy. Estimates of uncertainty in the
delivered doses are less than 3%.
The change in optical density then was measured for each of the irradiated dosime-
ters and used to calculate a calibration curve for the film. The calibration curve
relating the absorbed dose D (Gy) to a measured change in optical density AOD is
as follows:
D = 10.2(AOD)3 + 27.31(AOD)2 + 289.7AOD. (5.3)
All absorbed dose measurements in this work were obtained with a readout wavelength
of 600 nm.
Analysis
After each of the radioactive sources was allowed 10 half-lives to decay, the joint
phantoms were disassembled and the radiachromic film dosimeters were retrieved for
analysis. Four 1 cm x 1 cm samples were cut from the center of each dosimeter. For
each sample, the change in optical density AOD was measured and converted to an
absorbed dose D using the calibration curve described above (see Eqn. 5.3).
5.2.2 Results
The phantom experiments were completed twice with 165Dy sources and once with
an 166Ho source. The results are as follows.
16SDy. Results of the two 165Dy phantom experiments are shown in Table 5.7 as
absorbed dose factors Fi (cGy-cm 2/MBq-s) at depth in the phantom. In each of the
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Figure 5-3: Calibration curve for the radiachromic film dosimeters used in these
experiments.
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experiments, the absorbed dose was measured at 5 different depths, or positions: -1.0
mm, 0.0 mm, 0.74 mm, 1.74 mm, 2.74 mm. Four absorbed dose measurements were
obtained at each position, and the average dose was converted to an absorbed dose
factor according to the following relation:
Fi - DiASsource (5.4)
F, = ~ A ' (5.4)
where F is the absorbed dose factor (cGy-cm 2/MBq-s), Di is the absorbed dose
(Gy), A is the radionuclide's decay constant (s - l), So,,,rc is the surface area of the
radioactive filter paper assembly (36 cm2 ), and A is the amount of radioactivity
(MBq) inserted into the phantom. In each of the two experiments, variations in
measured doses at each of the 5 positions were seen to be small, typically less than
5%. The small variations were attributed to the high precision of the radiachromic
film dosimeters and the ease with which planar 165Dy sources of uniform activity
can be made. The error associated with each of the factors shown in Table 5.7,
however, is seen to be 15%. The increased errors associated with the factors are due
to uncertainties in accurately knowing the amount of radioactivity A inserted into
the phantom (see Section 5.2.3).
It is worth noting that dosimeters were not placed at the phantom position corre-
sponding to the synovial surface in treated joints. This is a position which is located
inside the radioactive source region. Including dosimeters there would have required
dividing the source into 2 smaller regions and preparing each of the 2 halves indi-
vidually. Upon assembling the phantom, a square of radiachromic film then could
have been sandwiched between the 2 radioactive source halves and the entire source-
film-source assembly inserted into the phantom. For radiation protection purposes,
however, it was decided that the source handling time should be as short as possible,
and the source was prepared as a single assembly.
In Figure 5-4, results of the two experiments are combined and compared with the
Monte Carlo calculations of absorbed dose factors versus depth in the mathematical
joint model.
166Ho. Results of the 166 Ho phantom experiment are shown in Table 5.8 as absorbed
dose factors Fi (cGy-cm 2/MBq-s) at depth in the phantom. In this case, absorbed
dose was measured at 6 depths, or positions, in the phantom: -1.0 mm, 0.0 mm,
0.74 mm, 1.74 mm, 2.74 mm, and 3.74 mm. Four absorbed dose measurements were
obtained at each position, and, again, the average dose was converted to an absorbed
dose factor using Eqn. 5.4.
As in the 165 Dy experiments, variations in the measured doses at each of the 6
positions were seen to be small, on the order of 5%. The errors associated with the
absorbed dose factors reported in Table 5.8 are seen to be much larger, however. Due
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Table 5.7: Results of the depth-dose measurements for 165Dy obtained using the joint
phantom. The results are expressed as absorbed dose factors (cGy-cm2 /MBq-s) at
depth in the phantom.
Factor Factor
Phantom position trial 1 trial 2
-1.0 mm, bone surface 5.1 x 10- 3 ± 15% 4.4 x 10- 3 ± 15%
0.0 mm, art cart surface 3.9 x 10-2 ± 15% 2.8 x 10-2 ± 15%
0.74 mm, synovium at 0.3 mm 4.1 x 10-2 ± 15% 2.8 x 10-2 ± 15%
1.74 mm, synovium at 1.3 mm 4.8 x 10- 3 ± 15% 4.4 x 10- 3 ± 15%
2.74 mm, synovium at 2.3 mm 8.4 x 10- 4 ± 15% 8.2 x 10- 4 ± 15%
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Figure 5-4: Comparison of the absorbed dose factors derived from measurements
obtained using planar S65Dy radioactive sources in the joint phantom with those
obtained using Monte Carlo radiation transport simulation in a mathematical model
of the joint.
MIT Nuclear Engineering Dept. LS Johnson~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I
I IT Nuclear Engineering Dept. LS Johnson I
Chapter 5. Experimental Beta Dosimetry 1101
Table 5.8: Results of the depth-dose measurements for 166Ho obtained using the joint
phantom. The results are expressed as absorbed dose factors (cGy-cm2 /MBq-s) at
depth in the phantom.
Phantom position Factor
-1.0 mm, bone surface 7.1 x 10-3 ± 15%
0.0 mm, art cart surface 3.3 x 10-2 ± 15%
0.74 mm, synovium at 0.3 mm 3.9 x 10-2 + 15%
1.74 mm, synovium at 1.3 mm 8.3 x 10-3 + 15%
2.74 mm, synovium at 2.3 mm 3.2 x 10-3 ± 15%
3.74 mm, synovium at 3.3 mm 1.1 x 10- 3 ± 15%
to the uncertainty in accurately knowing the amount of 166 Ho radioactivity A inserted
into the phantom, the errors associated with the factors were estimated to be 15%.
In Figure 5-5, results of the phantom experiments are compared with the Monte
Carlo calculations of absorbed dose factors versus depth in the mathematical joint
model.
5.2.3 Discussion
The measured phantom data presented above can be used to extrapolate radiation
dose distributions in treated joints. For example, to estimate the beta dose Di (cGy)
imparted to the bone surface or to the synovium at a depth of 0.3 mm, one multiplies
the appropriate absorbed dose factor F. (cGy-cm 2 /MBq-s) by the amount of injected
activity Ao (MBq) and divides the product by an estimate of the joint's total synovial
surface area S.,,, (cm2) and the injected radionuclide's decay constant A (s-l), so that:
Di = F A (5.5)
Consider the injection of 10,000 MBq (270 mCi) 16 5Dy into the knee. From Ta-
ble 5.7, the average absorbed dose factor for the bone surface is 4.74 x 10- 3 cGy-
cm2/MBq-s, and for the synovium at a depth of 0.3 mm it is 3.5 x 10-2 cGy-cm2/MBq-
s. Assuming uniform distribution of injected radioactivity, a total synovial surface
area of 250 cm2 (typical in the rheumatoid knee [17, 9]), and no leakage, the cal-
culated absorbed dose to the bone surface is 2200±15% cGy; to the synovium at a
depth of 0.3 mm, it is 17,00015% cGy.
As mentioned above, the principal source of uncertainty associated with the esti-
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Figure 5-5: Comparison of the absorbed dose factors derived from measurements
obtained using a planar 166Ho radioactive source in the joint phantom with those
obtained using Monte Carlo radiation transport simulation in a mathematical model
of the joint.
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mates is in accurately knowing the amount of radioactivity A inserted in the phan-
toms. When preparing the planar radioactive sources, uncertainties were introduced
in accurately determining the number of target atoms dissolved in nitric acid, in en-
suring that all the target atoms are dried onto the filter papers, and in accurately
knowing the neutron flux used to activate the filter paper assembly (the flux certainly
varies somewhat over the course of the irradiation). As a comparison, uncertainties
associated with the absorbed dose measurements made using the radiachromic film
dosimeters is on the order of 5%, or less.
Referring to Figures 5-4 and 5-5, results of both the 165Dy and 166Ho phantom ex-
periments were seen to be in agreement with the corresponding Monte Carlo estimates
of beta dose distributions in a mathematical model of the treated joint. Comparisons
of the Monte Carlo estimates with experimental results are of interest since the EGS4
code originally was developed for high-energy transport and only recently was mod-
ified to extend its useful range to include lower energies. The agreement indicates
that use of EGS4 to evaluate the dosimetry of low-energy electrons (< 2 MeV) in
heterogeneous media is an acceptable application of the code. The agreement indi-
cates more than this however. It also indicates that the results obtained here using
Monte Carlo radiation transport simulation and experiments in joint phantoms with
radiachromic film dosimeters and reactor-produced radionuclides are indeed accurate.
This conclusion is an important one, as well, since the dosimetry of low energy beta-
particles in heterogeneous media is a field recently receiving considerable attention
[86, 91, 87, 92, 93, 94].
5.3 Experiments in Cadavers
In this section, use of the knees of fresh, human cadavers to measure absorbed dose
at several positions in the joint is described. Each of the knees was injected with a
therapeutic dose of 165Dy ferric hydroxide macroaggregate which was prepared just
as it would have been for a living patient [?].
As mentioned in Section 5.1, the implantation of detectors in humans is possible,
but it entails risks and discomforts that generally are considered to be excessive for the
purposes of dosimetry alone. The logistics for internal measurements with cadavers
are less severe, but the procedure does have its drawbacks. For example, there are
problems in assuring that the distribution of radioactivity in cadavers is representative
of that in patients, since the lining cells and macrophages do not actively absorb
injected radionuclides. It may be difficult to obtain enough cadaver material for
several experiments. And the accurate positioning of radiation dosimeters in the
joint often is difficult to accomplish. Nonetheless, the use of cadavers does offer
possibilities for correlating measured and calculated doses that cannot be obtained in
living patients.
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5.3.1 Materials and methods
Cadavers
Four knees, cut from mid-thigh to mid-calf, were obtained from fresh, frozen cadavers
at the Harvard Medical School (Boston, MA). None of the knees had evidence of
structural joint changes associated with rheumatoid arthritis. Knees 3 and 4 were
obtained from the same cadaver. In each of the specimens, the suprapatellar pouch
was found to be intact and thus did not appear to present a path for leakage of
injected radioactivity out of the joint.
Dosimeters
Radiachromic film dosimeters were cut into 1 cm x 4 cm strips and wrapped in clear
plastic packing tape to prevent them from getting wet. The size of the strips was
large enough to allow 3 absorbed dose measurements per strip.
Implantation
In each of the four knees, a 15 cm midline incision was made from a distal point
just medial to the tibial tubercle to a proximal point along the thigh midline and
superior to the patella. The medial subcutaneous tissue then was raised to reveal
the medial retinaculum and the vastus medialis obliquus. The exposed quadriceps
tendon was cleared of overlying fat, and a standard medial parapatellar arthrotomy
was performed, i.e., the joint capsule was cut open. Then the patellofemoral ligament
was cut; the patella, everted; and the knee, flexed approximately 90° .
Next the radiachromic film dosimeters were stitched into 5 strategic locations
throughout the joint capsule using silk sutures. The locations were: in the pos-
terolateral corner adjacent to the popliteus hiatus, in the posteromedial corner just
anterior to the posterior capsule, adjacent to the anterior cruciate ligament, in the
lateral gutter of the suprapatellar pouch, and on the deep surface of the quadriceps
tendon (as listed in Table 5.9). At the latter three sites, the films were secured with
additional silk sutures. The knees were then closed and sewn tight at three separate
layers.
Injection
A therapeutic dose of lS6 Dy ferric hydroxide macroaggregate was prepared for injec-
tion following standard procedures [?]. The amount of prepared activity was measured
using a Capintec dose calibrator.
Using a 3 cc syringe attached to a three-way stopcock, each of the knees was
injected with radioactive '6 5Dy through a superolateral arthrocentesis portal, and the
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Table 5.9: Joint locations at which radiachromic dosimeters were positioned to mea-
sure absorbed dose in the knees of cadavers.
Joint location Description
A Posterolateral corner
B Posteromedial corner
C Adjacent to anterior cruciate ligament
D Lateral gutter
E Deep surface of quadriceps tendon
needle track was flushed with 1.5 ml saline. The knees then were manipulated through
two complete ranges of motion in an effort to distribute the injected radioactivity as
uniformly as possible. The knees were left alone for 24 h to allow time for the
radioactive dysprosium to decay. 16 5Dy has a 2.3 h half-life.
Gamma camera imaging
At 16 h after injection, planar images of the injected knees were obtained using a
Picker Dyna gamma camera set to image the 90 keV ' 65Dy gamma-ray with a 128
x 128 pixel matrix. The camera's collimator was rotated 180° and covered with an
absorbent vinyl pad and positioned so that the knees could be placed directly on top
of it for static images.
Analysis
At 24 h after injection, the knees were reopened, and the dosimeters were removed
for analysis. The method used to analyze the dosimeters in the cadaver experiments
was identical to that used in phantom experiments (see Section 5.2.1).
5.3.2 Results
Results of the 4 cadaver experiments are shown in Table 5.10 as average absorbed dose
factors (cGy-cm2 /MBq-s) at the 5 joint locations listed in Table 5.9. In each of the
4 experiments, 3 absorbed dose measurements were obtained at each joint location.
The average dose at each location then was converted to an average absorbed dose
factor according to the following relation:
Fi = DiA ' (5.6)A
M
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Table 5.10: Results of the absorbed dose measurements made at several strategic
locations in the knees of fresh, human cadavers. Each of the knees was injected with
a therapeutic dose of 165Dy ferric hydroxide macroaggregate. Results are listed as
absorbed dose factors (cGy-cm 2/MBq-s).
Factor Factor Factor Factor
Location knee 1 knee 2 knee 3 knee 4
A 2.3 x 10- 2 ± 5% 5.4 x 10 - 3 ± 20% 3.0 x 10- 2 ± 28% 4.1 x 10- 2 ± 9%
B 2.5 x 10- 2 + 5% 0 2.9 x 10-2 10% 1.9 x 10-2 + 17%
C 2.0 x 10- 2 + 6% 3.3 x 10- 3 ± 33% 2.0 x 10- 2 i 5% 3.6 x 10- 2 + 53%
D 7.5 x 10- 2 ± 5% 3.1 x 10- 2 ± 7% 6.9 x 10- 2 + 15% 6.0 x 10- 2 ± 80%
E 1.3 x 10-2 + 11% 1.0 x 10- 1 + 5% 5.1 x 10- 2 13% 5.0 x 10- 2 + 86%
where Fi is the average absorbed dose factor (cGy-cm 2 /MBq-s), Di is the average
absorbed dose (Gy), A is the decay constant for 65 Dy (8.37 x 10-5 s-1), S,,, is an
estimate of the total synovial surface area in the joint ( 250 cm2), and A is the
amount of injected radioactivity (MBq). The standard deviation also was calculated.
Errors reported in the table are equal to one standard deviation.
The errors associated with the reported factors are seen to range from 5 to 86%. In
this case, the errors are due primarily to non-uniform distributions of radioactivity in
the joints, which resulted in unequal irradiation of the 3 radiachromic film dosimeters
at each of the 5 joint locations.
In Figure 5-6, results of the cadaver experiments are compared with the Monte
Carlo calculations of absorbed dose factors versus depth in the mathematical joint
model. It is important to note that none of the absorbed dose measurements obtained
in the cadavers experiments was made at depth in tissue. Instead, each of the mea-
surements was made at a point located on the synovial surface. As a consequence, all
the results obtained in the cadaver experiments appear at the same position in the
165 Dy profile, on the synovial surface.
5.3.3 Discussion
Non-uniform distribution of injected radioactivity throughout treated joints is recog-
nized as a problem in radiation synovectomy, since rheumatoid synovium which does
not receive a therapeutic radiation dose may continue to promote the progression
of rheumatoid arthritis in the joint and prevent the relief of symptoms in patients
[1, 17, 9]. Regions of rheumatoid synovium located far from the point of injection
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Figure 5-6: Comparison of the absorbed dose factors derived from measurements
obtained in the knees of cadavers with the estimates of absorbed dose factors versus
depth obtained using Monte Carlo radiation transport simulation in a mathematical
model of the joint.
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or in joint recesses are particularly of concern. Results of the cadaver experiments
presented above provide a means of evaluating magnitude of the problem.
Referring to the results presented in Table 5.10, the distribution of injected ra-
dioactivity was seen to be non-uniform in each of the 4 cadaver experiments. If the
distributions had been uniform, the 5 absorbed dose factors reported in any one of
the 4 knees would have been equal to one another. Instead, the factors were seen to
vary from location to location in all 4 knees, with differences as little as 4.1 x 10-2
cGy-cm2 /MBq-s in knee 4 to as large as 1.0 x 10- 1 cGy-cm2/MBq-s in knee 2. For
the injection of 10,000 MBq (270 mCi) '16Dy into a knee with a synovial surface area
of 250 cm2 , the corresponding variations in absorbed dose are from as little as 20,000
cGy (in knee 4) to as much as 48,000 cGy (in knee 2). Gamma camera scans of the
knees 16 h after injection confirmed the unequal distribution.
It is important to note that the distribution of injected radioactivity obtained in
the knees of cadavers is worse that obtained in the knees of living patients. As de-
scribed in Chapter 2, radioactivity injected into rheumatoid joints is absorbed by the
surface layer of phagocytic lining cells. Autoradiographs of the synovial lining in live
knees injected with various radionuclides have shown a reasonably even distribution
of radioactivity in these cells for several days after injection [2, 3, 4]. In the knees
of cadavers however, there is no phagocytic absorption of injected radioactivity since
the lining cells and macrophages are dead. As a consequence, the radioactivity is free
to move about within the joint and to settle in its lowest recesses. While non-uniform
distribution of injected radioactivity may be a problem in live joints, the distribution
is even worse in the joints of cadavers.
Combining the results of the 4 cadaver experiments and comparing them with the
Monte Carlo calculation synovial surface dose in the joint model, the agreement was
seen to be good. As in the phantom experiments, the agreement indicates that the
results obtained here using Monte Carlo radiation transport simulation and experi-
ments in the joints of cadavers are indeed accurate.
5.4 Conclusion
Estimates of beta-particle dosimetry in radiation synovectomy can be obtained either
through calculation, e.g., using beta dose point kernels (see Section 1.1.1) or Monte
Carlo radiation transport simulation, or by experimental measurement in animals,
phantoms, and cadavers. The direct measurement of absorbed dose distributions in
the joints of patients is possible, but entails inconvenience, discomforts, and inaccu-
racies generally considered to be excessive.
In this chapter, experiments aimed at measuring beta dose distributions in joint
phantoms and the knees of cadavers were described. One goal of the experiments
was to obtain the depth-data necessary to extrapolate beta dose distributions in the
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joints of patients treated with radiation synovectomy. These data were measured in
the joint phantoms, and the results were presented in Table 5.7. Another goal of the
experiments was to obtain the data necessary to estimate the distribution of injected
radioactivity throughout treated joints. Using the knees of cadavers, these data also
were measured, and the results were presented in Table 5.10.
In the next three chapters, use of the 0°B(n,a) nuclear reaction as a probe to
examine the pathology of rheumatoid arthritis is discussed. In Chapter 6, a rationale
for the experiments is presented; and in Chapters 7, experiments aimed at determin-
ing the temporal and spatial distribution of 10B in live samples of excised human
rheumatoid synovium are described.
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Examining the Pathology of
Rheumatoid Arthritis
6.1 Introduction
An unanswered question in the treatment of rheumatoid arthritis through synovec-
tomy is: how much of the synovium must be removed or killed in order to arrest
progression of the disease and provide the patient with symptomatic relief? For the
most part, current treatments using low-energy beta-emitters or surgery can be de-
scribed as attempting to remove the entire synovial membrane. Existing data suggest,
however, that removal of only the surface layer of lining cells may be sufficient (see
below).
It is the purpose of this chapter to present the rationale for a series of experiments
aimed at answering the above question. The approach is to use the 10B(n,a) nuclear
reaction as a probe to examine the fundamental pathology of rheumatoid arthritis and
determine whether killing the synovial lining cells alone could arrest progression of the
disease, or whether killing the entire synovium is required. This nuclear reaction was
chosen specifically because the high LET, short range particles emitted are capable of
producing significant amounts of radiation-induced damage limited only to boronated
cells and their nearest neighbors. Provided one boron preparation can be used to
deliver 0 B exclusively to the lining cells and a different boron preparation can be
used to deliver 10B to the entire synovium, the reaction can be used to selectively kill
varying thicknesses of synovium. Various analytical techniques then can be used to
evaluate the treatment's effects on the progression of rheumatoid arthritis, both in
vitro and in vivo.
The chapter begins with a review of the data which support the hypothesis that
killing the lining cells alone may be sufficient to temporarily arrest progression of
rheumatoid arthritis and provide patients with symptomatic relief of the disease.
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Then, the '0 B(n,a) 7Li nuclear reaction is described, and the two boron preparations
selected to boronate either the lining cells alone or the entire synovium are presented.
Use of the reaction as a probe to examine the pathology of rheumatoid arthritis is
described in Chapter 8.
6.2 Is Removal of the Lining Cells Sufficient?
As described in Chapter 2, rheumatoid arthritis is a chronic autoimmune disease of
unknown origin affecting roughly 1% of the world's adult population [20]. Although
rheumatoid arthritis has many clinical manifestations, its characteristic feature is
persistent inflammation of the synovium. If left untreated, the inflammation leads
eventually to complete destruction of bone and articular cartilage. The physical pain,
deformation, and disability which result are enormous.
Treatments for rheumatoid arthritis traditionally are aimed at relieving the syn-
ovial inflammation, and there is a wide variety of drugs available which work for
most patients. For joints unresponsive to traditional drug therapy, however, alterna-
tive treatments are required. In the past, several alternatives have been developed.
These include surgery and radiation synovectomy, each of which is aimed at removing,
or killing, the inflamed synovium with the expectation that regenerated tissue will
be free of disease for 2 to 5 years and the pain and symptoms thereby temporarily
alleviated (see Chapter 2). Both procedures aim to remove several mm of tissue.
As understanding of the pathology of rheumatoid arthritis increases, however, it
appears that removal of the entire synovium may not be required to arrest progression
of the disease and provide patients with symptomatic relief. Instead, removal of only
the surface layer of lining cells may be sufficient. There are a number of reasons why
this hypothesis has come into favor and these are discussed below.
Pathology of rheumatoid arthritis. Although the precise mechanisms through
which bone and articular cartilage are destroyed by rheumatoid arthritis are not com-
pletely understood, most of the destruction is known to occur in juxtaposition to the
pannus that spreads to cover the articular cartilages [23]. This vascular granulation
tissue is composed of fibroblasts, small blood vessels, and numerous mononuclear
cells. More importantly, however, along its surface reside large numbers of intensely
active synovial lining cells [23]. As described in Section 2.3.2, these cells not only
are engaged in rapid, neoplastic-like proliferation, but they also are responsible for
secreting high levels of proinflammatory cytokines and destructive enzymes into the
joint [23]. There is now a good deal of evidence to suggest that the secreted cytokines
and enzymes go on to play a central role in the amplification and perpetuation of the
chronic synovial inflammation and in the subsequent degradation of articular carti-
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lage and bone [21]. It therefore seems reasonable to hypothesize that if the source
of proinflammatory cytokines and destructive enzymes were removed, i.e., the lining
cells were killed, then the progression of rheumatoid arthritis in the joint would be
arrested, at least temporarily.
Clinical experience. Over the past 40 years, clinical experience with radiation
synovectomy has demonstrated that a wide variety of beta-emitting radionuclides
can be used to slow progression of rheumatoid arthritis in treated joints and provide
patients with symptomatic relief of the disease (see Section 2.4). Large differences in
the decay energies of these radionuclides, however, result in significant variations in
the thickness of synovium killed by each. Since the low energy beta-emitters appear
to be as effective as those with substantially greater soft tissue penetration [8], it
seems reasonable to conclude that the localized dose imparted by low energy emitters
is sufficient to slow the progression of rheumatoid arthritis. For the most part, this
localized dose is delivered to the first mm or so of synovium, a range which is sufficient
to kill the surface layer of lining cells. The hypothesis, therefore, is that the localized
dose imparted by the low energy emitters kills the true target, i.e., the lining cells,
and that deeper penetration is not required.
In addition, radiation synovectomy is known through clinical experience to be
most effective in the earlier stages of rheumatoid arthritis [8]. In studies in which
rheumatoid arthritis patients have been divided into groups exhibiting varying stages
of the disease, patients treated at earlier stages invariably respond more favorably
than those treated at later stages. Since the early stages of rheumatoid arthritis are
characterized by large numbers of intensely active, proliferating lining cells with little
joint damage, and the later stages of rheumatoid arthritis are characterized by fewer
and less active lining cells but extensive cartilage damage, it seems reasonable to
suppose that removing the lining cells (before the onset of cartilage destruction) is
essential to producing favorable results in patients. Again, the hypothesis is that only
the lining cells must be killed.
It is worth adding that radiation synovectomy has also been used unsuccessfully
to control the symptoms of patients with osteoarthropathy [95, 96]. In these patients,
symptoms have arisen due to advanced destruction of articular cartilage and bone-on-
bone erosions; the surface layer of synovial lining cells in the affected joints is likely
to be nonexistent and plays no central role in the progression of the disease. As a
result, the radiation therapy provides no benefit.
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Table 6.1: Thermal neutron capture cross section values of various nuclides.
Nuclide Cross section
3He 5,500 b
6 Li 953
lB 3837
113Cd 20,000
149Sm 41,500
157Gd 240,000
s55Gd 58,000
174Hf 400
199Hg 2,000
235U 678
6.3 10B(n,a) Nuclear Reaction
There are a number of nuclides which have a natural affinity for absorbing thermal
neutrons, i.e., neutrons with kinetic energy t 0.025 eV. This property, referred to as
the thermal neutron capture cross section, is measured in barns, where 1 b = 10-24
cm2. A short list of nuclides with high thermal neutron capture cross sections can be
found in Table 6.1.
A naturally occurring isotope of boron, l°B has one of the highest thermal neutron
capture cross sections of the non-radioactive nuclides. Upon capturing a thermal
neutron, the nuclide undergoes an (n,a) nuclear reaction and releases an a-particle
and a recoiling 7Li ion. In 94% of the reactions, a 0.48 MeV 7-ray is also released.
10B + nth - a +7 Li + (0.48 MeV y in 94% of the reactions) (6.1)
The nuclear reaction has a total Q value of 2.79 MeV. If the reaction proceeds without
releasing a 0.48 MeV -ray, then its energy is divided between the two particles,
such that the a-particle is released with 1.78 MeV kinetic energy, and the 7Li ion is
released with 1.01 MeV kinetic energy. On the other hand, if the reaction results in
the emission of a 0.48 MeV 7y-ray, then only 2.33 MeV is available to the particles; and
the a-particle is released with 1.47 MeV kinetic energy, while the 7Li ion is released
with 0.84 MeV kinetic energy.
Both the particles released by the reaction are high LET, short range particles,
i.e., they give rise to closely spaced ionizations in sharply defined linear tracks that
have a combined range in tissue of approximately 10-14 m, a distance which is onMIT.~~ Nuclear Engineering Dept. LS JohnsonI,~~~~~~~~LS JohnsoniMIT Nuclear Engineering Dept.
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the order of a typical cell diameter. As a result, they are capable of generating large
amounts of radiation-induced damage in boronated cells exposed to thermal neutrons
and their nearest neighbors. In general, this damage is irreversible; and if the cell
nucleus is involved, it could lead eventually to cell death.
The theoretical advantage of the reaction is that it is a two component, or binary,
system. The first component consists of the delivery of 10B to the target cells, while
the second component involves the exposure of boronated cells to thermal neutrons.
Combined, the two components provide a means to selectively deliver a therapeutic
radiation dose limited only to boronated cells and their nearest neighbors.
Thermal neutron irradiation of the target cells, however, also involves the irra-
diation of other, non-target, tissues located in the target's vicinity. Although the
thermal neutron capture cross sections of the elements normally found in the body's
tissues are several orders of magnitude lower than that of 10B (see Table 6.2), two of
these elements, H and N, are present in such high concentrations that their capturing
of neutrons contributes significantly to the total radiation absorbed dose imparted to
all the exposed tissues. Thermal neutron capture in 1H, for instance, results in an
(n,) nuclear reaction and creates an extended source of deeply-penetrating photons
capable of irradiating the entire body. Thermal neutron capture in 14N, on the other
hand, results in an (n,p) nuclear reaction, creates a source of high LET, short range
protons in all the cells exposed to thermal neutrons.
To minimize this dose to non-target tissues, 10B concentrations (parts per million
or ppm) delivered to the target cells should be as large as possible so that the neutron
fluence (n/cm:") can be kept as small as possible. The result is to maximize the
likelihood of inducing the ' 0 B(n,a)7 Li nuclear reaction in target cells while minimizing
that of the ' 4N(n,p)14 C and 'H(n,7) 2 H reactions in non-target tissues. It has been
estimated that a target cell 10B concentration of 50 ppm would result in an absorbed
dose to the target cells that is over 7 times greater than that to surrounding, non-
target tissues [97].
A major advantage of a binary system is that the two components can be man-
aged independently of one another. For instance, the time interval between boron
administration and thermal neutron irradiation can be chosen to optimize the boron
concentration differential between target and non-target cells. In addition, the ther-
mal neutron beam often can be collimated and directed to limit the exposure of
non-target cells. The system thus can be manipulated to maximize the dose to target
cells while minimizing that to non-target cells.
6.3.1 Two Boron Preparations
The two boron preparations chosen to selectively boronate either the lining cells
alone or the entire synovium are, respectively, boron particulate and boric acid. The
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Table 6.2: Thermal neutron
in the body's tissues.
capture cross section values of elements normally found
Element Cross section
H 0.332 b
C 0.0037
N 1.75
O 0.0002
Na 0.536
Mg 0.069
P 0.19
S 0.52
Ca 0.44
C1 33.8
rationale for choosing these two preparations is described below.
Boron particulate. As described in Chapter 2, type-A lining cells are phagocytic
and have elongated bodies which send processes mostly toward the synovial surface
where they emerge and are available to absorb foreign matter and waste from the
synovial fluid. Boron particulate (i.e., boron metal in particulate form) injected into
the synovial fluid and large enough to be identified as foreign matter by these cells
(1 nm to 5 tm) thus should be actively absorbed. Macrophages along the synovial
surface also should be able to identify and phagocytize the particulate. As a result,
it appears reasonable to hypothesize that high concentrations of 10°B, in particulate
form, can be delivered to the type-A lining cells and macrophages. In Chapter 7,
in vitro experiments aimed at verifying the above hypothesis and determining the
temporal and spatial distributions of boron particulate uptake by the lining cells are
described.
Boric acid. Use of the 10B(n,a) nuclear reaction to selectively kill the entire syn-
ovium also is of interest. Killing several mm of tissue however requires a reasonably
uniform distribution of 10B throughout the entire synovium. Boron particulate can-
not be used to obtain such a distribution, since the cells capable of absorbing the
particulate are not found in abundance throughout the entire synovium; they are
found instead almost exclusively in a synovial surface layer less than 0.5 mm thick.
Use of boric acid, H3BO3, is proposed as an alternative. Boric acid is an inexpen-
sive, non-toxic, water soluble compound which, like other water soluble compounds,
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can be expected to rapidly and freely diffuse throughout the entire synovium. The
experiments mentioned above and used to determine the temporal and spatial distri-
bution .of boron particulate uptake by the lining cells also were used to examine the
diffusion of boric acid throughout the entire synovium. Results of the experiments
are found in Chapter 7.
6.4 Conclusion
In this chapter, use of the 10 B(n,a) 7 Li nuclear reaction as a probe to examine the
fundamental pathology of rheumatoid arthritis was presented. For various reasons,
based on clinical experience and current understanding of the pathology of rheuma-
toid arthritis, it appears reasonable to hypothesize that complete removal, i.e., killing,
of the lining cells alone could stop the inflammatory response and prevent additional
cytokine and enzyme secretion into the joint, at least temporarily. Two boron prepa-
rations (boron particulate and boric acid) thus were proposed as candidates to ex-
amine the effect of selectively killing the lining cells alone or the entire synovium.
The 10 B(n,a) reaction was chosen specifically because the high LET, short range par-
ticles emitted are capable of generating large amounts of radiation damage only in
boronated cells exposed to thermal neutrons and their nearest neighbors. In general,
this damage is irreversible; and if the cell nucleus is involved, it can lead eventually
to cell death.
In the next chapter, experiments aimed at quantifying the temporal and spatial
distribution of boron particulate and boric acid uptake in excised samples of human
rheumatoid synovium are described. Prompt gamma neutron activation analysis was
used to quantify the temporal distribution of 10B uptake in the samples, while neutron
induced alpha-track autoradiography was used to examine the spatial distribution.
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Chapter 7
Temporal and Spatial Distribution
of 10B Uptake
7.1 Introduction
Before using the °'B(n,a) nuclear reaction to examine the effect of killing the lining
cells alone versus the entire synovium, information regarding the distribution of 10B
in the synovium is needed. In particular, quantitative information regarding the
temporal and spatial distribution of boron particulate and boric acid uptake is needed.
In this chapter, use of prompt gamma neutron activation analysis and neutron-
induced alpha-track autoradiography to determine the temporal and spatial distri-
bution of 10B uptake in live, human rheumatoid synovium is described. The prompt
gamma neutron activation analysis experiments are described first. Samples of hu-
man rheumatoid synovium were incubated for varying time periods in vitro with either
boron particulate or boric acid. Then activation analysis was used to determine the
bulk 10B content of each sample. The neutron-induced alpha-track autoradiography
experiments are described second. Again, samples of human rheumatoid synovium
were incubated in vitro with either boron particulate or boric acid. Then the sam-
ples were sliced and autoradiography was used in an attempt to examine the spatial
distribution of 10B in each.
7.2 Prompt Gamma Neutron Activation Analy-
sis
Neutron activation analysis, in general, is an analytical technique aimed at quanti-
fying the elemental composition of some materials. The sample to be evaluated is
exposed to a flux of neutrons, typically from a nuclear reactor. Since many atomic nu-
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clei have high thermal neutron capture cross sections for (n,')-type nuclear reactions,
the irradiation results in the production of a great variety of gamma-ray emitting
radionuclides, each of which decays with a characteristic energy and half-life. Spec-
troscopic analysis of the emitted gamma-rays is used to identify radionuclides in the
sample. Sometimes the product of a nuclear reaction has such a short half-life that
the emitted gamma-rays can only be measured during the actual time of irradiation.
When sample irradiation and spectroscopic analysis of the emitted gamma-rays are
conducted simultaneously, the technique is called prompt gamma neutron activation
analysis.
In prompt gamma neutron activation analysis, the activity of a given radionuclide,
which is present only during irradiation, is given by the following expression:
A = Noa, (7.1)
where A is the activity (Bq), N is the number of target atoms, b is the flux of thermal
neutrons (n/cm2 -s), and a is the thermal neutron capture cross section (cm2 ).
While Eqn. 7.1 can be used to calculate N for a given thermal neutron flux b,
cross section , and absolute activity A, accuracy of the analysis is subject to a wide
variety of errors, including variations in the thermal neutron flux and difficulties in
determining the absolute activity of the sample. A simpler approach to determining
N is based on a comparison of the sample's activity to that of a standard. The sample
and standard are activated and measured under as nearly identical conditions as is
possible. If the standard contains a known number N. of the target atoms to be
quantified, then the number of target atoms in the sample N, is given by:
AmN. = N. A, (7.2)
where A_ is the activity of the product radionuclide in the sample and A, is the ac-
tivity in the standard [98]. This relative approach was used in this work to determine
the bulk 'OB content of samples of human rheumatoid synovium incubated in vitro
with either boron particulate or boric acid (see Section 7.2.1).
MIT prompt gamma neutron activation analysis facility
A prompt gamma neutron activation analysis facility is operated at the MIT Nuclear
Reactor Laboratory (Cambridge, MA) using a diffracted thermal neutron beam. The
beam has been diffracted to result in significantly reduced numbers of fast neutrons
and core gamma-rays at the sample position. As a consequence, very short sample-to-
detector distances to be used during irradiation without overwhelming the detector.
The short distances provide a means to compensate for the loss of thermal neutron
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flux intensity due to diffraction. The resulting sensitivity of the facility, i.e., the
smallest concentration of target atoms it can be used to measure, exceeds that of
similar, direct beam facilities operated at nuclear reactors twice as powerful as the
MIT reactor [99].
A schematic diagram of the facility is shown in Figure 7-1. A well moderated
beam of thermal neutrons emerging from the reactor's D20 reflector is incident on
a multilayered graphite monochromator. The monochromator is composed of 3 thin
( 3 mm) pyrolytic graphite crystals which have been aligned to diffract the incident
beam by 21° . The reflected neutrons have 0.0143 eV kinetic energy. To further
reduce contamination of the diffracted beam by fast neutrons and gamma-rays, a
single sapphire crystal (15 cm long x 5 cm diameter) is positioned downstream of
the monochromator. The crystal transmits 80% of the 0.0143 eV neutrons while
transmitting less than 1% of the epithermal neutrons, 0.5% of the fast neutrons, and
3 to 20% of the gamma-rays in the energy range 1 to 6 MeV, respectively. Collimators
are used downstream of the crystal to define the final beam shape. At the sample
position (0.9 m from the monochromator), the emerging beam of 0.0143 eV neutrons
has a flux of 6x10 n/cm 2 -s and a diameter of m 1-2 cm.
A 122 cm3 n-type solid state Ge detector views the sample at a 900 angle. To
reduce the damaging effects of stray neutrons and the background count of scattered
gamma-rays, the sides of the detector are shielded by at least 7.5 cm lead and 4
cm lithium carbonate. The sample-facing end of the detector is shielded from stray
neutrons by 1.25 cm lithium carbonate, enriched in Li. The resulting background
count rates are sufficiently low to allow the detector to be positioned very close to
the sample, - 4 cm away.
A multichannel analyzer (MCA) is used for spectroscopic analysis of the prompt
gamma-rays. The MCA is a Canberra Series 85 analyzer with 4096 channels.
Prompt gamma neutron activation analysis of 0B
Use of prompt gamma neutron activation analysis to determine the 10B content of
materials has been reported by others [100, 101, 102, 103]. The prompt gamma-ray
detected is the 478 keV gamma-ray emitted from the excited state of 7Li in 93.5%
of °'B(n,a) nuclear reactions. Advantages of the technique include the fact that the
bulk 10B content of material samples can be determined regardless of the chemical
form of the boron. Prompt gamma neutron activation analysis also is non-destructive,
resulting in no observable changes to the samples.
7.2.1 Materials and Methods
Samples of human rheumatoid synovium were incubated for varying time periods
with either boron particulate or boric acid. Then prompt gamma neutron activation
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Figure 7-1: Schematic diagram of the prompt gamma neutron activation analysis
facility operated at MIT. The facility uses a diffracted thermal neutron beam to
reduce the numbers of fast neutrons and gamma-rays at the sample position.
MIT Nuclear Engineering Dept. LS Johnson
I MIT Nuclear Engineering Dept. LS Johnsoni
Chapter 7. Temporal and Spatial Distribution of 0B Uptake 130
Figure 7-2: Scanning electron micrograph of the boron particulate. Magnification
165 x. A 60 Am bar at the bottom of the micrograph can be used to estimate the size
distribution of the particles.
analysis was used to determine the bulk 10B content of each sample.
The boron particulate is 99.9% boron metal, enriched in l°B (94%). As shown
in Figures 7-2 and 7-3, the particles are spherical and have a wide distribution of
sizes. The larger particles are seen to be nearly 40 Am in diameter, while the smaller
particles are less than 5 Am. The average-sized particle is estimated to have a diameter
of x 15 Am.
The boric acid was prepared by dissolving H3 B03 in deionized water. The H3 B03
used is Standard Reference Material 951, as certified by the National Bureau of Stan-
dards (Washington, D.C.). It was prepared by the JT Baker Company (Phillipsburg,
NJ) for the Argonne National Laboratory (Argonne, IL) and is 19.827% 10B. For
these experiments, a 400 ppm-'1B boric acid solution was prepared by dissolving 310
mg H3B0 3 per ml deionized water.
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Figure 7-3: Scanning electron micrograph of the boron particulate taken at a higher
magnification 1000 x.
I
I MIT Nuclear Engineering Dept. LS Johnsoni
Chapter 7. Temporal and Spatial Distribution of 10B Uptake 132
Incubation
Boron particulate. Live, human rheumatoid synovium was obtained from the
operating room at Brigham and Women's Hospital (Boston, MA) and cut into several
samples, each x 0.3-0.4 g. The samples were divided into the following groups:
1. 4 samples sprinkled with 10 mg particulate and incubated in medium for 1 h
2. 4 samples sprinkled with 10 mg particulate and incubated in medium for 24 h
3. 4 samples incubated in medium for 24 h, then sprinkled with 10 mg particulate
and incubated in fresh medium for 1 h
4. 2 samples incubated in medium for 24 h as controls.
The incubation medium was RPMI 1640 cell culture medium, which is 1% penicillin
streptomycin and 10% fetal bovine serum, and has been heat inactivated. After
incubation, each of the samples was rinsed of excess particulate for about 1 min using
a gentle stream of saline solution. The rinsed samples then were sealed in teflon vials
for activation analysis.
Boric acid. The 400 ppm-l°B boric acid solution was mixed with RPMI cell culture
medium to yield a boronated incubation medium having a 10B concentration of 90
ppm. Samples of live, human rheumatoid synovium were obtained and cut into
samples as described above, but divided into the following groups:
1. 4 samples incubated in boronated medium for 1 h
2. 4 samples incubated in boronated medium for 4 h
3. 4 samples incubated in boronated medium for 24 h
4. 2 samples incubated in medium (non-boronated) for 24 h as controls.
After incubation, each of the samples was rinsed of excess boron for about 1 min
using a gentle stream of saline solution. The rinsed samples then were sealed in teflon
vials for activation analysis.
Analysis
Calibration curve. Standard solutions of 20, 40, and 50 ppm-l°B boric acid were
prepared and packaged in teflon vials for comparison with the samples. A calibration
curve was constructed as follows.
An empty teflon vial was analyzed at the MIT prompt gamma neutron activation
analysis facility to determine the background count rate of gamma-rays resulting from
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the 1H(n,7) nuclear reaction. To determine the background count rate of gamma-rays
resulting from the 10B neutron capture reaction, a teflon vial filled with deionized
water was analyzed. The boron contents of deionized water and soft tissue were
assumed to be reasonably similar. Each of the standard solutions then was analyzed
to determine its count rates of H and l°B gamma-rays.
The concentration of 10B in the standards was plotted versus the following ratio:
B=- Bbg
(7.3)H.- Hbg'
where B, and H. are, respectively, the 10B and 1H count rates of the sample and
Bbg and Hbg are, respectively, the background count rates of l°B and 1H. The ratio
is directly proportional to the absolute activity of 10B induced in each standard.
A sample calibration curve is shown in Figure 7-4. The ratio of l°B to H count
rates has been used to reduce the effects of inconsistent sample positioning in the
beam, any variations in the thermal neutron flux over the course of the analysis, and
to avoid having to determine the absolute activity A of each sample.
Sample analysis. To analyze the samples of boronated synovium, each was irra-
diated for 300 s to determine the count rates of l°B and 1H gamma-rays. Then, the
ratio defined above was calculated and used with the calibration curve to estimate
the bulk 10B content of each sample.
7.2.2 Results
Results of the experiments are presented in Tables 7.1 and 7.2 as average bulk 10B
concentrations in each of the 8 groups of samples delineated above.
Boron particulate. For the samples incubated with boron particulate, a substan-
tial amount of boron uptake is seen to occur within the first hour of incubation,
resulting in an average bulk 10B concentration of 860+29% ppm. With 24 h of in-
cubation, the absorption of the particulate is seen to continue, and the average bulk
10B concentration increases to 2300+70% ppm. In the control samples, which were
incubated for 24 h in medium alone, the average bulk 10B concentration is less than
1 ppm.
It also is of interest to have an indication of how long the excised synovium can be
expected to remain active in vitro. With this question in mind, an additional group of
samples first was incubated in medium for 24 h, then sprinkled with boron particulate
and incubated in fresh medium for 1 h, and finally rinsed and packaged for analysis.
The results show an average bulk 10B concentration in this group of 1500+33% ppm.
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MIT prompt gamma neutron activation
for the analysis
analysis facility.
of bulk 0°B content at the
LS Johnson 
4
3
0co
I
m
2
1
0
IMI[T Nuclear Engineering Dept.
....... 
Chapter 7. Temporal and Spatial Distribution of 1 B Uptake 135
Table 7.1: Temporal distribution of bulk BORON PARTICULATE uptake in human
rheumatoid synovium.
Group l°B Concentration
1 h incubation with B particulate 860±29% ppm
24 h incubation with B particulate 2300i70%
24 h incubation and then 1 h incubation with B particulate 1500±33%
24 h incubation in medium only (control) <1
Table 7.2: Temporal distribution of bulk BORIC ACID uptake in human rheumatoid
synovium.
Group 10B Concentration
1 h incubation in boronated medium 40±15% ppm
4 h incubation in boronated medium 41±15%
24 h incubation in boronated medium 52±15%
24 h incubation in non-boronated medium (control) <1
The excised synovium thus can be expected to remain active for at least 24 h.
Boric acid. For the samples incubated with boric acid, substantial absorption again
is seen in the samples incubated for only 1 h. Samples incubated in boronated medium
(90 ppm 10B) for 1 h demonstrate an average bulk 10B concentration of 40±15% ppm.
With 4 h of incubation in the boronated medium, the average bulk 10B concentration
remains nearly constant at 41±15% ppm. With a much longer incubation time of 24
h, however, it is seen to increase to 52±15% ppm. The control samples, incubated for
24 h in non-boronated medium, have an average bulk 10B concentration of less than
1 ppm.
It is important to realize that the concentrations reported above are bulk concen-
trations of 10B in the analyzed samples. Information regarding the spatial distribution
of 10B in the samples is not included. Instead, the reported bulk concentrations es-
sentially reveal the relative number of 10B atoms in the entire irradiation volume, av-
eraged over that volume and over the number of samples in each group. Experiments
aimed at determining the spatial distribution of 10B in the samples are presented in
the next section.
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7.3 Neutron-induced Alpha-track Autoradiogra-
phy
Autoradiography, in general, is an established imaging technique which has been de-
veloped to quantify the spatial distribution of various radionuclides in sliced material
samples [104, 105, 106]. Typically, the sample slice is placed against an x-ray film.
Then, as the radionuclide in the slice decays, radiation emitted from the slice interacts
with the layer of silver bromide in the film. After the film is developed, a map of the
distribution of radionuclides in the sample is displayed, with dark areas of the film
corresponding to radioactivity in the sample [107]. However, this procedure can only
be used to examine the spatial distribution of radionuclides. To examine the spatial
distribution of non-radioactive nuclides, e.g., l°B, other techniques are required.
In some cases, it is possible to label the non-radioactive nuclide of interest with
tritium and to use beta-autoradiography to examine the distribution of tritium in
the sample slices [108]. In other cases, it is possible to mount the sample slice on
a detector and irradiate the assembly with thermal neutrons to induce (n,a)-type
nuclear reactions in the slice [109, 110, 101]. Some of the emitted alpha-particles
will emerge from the slice in the direction of the detector and create tracks of stress
points in it. By chemical etching, these tracks can be transformed into pits that are
visible with the aid of an optical microscope. The latter technique is called neutron-
induced alpha-track autoradiography, and this technique was used here in an attempt
to examine the spatial distribution of 1'B in samples of human rheumatoid synovium
incubated in vitro with either boron particulate or boric acid (see Section 7.3.1).
Neutron-induced alpha-track autoradiography of l °B
In neutron-induced alpha-track autoradiography of 10B, alpha-particles emitted from
the 10B(n,a) nuclear reaction are recorded in a track-etch detector [111]. By chemical
etching, pits visible with the aid of an optical microscope are formed at the sites where
alpha-particles have passed through the detector material and created stress point
tracks in it. The size of each pit depends on the amount of energy deposited by the
alpha-particles and on the etching techniques that are used (e.g., time, temperature,
etchant, etc.) [112]. To determine quantitative information regarding the spatial
distribution of 10B in the samples, the number of tracks in a region of known area
can be counted and compared with the numbers obtained from standard specimens
of known 10B concentration, prepared in the same manner as the samples [113].
Suitable track-etch detectors for neutron-induced alpha-track autoradiography in-
clude cellulose nitrate LR 115 type 1 films (Kodak) [114] and polycarbonate CR 39
plates (allyl diglycol carbonate, American Acrylics and Plastic, CT). Both track-etch
detectors are insensitive to gamma-rays and beta-particles, which eliminates the need
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to distinguish between different types of tracks. However, both detectors are sensi-
tive to protons with less than 400 keV kinetic energy, such as those produced by the
14 N(n,p)' 4 C nuclear reaction. The cellulose nitrate films have the added disadvantage
of containing N so that protons emitted from the neutron capture reaction in N in the
detector itself can interfere with the evaluation. CR 39, on the other hand, contains
no N. CR 39 thus is the track-etch detector used here in an attempt to examine the
spatial distribution of l°B in boronated synovium.
7.3.1 Materials and Methods
Samples of human rheumatoid synovium were incubated with either boron particulate
or boric acid. Then the samples were sliced using a cryostatic mycrotome. When a
slice to be imaged was obtained, it was mounted directly onto a polycarbonate CR
39 track-etch detector for irradiation. The very next slice then was mounted onto
a glass slide for staining. Neutron-induced alpha-track autoradiography was used in
an attempt to examine the spatial distribution of 'OB in the slices mounted on CR
39, while the slices mounted on glass slides were stained for histological analysis.
Superimposition of the etched tracks and stained tissue slices then could be used to
examine the spatial distribution of 10B in the samples [115].
The boron particulate, as described in Chapter 7, is 99.9% boron metal, enriched
in "'B (94%). As shown in Figures 7-2 and 7-3, the particles are spherical and have
a wide distribution of sizes, ranging from 5 to 40 pm. The average-sized particle is
estimated to have a diameter of t 15 itm.
The boric acid was prepared by dissolving H3B03 in deionized water. As described
in Chapter 7, the H3BO3 used is Standard Reference Material 951, as certified by the
National Bureau of Standards (Washington, D.C.). For these experiments, a 400 ppm-
10B boric acid solution was prepared by dissolving 310 mg H3BO3 per ml deionized
water. The boric acid solution then was mixed with RPMI cell culture medium to
yield a boronated incubation medium with a 10B concentration of 90 ppm.
Sample incubation and slicing
Live, human rheumatoid synovium was obtained from the operating room at Brigham
and Women's Hospital (Boston, MA) and cut into several samples, each 0.3-0.4 g.
The samples were divided into the following groups:
1. 3 samples sprinkled with 10 mg boron particulate and incubated in medium for
2h
2. 3 samples incubated in boronated medium (boric acid and medium) for 2 h
3. 3 samples incubated in medium only (control)
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The incubation medium was RPMI 1640 cell culture medium, which is 1% penicillin
streptomycin and 10% fetal bovine serum, and has been heat inactivated. After incu-
bation, each of the samples was rinsed of excess boron for about 1 min using a gentle
stream of saline solution. Then samples were frozen, to fix the spatial distribution
of 10B in the synovium, and embedded in Optical Cutting Temperature compound
(Miles, Inc., Diagnostic Division, Elkhart, IN).
Using a cryostatic microtome, the frozen samples were cut into 10 pm slices. When
a slice to be imaged was obtained, it was mounted directly onto a polycarbonate CR
39 track-etch detector for irradiation, and the very next slice was mounted onto a
glass slide for staining.
Neutron irradiation
The slices mounted on CR 39 track-etch detectors were packed in dry ice and ir-
radiated at the MIT Nuclear Reactor Laboratory (Cambridge, MA) for 15 min at
100 kW in beam port position 1PH1. The capture of thermal neutrons by 10B in
the slices resulted in the emission of alpha-particles and recoiling 7Li ions from the
0°B disintegration sites. Some of the emitted particles emerge from the slice in the
direction of the detector and create tracks of stress points in it.
Etching
The polycarbonate CR 39 detectors were etched by soaking for 18 min in 6.5 N NaOH
at 70 C. Pits were formed in the detectors at the sites of stress point tracks produced
by particles emerging from the slices during irradiation.
Staining
The sample slices mounted on glass slides were stained with hematoxylin-eosin, fol-
lowing a standard procedure that has been used for over a century to stain cell
membranes and nuclei.
Analysis
The spatial distribution of pits was correlated to the stained sample slices using the
superimposition technique [115]. Micrographs of both the etched detectors and the
stained slices were obtained and scanned into a computer. Then the digitized images
were superimposed to reveal the spatial distribution of 10B in the samples.
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7.3.2 Results
Virtually no tracks were found on any of the CR 39 track-etch detectors. As a
consequence, information regarding the spatial distribution of 10B in the samples of
boronated synovium was not obtained. There are a number of possible reasons why
tracks were not formed on the detectors, and these are discussed in the next section.
7.4 Discussion
Before using the 1°B(n,a) nuclear reaction to examine the effect of killing the lining
cells alone versus the entire synovium, quantitative information regarding 10B up-
take in human rheumatoid synovium is needed. Prompt gamma neutron activation
analysis was used to obtain the temporal distribution of 0B uptake in synovial sam-
ples incubated in vitro with either boron particulate or boric acid. Neutron-induced
alpha-track autoradiography was used in an attempt to obtain the spatial distribution
of 10B uptake in the samples.
Prompt gamma neutron activation analysis
Prompt gamma neutron activation analysis was used to demonstrate and quantify
the bulk uptake of boron particulate and boric acid as a function of time in excised
samples of live, human rheumatoid synovium. The results indicate that for both boron
preparations a substantial amount of uptake occurs within the first hour of incubation,
and the uptake increases gradually with time, over the next 24 h. For instance, in the
samples incubated with boron particulate, the average bulk 10B concentration at the
end of the first hour was nearly 1000 ppm. At the end of 24 h, the average bulk 10B
concentration increased to roughly 2000 ppm. In the samples incubated with boric
acid (90 ppm-1 0 B boronated incubation medium), the average bulk 10B concentration
at the end of the first hour was roughly 40 ppm, nearly half that of the incubation
medium. At the end of 24 h, the average bulk 10B concentration increased to roughly
50 ppm.
For the boron particulate experiments, variations associated with the measured
concentrations in each of the 4 sample groups were seen to be high, z 30-70%. Prin-
cipal sources of the variations included difficulties in obtaining hearty explants of
actively inflamed, human rheumatoid synovium and in ensuring that the dissected
samples included an active layer of synovial lining cells. If the samples are not suffi-
ciently active or if the layer is not included, then the uptake of boron particulate by
the target cells (i.e., the lining cells) clearly will be affected. Most of the uncertainty
in the measured 'OB concentrations in the boron particulate experiments is believed
to be due to these two problems. As a comparison, uncertainties associated with the
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activation analysis of the samples are on the order of 10%, or less [99].
For the boric acid experiments, uncertainties associated with the measured con-
centrations are seen to be significantly smaller, - 15%. In this case, the difficulties
encountered in the boron particulate experiments are less important, since the up-
take of boric acid relies on passive diffusion rather than active phagocytosis. As a
consequence, it is less critical in the boric acid experiments for the synovial samples
to be active or to include a layer of lining cells.
Neutron-induced alpha-track autoradiography
Neutron-induced alpha-track autoradiography was used in an attempt to examine the
spatial distribution of 10B uptake in samples of excised human rheumatoid synovium
incubated with either boron particulate or boric acid. The results, unfortunately, did
not reveal the desired information. Instead, virtually no alpha-particle tracks were
seen on any of the CR 39 track-etch detectors.
For the boron particulate experiments, possible explanations of the result include
the following. As described above, the uptake of particulate matter in synovium is
the result of phagocytic absorption by the type-A lining cells and macrophages. If
the synovial samples used were not sufficiently hearty or if an active layer of lining
cells was not included, then the uptake of boron particulate by the synovium clearly
would have been affected. Also, the 10 m slice size was too small to allow some
of the particles to be included in the slices. In this case, tracks may not have been
visible because boron had not been absorbed or because some of the particulate had
been removed during slicing.
For the boric acid experiments however, the above explanations are not relevant
since the uptake of boric acid relies on passive diffusion and the size of the "particles"
is too small for them to have been removed from the samples during slicing. Other
possible explanations are as follows. First, the boronated incubation medium may not
have been prepared as intended. Although unlikely, it is possible that boric acid was
not added to the incubation medium. Second, Neutrons may not have been available
at the sample position during irradiation. In the past, other researchers using the
beam port position PH1 to examine the spatial distribution of '0 B in sliced tissue
samples using neutron-induced alpha-track autoradiography also saw no tracks [116].
With the aid of gold foils, they determined that the thermal neutron flux at the
sample position was substantially lower than it should have been and efforts were
made to correct the correct the problem. Third, the etching techniques used may
have been inadequate to transform stress point tracks to microscopically visible pits,
i.e., the etching time, temperature, and etchant strength may have been inadequate.
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7.5 Conclusion
In this chapter, the uptake of 0°B in excised samples of human rheumatoid synovium
was demonstrated and quantified. Prompt gamma neutron activation analysis was
used to examine the temporal distribution of 10B uptake in the samples. For both
boron particulate and boric acid, substantial bulk uptake after 1 h of incubation was
observed; and over the next 24 h, the uptake was shown to increase gradually.
Information regarding the spatial distribution of 10B in the samples was not ob-
tained. For the uptake of boron particulate, which is expected to be limited to type-A
lining cells and macrophages (see Section 6.3.1), variations in the spatial distribution
of 10B in the samples are hypothesized to be quite large. High concentrations of 10B
are hypothesized to arise in the lining cells and macrophages, for instance, with very
little, if any, 10B in other cells of the sample. A bulk 10B concentration of 1000 ppm
thus may correspond to a synovial surface concentration of several 1000s of ppm, with
little, or no, 10B elsewhere in the sample. For the uptake of boric acid, on the other
hand, a uniform spatial distribution of 10B is hypothesized to arise throughout the
entire synovium. Unfortunately, data supporting the hypotheses were not obtained.
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Conclusion
The aims of this thesis were: to evaluate beta-particle dosimetry in radiation syn-
ovectomy using Monte Carlo radiation transport simulation, experiments in joint
phantoms, and experiments in the knees of cadavers; to provide a rationale for the
use of the '°B(n,a) nuclear reaction to examine the pathology of rheumatoid arthri-
tis; and to determine the temporal and spatial distribution of '0B uptake in excised
samples of live, human rheumatoid synovium.
Evaluating beta-particle dosimetry in radiation synovectomy is a difficult problem
for a variety of reasons. The approach taken in this thesis was to evaluate the dosime-
try in 3 different ways: through Monte Carlo simulation of radiation transport in a
mathematical model of the rheumatoid joint, through experiments in joint phantoms
using radiachromic film dosimeters and reactor-produced radionuclides, and through
experiments in the knees of fresh, human cadavers using radiachromic film dosimeters
and reactor-produced 165Dy. Results of the evaluation are reviewed below.
Following the evaluation of beta-particle dosimetry in radiation synovectomy, the
second half of this thesis was devoted to the use of the '°B(n,a) nuclear reaction to
examine the pathology of rheumatoid arthritis. As described in Chapter 6, there is a
variety of data which support the hypothesis that killing the surface layer of synovial
lining cells in rheumatoid joints is sufficient to temporarily arrest the progression of
rheumatoid arthritis in the joint and provide patients with symptomatic relief of the
disease. The proposed approach is to use the 10°B(n,a) nuclear reaction as a probe to
determine whether killing the lining cells alone could arrest progression of rheumatoid
arthritis, or whether killing the entire synovium is required. While the question itself
was not answered in this thesis, necessary information regarding the uptake of 10B in
human rheumatoid synovium was obtained and is reviewed here.
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8.1 Beta-particle Dosimetry in Radiation Synovec-
tomy
Beta-particle dosimetry in rheumatoid synovial joints is a difficult problem for a
variety of reasons. These include the physical difficulties associated with the beta-
dosimetry of low-energy electrons in heterogeneous media and the biological and
anatomical difficulties associated with the non-uniform distribution of lining cells
in rheumatoid joints and the non-uniform distribution of radioactivity within them;
leakage of radioactivity from the joint, which may be variable; area of the surface of
the synovial membrane over which the administered activity is distributed, etc. [9].
The approach taken in these thesis was first to idealize the biological and anatomical
factors since they are so highly variable and difficult to determine on a patient by
patient basis. Then Monte Carlo calculations were coupled with experiments in joint
phantoms and the knees of cadavers to address the physical difficulties and complete
an accurate evaluation of the dosimetry for the idealized system.
8.1.1 Monte Carlo calculations
As described in Chapter 4, the evaluation began with a series of Monte Carlo calcu-
lations of beta dose distributions in a mathematical model of the treated joint. The
Monte Carlo method has proved to be a powerful and versatile tool useful for solving
a wide variety of problems. In particular, the method provides an economical and
accurate technique for estimating absorbed dose distributions in irradiated media.
With the aid of Monte Carlo, these distributions typically can be calculated for any
source-to-target configuration, in any simulation geometry, and for any characterized
radiation source. An added advantage of the method is that users of Monte Carlo
codes also may have the option of "turning off" the simulation of certain types of
interactions and manipulating geometry or material specifications, in order to inves-
tigate their individual contributions to dosimetry in the problem at hand.
Results of the Monte Carlo calculations completed in this thesis were presented
as absorbed dose factors (cGy-cm 2/MBq-s) at depth in bone, articular cartilage,
the fluid-filled joint capsule, and synovium, and can be used to extrapolate beta
dose distributions in treated joints. Effects of the presence of bone in the joint and
extension of the radiation source region (due to increased volumes of joint fluid and
numbers of lining cells) on dosimetry also were evaluated. Radiation backscatter due
to the presence of bone was seen to be minimal and not to contribute dose to the
synovium. Extension of the source was seen to result in increases in synovial dose
at depth and decreases in the bone surface dose. This finding was attributed to
the fact that the increased numbers of lining cells resulted in spatial distributions of
radioactivity deeper into the synovium, and thus away from bone.
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The results of the evaluation are intended to provide guidance for clinicians con-
cerned with radionuclide selection and the amount of radioactivity to administer in
radiation synovectomy. Definite data on the absorbed dose required at depth in syn-
ovium for successful therapy have not been established. For a given areal concentra-
tion of injected radioactivity uniformly distributed throughout the joint capsule and
along a surface layer of lining cells, however, absorbed dose to tissue (synovium), ar-
ticular cartilage, and bone are easily estimated with the results shown in Figures 4-10
through 4-17.
Absorbed dose to the bone surface is particularly of interest since the International
Commission on Radiation Protection has identified this tissue region as one of two
principal radiosensitive targets to be protected in procedures involving bone irradia-
tion [13]. Considering the fact that it may be necessary to kill only the surface layer
of lining cells in rheumatoid joints to arrest the progression of rheumatoid arthritis
and provide patients with symptomatic relief of the disease, use of the lower-energy
beta-emitters (e.g., 153Sm, i6 5 Dy, 169Er, and 'l8 Re) may be best in radiation syn-
ovectomy since these radionuclides present a significantly lower radiation hazard to
bone than the higher-energy beta-emitters when administered in quantities sufficient
to deliver therapeutic doses to the lining.
8.1.2 Experimental dosimetry
Next, evaluation of the dosimetry continued with a series of experiments conducted
in joint phantoms and the knees of cadavers using radiachromic film dosimeters and
reactor-produced radionuclides. The experiments were of interest because suitability
of the EGS4 Monte Carlo radiation transport code to evaluate the dosimetry of low-
energy electrons (less than 2 MeV) in heterogeneous media has not been extensively
tested.
As described in Chapter 3, the EGS code originally was developed to simulate
high-energy electron and photon transport and only recently was modified to extend
its useful range to include lower energies. Because of its high-energy origin, where
forward scattering dominates, EGS has been described as suffering from a number of
inherent "weaknesses" associated with the condensed history transport of low-energy
electrons: multiple scattering according to the theory of M6liere, bremsstrahlung dif-
ferential in energy only, and a simple treatment of low-energy electrons and photons,
as compared with ETRAN. As a consequence, during recent years low-energy electron
transport in EGS4 has been improved, mainly through the inclusion of user-defined
restrictions in step-sizes (variable name ESTEPE) to yield a more accurate system [63].
Other additions include electron transport down to 10s of keV, Rayleigh scattering,
and bremsstrahlung differential in angle, as well as energy.
In the present work, the aim of the experiments was to obtain the measured data
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necessary to verify the accuracy of the resulting EGS4 electron transport code pack-
age, i.e., the default version of EGS4 with the inclusion of the improvements named
above. Results of the experiments indicated that the Monte Carlo calculations of
beta-particle dosimetry in a model of the rheumatoid joint were indeed accurate. Use
of the EGS4 code to evaluate the dosimetry of low-energy electrons in heterogeneous
media thus, in this case, is an acceptable application of the code.
8.2 Use of the 1 0B(n,a) Nuclear Reaction to Ex-
amine the Pathology of Rheumatoid Arthri-
tis
In the remainder of this thesis, the focus was shifted from beta-particle dosimetry in
radiation synovectomy to use of the l°B(n,a) nuclear reaction as a probe to examine
the pathology of rheumatoid arthritis and determine whether killing the surface layer
of lining cells in synovial joints is sufficient to arrest progression of the disease. The
proposed approach is to use two different boron preparations (boron particulate and
boric acid) to selectively boronate either the lining cells alone or the entire synovium.
The 1 0B(n,a) nuclear reaction then can be used to selectively damage and kill only
the boronated cells and their nearest neighbors. The 1 B(n,a) nuclear reaction was
chosen specifically because the range of the emitted particles is short, on the order of
10 pm, a distance which closely approximates the diameter of typical cells.
While the above question was not answered in this thesis, preliminary studies
of l°B uptake in excised samples of human rheumatoid synovium were completed.
Prompt gamma neutron activation analysis of the samples indicated that substantial
amounts of both boron preparations are absorbed within the first hour of incuba-
tion and the absorption increases gradually over the next 24 h. Neutron-induced
alpha-track autoradiography to obtain spatial information regarding the distribution
of 0°B in the samples was attempted but was unsuccessful. A number of possible
explanations for the result were given in Chapter 7. In spite of the lack of spatial
information, the preliminary studies did demonstrate the uptake of both boron par-
ticulate and boric acid in the synovial samples. And this observation represents the
starting point for variety of in vitro and in vivo experiments aimed at answering the
above question. The experiments are described below.
8.3 Recommendations for Future Work
Future work first should be aimed at repeating the neutron-induced alpha-track au-
toradiography experiments to examine the spatial distribution of boron particulate
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and boric acid uptake by excised samples of human rheumatoid synovium. To avoid
the problem of removing boron particulate from the samples during slicing, smaller
particles (less than 10 im in diameter) should be purchased and used in the experi-
ments.
Once the autoradiography has been completed, then in vitro and in vivo exper-
iments aimed at determining the thickness of rheumatoid synovium which must be
removed to arrest progression of rheumatoid arthritis should be conducted. The pos-
sible development of neutron capture therapy as a novel treatment for rheumatoid
arthritis also should be investigated. Each of these recommendations is discussed in
this section.
8.3.1 Examining the pathology of rheumatoid arthritis
Work presented in the second half of this thesis was aimed at obtaining the preliminary
data necessary to begin an examination of the pathology of rheumatoid arthritis
using the l°B(n,a) nuclear reaction as a probe. In particular, it is of interest to
determine whether killing the surface layer of synovial lining cells in rheumatoid
joints is sufficient to temporarily arrest the progression of rheumatoid arthritis, or
whether killing the entire synovium is required.
In vitro experiments
Using boron particulate and boric acid, the effect of killing the lining cells alone
versus the entire synovium could be examined in vitro using samples of live, human
rheumatoid synovium obtained from the operating room. The procedure is as follows.
Samples of rheumatoid synovium are incubated for varying time periods with
either boron particulate or boronated incubation medium (i.e., boric acid and cell
culture medium). After incubation, the samples are rinsed of any excess boron and
irradiated with thermal neutrons to induce the 0°B(n,a) nuclear reaction.
Effects of the treatment are analyzed by co-incubating the treated samples with
articular cartilage explants and later examining the explants for signs of cytokine-
induced degradation. Articular cartilage explants co-incubated with active rheuma-
toid synovium have been shown to degrade over time, whereas explants co-incubated
with either healthy synovium or inactivated synovium do not degrade [117]. The
extent of cartilage degradation is quantified by measuring the proteoglycan content
of the incubation medium. Articular cartilage dissolved in vitro by active rheumatoid
synovium has been shown to release large amounts of proteoglycan into the incubation
medium, and methods of quantifying the released amount are available [117]. Pro-
teoglycan content of the incubation medium thus can be used to determine whether
or not killing either the lining cells alone or the entire synovium arrests the destruc-
tion of articular cartilage in vitro. Provided in vitro experiments indicate that the
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'°B(n,a) nuclear reaction can be used to arrest destruction of the articular cartilage
explants, then in vivo experiments should be performed to verify the results in the
intact organism.
Irradiation parameters. Monte Carlo radiation transport simulation could be
used to determine the irradiation parameters required to deliver a therapeutic radi-
ation dose to the boronated cells and their nearest neighbors without subjecting the
remaining cells to an unacceptable radiation hazard.
Monte Carlo radiation transport simulation is used extensively in neutron capture
therapy research (see below), both for the design of suitable neutron beams and the
evaluation of radiation dosimetry. The Monte Carlo code most commonly used is MCNP
(Monte Carlo for Neutron and Photon Transport) [118], which generally considered to be
the most sophisticated code of its kind. Using MCNP, irradiation parameters, such as
the irradiation time required to deliver a therapeutic absorbed dose to boronated cells
for a given flux of thermal or epithermal neutrons, could be determined. Radiation
dose imparted to other, non-boronated, cells also could be calculated.
In vivo experiments.
To verify in vitro results in the intact organism, an antigen-induced arthritis model in
rabbits could be used [7, 8], again with boron particulate and boric acid, to examine
the effect of killing the lining cells alone or the entire synovium. The procedure is as
follows.
Mature, male New Zealand white rabbits are injected subcutaneously on two
separate occasions with 10 0.1 ml shots of ovalbumin in Freund's complete adjuvant
(10 mg/ml). The shots are delivered to various locations on the animal's back. The
two sets of 10 injections are to be separated by 3 weeks [119].
Three weeks after the second set of injections, the animal is considered to be
"sensitized," and a single 5 mg shot of ovalbumin directly into the knee is used to
induce a monoarticular arthritis. The reaction develops within hours of induction,
and acute synovial inflammation develops within 3 to 4 days. After 2 weeks, the
antigen-induced arthritis model progresses to a chronic synovial inflammation. If left
untreated, osteophyte formation and articular cartilage destruction are evident within
2 months [119].
Next, the two boron preparations are injected directly into the arthritic rabbit
knees. After allowing optimal time for uptake and flushing the joints of excess boron,
the boronated joints then are irradiated with an external beam of thermal neutrons.
At various endpoints after irradiation, the rabbits are sacrificed, and their knees are
dissected and histologically analyzed to assess the effects of killing either the lining
cells alone or the entire synovium.
I
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Figure 8-1: Mathematical joint model which could be used to evaluate various ir-
radiation parameters required to deliver therapeutic synovial doses in as short an
irradiation time as is possible.
Irradiation parameters. Again, CNP could be used to determine the irradiation
parameters required to optimize the resulting absorbed dose distributions in treated
joints. A simple, cylindrical joint model (such as that shown in Fig. 8-1) could be used
in the simulations. In the model, varying concentrations of 10B could be specified in
the boronated lining cells region and used to investigate its effect on absorbed dose
distributions in the treated joint.
Neutron Capture Therapy for Rheumatoid Arthritis
If the above experiments indicate that the 'OB(n,a) experiment can be used to arrest
progression of rheumatoid arthritis, then development of neutron capture therapy as
a novel treatment for the disease should be considered. Like radiation synovectomy,
neutron capture therapy is a radiation therapy currently being developed for use in
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the US.
Neutron capture therapy research has been aimed primarily at the destruction
of brain tumors [120]. The approach has been to inject patients with stable boron
compounds in solution which are carried though the patient by physiological path-
ways to the tumor site where they are expected to be preferentially absorbed and
concentrated in the tumor. After allowing time for maximal tumor-to-healthy brain
and tumor-to-blood ratios of boron concentration to be achieved, the tumor site then
is irradiated with an external beam of thermal or epithermal neutrons. Epithermal
neutron beams are sometimes used to account for the loss of neutrons in tissue, since
they generally are required to penetrate several cm of brain before reaching the tumor.
Upon reaching the boronated tumor, some of the neutrons are captured by 10B nuclei
and induce the (n,a) nuclear reaction. Both the particles released by the reaction are
high LET, short range particles, i.e., they give rise to closely spaced ionizations in
sharply defined linear tracks that have a combined range in tissue of approximately
10-14 pm, a distance which is on the order of a typical cell diameter. As a result, they
are capable of generating large amounts of radiation-induced damage in boronated
tumor cells exposed to thermal neutrons, and their nearest neighbors. In general, this
radiation damage is irreversible; and if the cell nucleus is involved, it eventually may
lead to cell death.
A major advantage of the procedure is the fact that as soon as the neutron beam
is shut off, the nuclear reactions are no longer induced and irradiation of the patient is
complete. In patients treated with radionuclide therapy, on the other hand, irradiation
is not as easily controlled. Radioactive emissions continue to irradiate these patients
internally for as long as the radionuclide remains in the body. As mentioned in
Section 2.4, the chief obstacle to wide-spread acceptance of radiation synovectomy is
concern of excessive extraarticular irradiation due to leakage of injected radioactivity
away from the joint. Internal irradiation of the liver, spleen, and draining inguinal
lymph nodes are particularly of concern. While use of neutron capture therapy in
the treatment rheumatoid arthritis would not avoid all extraarticular irradiation,
concerns of subjecting patients to an unnecessary radiation hazard clearly could be
reduced, particularly if the neutron beam is well collimated and aimed directly at
the treated joint and if high concentrations of 10B can be achieved in the target cells.
The envisioned procedure is as follows.
8.3.2 Procedure
Rheumatoid joints to be treated with neutron capture therapy are injected with
either boron particulate or boric acid in solution, depending on whether the lining
cells alone or the entire synovium is to be killed. After allowing time for 10B uptake
by the target cells, any remaining boron solution is aspirated from the joint. The joint
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capsule then is flushed once or twice to rinse the cartilagenous surfaces of any excess
boron. Depending on the size of the joint, it is irradiated with an external beam of
either thermal or epithermal neutrons. Desired radiobiological effects of the treatment
include complete destruction of the cells responsible for promoting the progression of
rheumatoid arthritis in the joint with the expectation that regenerated tissue will be
free of disease for 2 to 5 years, and the pain and symptoms thereby alleviated, as in
radiation synovectomy.
It is important to note that based on the preliminary studies of bulk 10B uptake
reported here, the 10B concentrations obtained in the synovium (either the lining
cells alone or the entire synovium) should be substantially higher (20 to 40 times
higher) than those obtained in the treatment of brain tumors [120]. The irradiation
time required to deliver a therapeutic dose to the synovium thus is expected to be
significantly shorter (less than 5% of that required for the treatment of brain tumors).
As a consequence, the radiation dose imparted to other, non-target, tissues by thermal
neutron capture in H and N (see Section 6.3) would be substantially reduced (by 95%
or more).
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